sbfm_10k

0001654954-21-003507.txt : 20210330 0001654954-21-003507.hdr.sgml : 20210330 20210330152413 ACCESSION NUMBER: 0001654954-21-003507 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 56 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210330 DATE AS OF CHANGE: 20210330 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sunshine Biopharma, Inc CENTRAL INDEX KEY: 0001402328 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 205566275 STATE OF INCORPORATION: CO FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-52898 FILM NUMBER: 21786228 BUSINESS ADDRESS: STREET 1: 6500 TRANS-CANADA HIGHWAY STREET 2: 4TH FLOOR CITY: POINTE-CLAIRE STATE: A8 ZIP: H9R 0A5 BUSINESS PHONE: 514-426-6161 MAIL ADDRESS: STREET 1: 6500 TRANS-CANADA HIGHWAY STREET 2: 4TH FLOOR CITY: POINTE-CLAIRE STATE: A8 ZIP: H9R 0A5 FORMER COMPANY: FORMER CONFORMED NAME: Mountain West Business Solutions, Inc DATE OF NAME CHANGE: 20071030 FORMER COMPANY: FORMER CONFORMED NAME: mountain west business solutions,inc DATE OF NAME CHANGE: 20070607 10-K 1 sbfm_10k.htm ANNUAL REPORT sbfm_10k

U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-K

(Mark one)

☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2020

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF1934 for the transition period from ________________ to________________________.

Commission File Number 000-52898

SUNSHINE BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

Colorado		20-5566275
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

6500 Trans-Canada Highway

4th Floor

Pointe-Claire, Quebec, Canada H9R 0A5

(Address of principal executive offices)

(514) 426-6161

(Registrant’s Telephone Number, including area code)

Securities registered pursuant to Section 12(b) of the Act: None

Securities registered pursuant to Section 12(g) of the Act:

Title of each class		Name of each exchange on which registered
Common Stock, par value $0.001 per share		OTC Markets Pink

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☑

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes ☐ No ☑

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☑ No ☐ Yes

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☑

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter on June 30, 2020 was $2,790,475.

As of March 30, 2021, the Registrant had 465,005,925 shares of Common Stock issued and outstanding.

DOCUMENTS INCORPORATED BY REFERENCE - None

TABLE OF CONTENTS

		Page No.
Index

PART I		3

Item 1. Business		3

Item 1A. Risk Factors		11

Item 1B. Unresolved Staff Comments		11

Item 2 Properties		11

Item 3. Legal Proceedings		12

Item 4. Mine Safety Disclosures		12

PART II		13

Item 5. Market for the Registrant’s Common Equity and Related Stockholder Matters and Issuer Purchases of Equity Securities		13

Item 6. Selected Financial Data		15

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations		15

Item 7A. Quantitative and Qualitative Disclosures About Market Risk		21

Item 8. Financial Statements and Supplementary Data		21

Item 9. Changes in and Disagreements on Accounting and Financial Disclosure		22

Item 9A. Controls and Procedures		22

Item 9B. Other Information		23

PART III		24

Item 10. Directors, Executive Officers and Corporate Governance		24

Item 11. Executive Compensation		25

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters		27

Item 13. Certain Relationships and Related Transactions, and Director Independence		28

Item 14. Principal Accounting Fees and Services		28

PART IV		29

Item 15. Exhibits, Financial Statement Schedules		29

Signatures		31

FORWARD LOOKING STATEMENTS

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. The statements regarding Sunshine Biopharma Inc. contained in this Report that are not historical in nature, particularly those that utilize terminology such as “may,” “will,” “should,” “likely,” “expects,” “anticipates,” “estimates,” “believes” or “plans,” or comparable terminology, are forward-looking statements based on current expectations and assumptions, and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements.

Important factors known to us that could cause such material differences are identified in this Report. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any future disclosures we make on related subjects in future reports to the SEC.

PART I

ITEM 1. BUSINESS

History

We were incorporated in the State of Colorado on August 31, 2006 under the name “Mountain West Business Solutions, Inc.” Until October 2009, our business was to provide management consulting services to small and home-office based companies.

In October 2009, we acquired Sunshine Biopharma, Inc., a Colorado corporation holding an exclusive license (the “License”) to a new anticancer drug bearing the laboratory name, Adva-27a. As a result of this transaction we changed our name to “Sunshine Biopharma, Inc.” and our officers and directors resigned their positions with us and were replaced by Sunshine Biopharma, Inc.’s management at the time, including our current CEO, Dr. Steve N. Slilaty, and our current CFO, Camille Sebaaly each of whom remain part of our current management. Our principal business became that of a pharmaceutical company focusing on the development of our licensed Adva-27a anticancer compound. In December 2015 we acquired all issued and pending patents pertaining to our Adva-27a technology and terminated the License.

In October 2012, we published the results of our initial preclinical studies of Adva-27a in the peer-reviewed journal, ANTICANCER RESEARCH. The preclinical studies were conducted in collaboration with Binghamton University, a State University of New York. The publication is entitled “Adva-27a, a Novel Podophyllotoxin Derivative Found to Be Effective Against Multidrug Resistant Human Cancer Cells” [ANTICANCER RESEARCH Volume 32, Pages 4423-4432 (2012)].

In July 2014, we formed a wholly owned Canadian subsidiary, Sunshine Biopharma Canada Inc. (“Sunshine Canada”), for the purposes of offering generic pharmaceutical products in Canada and elsewhere around the world. In April and June 2016 Sunshine Canada signed licensing agreements for four (4) generic prescription drugs for the treatment of breast cancer, prostate cancer and BPH (Benign Prostatic Hyperplasia).

In January 2018, we acquired all of the issued and outstanding shares of Atlas Pharma Inc. (“Atlas”), a Health Canada certified company dedicated to chemical analysis of pharmaceutical and other industrial samples. Effective April 1, 2019, we re-assigned all of our stock in Atlas back to the original owner in exchange for the Atlas related debt. See “Discontinued Analytical Chemistry Services Operations” below for a more detailed explanation of this acquisition and the subsequent disposition thereof in April 2019.

In March 2018, we formed NOX Pharmaceuticals, Inc., a wholly owned Colorado corporation, and assigned all of our interest in our Adva-27a anticancer compound to that company. NOX Pharmaceuticals, Inc.’s mission is to research, develop and commercialize proprietary drugs including Adva-27a.

In December 2018, we completed the development of a new nutritional supplement which we trademarked Essential 9™. This new supplement is an over-the-counter tablet comprised of the nine amino acids which the human body cannot make. Essential 9™ has been authorized for marketing by Health Canada under NPN 80089663. On March 12, 2019, Essential 9™ became available for sale on Amazon.ca and shortly thereafter on Amazon.com.

Effective February 1, 2019, we completed a 20 to 1 reverse split of our $0.001 par value Common Stock reducing the issued and outstanding shares of Common Stock from 1,713,046,242 to 85,652,400 (the “First Reverse Stock Split”). The number of authorized shares of our $0.001 par value Common Stock remained at 3,000,000,000 shares.

In November 2019, we received Health Canada approval for a new Calcium-Vitamin D supplement. Health Canada issued NPN 80093432 through which it authorized us to manufacture and sell the new Calcium-Vitamin D supplement under the brand name Essential Calcium-Vitamin Dtm.

Our principal place of business is located at 6500 Trans-Canada Highway, 4th Floor, Pointe-Claire, Quebec, Canada H9R 0A5. Our phone number is (514) 426-6161 and our website address is www.sunshinebiopharma.com.

Business Operations

2020 Events

Effective April 6, 2020, we completed another 20 to 1 reverse split of our $0.001 par value Common Stock, reducing the issued and outstanding shares of Common Stock from 1,193,501,925 to 59,675,417 (the “Second Reverse Stock Split”). The authorized capital of our Common Stock remained as previously established at 3,000,000,000 shares. Except in the paragraphs describing the reverse stock splits, all references in this Report to our Common Stock as well as the price per share of Common Stock are presented on a post First and Second Reverse Stock Splits basis.

On May 22, 2020, we filed a patent application in the United States for a new treatment for Coronavirus infections, including COVID-19. Our patent application covers composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease (Mpro), an enzyme that is essential for viral replication. The small molecules covered by the patent application were computer modelled and designed by Dr. Steve N. Slilaty, our CEO. The patent application has a priority date of May 22, 2020.

On June 17, 2020, we filed an amendment to our Articles of Incorporation (the “Amendment”) with the Secretary of State for the State of Colorado, to eliminate the Series “A” Preferred Shares consisting of Eight Hundred and Fifty Thousand (850,000) shares, par value $0.10 per share, and the designation thereof, such shares to be returned to the status of undesignated shares of Preferred Stock. In addition, the Amendment increased the number of authorized Series “B” Preferred Shares from Five Hundred Thousand (500,000) to One Million (1,000,000) shares.

Also on June 17, 2020, our Board of Directors authorized the issuance of Five Hundred Thousand (500,000) shares of our Series “B” Preferred Stock in favor of Dr. Steve N. Slilaty, our CEO and a director, in consideration for his development of a new treatment for Coronavirus infections, including COVID-19. The Series “B” Preferred Stock is non-convertible, non-redeemable, non-retractable and has a superior liquidation value of $0.10 per share. Each share of Series “B” Preferred Stock is entitled to 1,000 votes per share. This issuance brought the total number of Series “B” Preferred Stock held by Dr. Slilaty to 1,000,000 shares.

On September 8, 2020, we executed a financing agreement with RB Capital Partners, Inc., La Jolla, CA, who has agreed to provide us with a minimum of $2 million in convertible debt financing over the next three to six months pursuant to the terms and conditions included in relevant Promissory Notes (the “Promissory Notes”). The Promissory Notes bear interest at the rate of 5% per annum and are fully convertible into shares of shares of our Common Stock at a conversion price equal to the market value of our Common Stock on the applicable conversion date or $0.30 per share, whichever is greater. The Promissory Notes have a maturity date of two years from the date of issuance and must be fully converted on or before the maturity date. We have the right under these Promissory Notes to pay off all or any part of the Promissory Notes at any time without penalty. As of the date of this Report, we have received a total of $2,050,000 in funding under this agreement.

Effective October 6, 2020, we entered into a Research Agreement (the “Agreement”) with the University of Georgia Research Foundation, Inc. (“UGARF”), representing the University of Georgia (“UGA”). The purpose of the Agreement is to memorialize the terms of our working together with UGA to conduct the necessary research and development to advance our Anti-Coronavirus lead compound, SBFM-PL4 (or derivatives thereof) through various stages of preclinical development, animal studies and clinical trials for Coronavirus infections. The Agreement grants us an exclusive worldwide license for all of the intellectual property developed by UGA, whether alone or jointly with us.

Proprietary Drug Development Operations

SBFM-PL4 Anti-Coronavirus Treatment

Viruses carry minimal genetic information as they rely, for the most part, on host cellular machinery to multiply. Coronavirus has a positive-sense RNA genome consisting of approximately 30,000 nucleotides, a genome size that places it among the larger sized viruses. A positive-sense RNA genome is effectively a messenger RNA which allows the virus to express its genes immediately upon gaining entry into the host cell without the need for any prior replication or transcription steps as is the case with negative-sense RNA or DNA viruses. This is part of what makes Coronavirus a highly aggressive pathogen. Many of the causative agents of serious human diseases are positive-sense RNA viruses, including Hepatitis C, Zeka, Polio, West Nile, Dengue, Cardiovirus, and many others. Some positive-sense RNA viruses, such as the rhinoviruses that cause the common cold, are less clinically serious but they are responsible for widespread morbidity on a yearly basis.

The initial genome expression products of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, are two large polyproteins, referred to as pp1a and pp1ab. These two polyproteins are cleaved at 15 specific sites by two virus encoded proteases (Mpro and PLpro) to generate 16 different non-structural proteins essential for viral replication. Mpro and PLpro represent an attractive anti-viral drug development targets as they play a central role in the early stages of viral replication. The crystal structure of Mpro shows the presence of an active site Cysteine (Cys145) and a coordinated active site Histidine (His41), both of which are essential for the enzyme’s proteolytic activity. Similarly, PLpro, also a Cysteine Protease, has an active site Cysteine at position 112 and a Histidine at 273. The following is a summary of the development to date of our Coronavirus Treatment project:

●

On May 22, 2020, we filed a patent application in the United States for a new treatment for Coronavirus infections. Our patent application covers composition subject matter pertaining to small molecules for inhibition of the Coronavirus main protease (Mpro), an enzyme that is essential for viral replication. The small molecules covered by the patent application were computer modelled and designed by Dr. Steve N. Slilaty, our CEO. The patent application has a priority date of May 22, 2020.

●

In August 2020, we completed the synthesis of four different potential inhibitors of Coronavirus protease. These compounds are based on the technology described in our patent application filed on May 22, 2020.

●

In September 2020, we completed the screening of our four compounds and subsequently identified a lead Anti-Coronavirus drug candidate (SBFM-PL4). The screening which pinpointed the lead compound was performed at the University of Georgia, College of Pharmacy under the leadership of Dr. Scott D. Pegan, Director of the Center for Drug Discovery and Interim Associate Head of Pharmaceutical and Biomedical Sciences.

●

In October 2020, we expanded our collaboration with Dr. Scott Pegan group by entering into a research agreement with the University of Georgia to further develop our Anti-Coronavirus lead compound, SBFM-PL4. We will proceed by conducting the in vitro studies followed by cell culture assays and assessment in Coronavirus infected mice before entering human clinical trials.

●

On February 1, 2021, we entered into an exclusive license agreement with the University of Georgia for two Anti-Coronavirus compounds which the University of Georgia had previously developed and patented. We are currently advancing the development of these two compounds in parallel with our SBFM-PL4 by conducting a transgenic mice study in collaboration with the University of Georgia. The mice being used in the study have been genetically engineered to express the human angiotensin-converting enzyme 2 (hACE2) transmembrane protein in their lungs making them susceptible to lethal infection by SARS-CoV-2, the causative agent of COVID-19. The SARSCoV-2 virus uses the hACE2 receptor to gain entry into human cells to replicate. The goal of the study is to determine if our protease inhibitors will protect the hACE2-transgenic mice from disease progression and death following infection with SARS-CoV-2 virus. Should these mice studies prove successful, we plan to submit the results to the FDA for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I clinical trial setting. The implications of a COVID-19 treatment becoming available are vast. This is particularly the case in view of the fact that some of the variants emerging around the world are more virulent and may escape neutralization by the current vaccines.

Adva-27a Anticancer Drug

Since inception, our proprietary drug development activities has focused on the development of a small molecule called Adva-27a for the treatment of aggressive forms of cancer. A Topoisomerase II inhibitor, Adva-27a has been shown to be effective at destroying Multidrug Resistant Cancer cells including Pancreatic Cancer cells, Breast Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Sunshine Biopharma is direct owner of all issued and pending worldwide patents pertaining to Adva-27a including U.S. Patents Number 8,236,935 and 10,272,065.

Figure 1

Adva-27a is a GEM-difluorinated C-glycoside derivative of Podophyllotoxin (see Figure 1). Another derivative of Podophyllotoxin called Etoposide is currently on the market and is used to treat various types of cancer including leukemia, lymphoma, testicular cancer, lung cancer, brain cancer, prostate cancer, bladder cancer, colon cancer, ovarian cancer, liver cancer and several other forms of cancer. Etoposide is one of the most widely used anticancer drugs. Adva-27a and Etoposide are similar in that they both attack the same target in cancer cells, namely the DNA unwinding enzyme, Topoisomerase II. Unlike Etoposide however, Adva-27a is able to penetrate and destroy Multidrug Resistant Cancer cells. Adva-27a is the only compound known today that is capable of destroying Multidrug Resistant Cancer. In addition, Adva-27a has been shown to have distinct and more desirable biological and pharmacological properties compared to Etoposide. In side-by-side studies using Multidrug Resistant Breast Cancer cells and Etoposide as a reference, Adva-27a showed markedly greater cell killing activity (see Figure 2).

Figure 2

Our preclinical studies to date have shown that:

●

Adva-27a is effective at killing different types of Multidrug Resistant cancer cells, including Pancreatic Cancer Cells (Panc-1), Breast Cancer Cells (MCF-7/MDR), Small-Cell Lung Cancer Cells (H69AR), and Uterine Sarcoma Cells (MES-SA/Dx5).

●

Adva-27a is unaffected by P-Glycoprotein, the enzyme responsible for making cancer cells resistant to anti-tumor drugs.

●

Adva-27a has excellent clearance time (half-life = 54 minutes) as indicated by human microsomes stability studies and pharmacokinetics data in rats.

●

Adva-27a clearance is independent of Cytochrome P450, a mechanism that is less likely to produce toxic intermediates.

●

Adva-27a is an excellent inhibitor of Topoisomerase II with an IC50 of only 13.7 micromolar (this number has recently been reduce to 1.44 micromolar as a result of resolving the two isomeric forms of Adva-27a).

●

Adva-27a has shown excellent pharmacokinetics profile as indicated by studies done in rats.

●

Adva-27a does not inhibit tubulin assembly.

These and other preclinical data have been published in ANTICANCER RESEARCH, a peer-reviewed International Journal of Cancer Research and Treatment. The publication which is entitled “Adva-27a, a Novel Podophyllotoxin Derivative Found to Be Effective Against Multidrug Resistant Human Cancer Cells” [ANTICANCER RESEARCH 32: 4423-4432 (2012)] is available on our website at www.sunshinebiopharma.com.

We have been delayed in our clinical development program due to lack of funding. Our fund raising efforts are continuing and as soon as adequate financing is in place we will continue our clinical development program of Adva-27a by conducting the following next sequence of steps:

●

GMP Manufacturing of 2 kilogram for use in IND-Enabling Studies and Phase I Clinical Trials

●

IND-Enabling Studies

●

Regulatory Filing (Fast-Track Status Anticipated)

●

Phase I Clinical Trials (Pancreatic Cancer Indication)

Adva-27a’s initial indication will be Pancreatic Cancer for which there are currently little or no treatment options available. We are planning to conduct our clinical trials at McGill University’s Jewish General Hospital in Montreal, Canada. All aspects of the clinical trials in Canada will employ FDA standards at all levels.

According to the American Cancer Society, nearly 1.5 million new cases of cancer are diagnosed in the U.S. each year. While particularly effective against Multidrug Resistant Cancer, we believe Adva-27a can potentially treat all cancer types, particularly those in which Topoisomerase II has been amplified. We believe that upon successful completion of Phase I Clinical Trials we may receive one or more offers from large pharmaceutical companies to buyout or license our drug. However, there are no assurances that our Phase I Trials will be successful, or if successful, that any pharmaceutical companies will make an acceptable offer to us. In the event we do not consummate such a transaction, we will require significant capital in order to manufacture and market our new drug on our own. The following, Figure 3, is a space-filling molecular model of our Adva-27a.

Figure 3

Generic Pharmaceuticals Operations

In 2016, our Canadian wholly owned subsidiary, Sunshine Biopharma Canada Inc. (“Sunshine Canada”), signed Licensing Agreements with a major pharmaceutical company for four prescription generic drugs for the treatment of Breast Cancer, Prostate Cancer and Enlarged Prostate. We have since been working towards commencement of marketing of these pharmaceutical products under our own, Sunshine Biopharma, label. These four generic products are as follows:

●

Anastrozole (brand name Arimidex® by AstraZeneca) for treatment of Breast Cancer;

●

Letrozole (brand name Femara® by Novartis) for treatment of Breast Cancer;

●

Bicalutamide (brand name Casodex® by AstraZeneca) for treatment of Prostate Cancer;

●

Finasteride (brand name Propecia® by Merck) for treatment of BPH (Benign Prostatic Hyperplasia)

Sunshine Canada is currently in the process of securing a Drug Identification Number (“DIN”) for each of these products from Health Canada. We are also required to obtain a Drug Establishment License (“DEL”) from Health Canada. Upon receipt of the DEL and DIN’s, we will be able to accept orders for our own label SBI-Anastrozole, SBI-Letrozole, SBI-Bicalutamide and SBI-Finasteride. We cannot estimate the timing for our obtaining either the DIN’s or the DEL due to variables involved that are out of our control. Figure 4 shows our 30-Pill blister pack of Anastrozole.

Figure 4

We currently have a number of additional Generic Pharmaceuticals under review for in-licensing. While no assurances can be provided that we will acquire the rights to any additional generic drugs, we believe that a larger product portfolio will provide us with more opportunities and a greater reach into the marketplace.

Various publicly available sources indicate that the worldwide sales of generic pharmaceuticals are over $500 billion per year. In the United States and Canada, the sales of generic pharmaceuticals are approximately $115 billion and $5 billion, respectively. The generic pharmaceuticals business is fairly competitive and there are several multinational players in the field including Teva (Israel), Novartis - Sandoz (Switzerland), Hospira (USA), Mylan (Netherlands), Sanofi (France), Fresenius Kabi (Germany) and Apotex (Canada). While no assurances can be provided, with our offering of Canadian approved products we believe that we will be able to access a small percentage of the generic pharmaceutical marketplace.

Nutritional Supplements Operations

In December 2018, we completed the development of Essential 9tm, the first in a line of essential micronutrients products that we are planning to launch. On December 14, 2018, Health Canada issued NPN 80089663 through which it authorized Sunshine Biopharma Inc. to manufacture and sell the Essential 9tm product. Our Essential 9tm nutritional supplement tablets contain a balanced formula of the 9 Essential Amino Acids that the human body cannot make. Essential Amino Acids are 9 out of the 20 amino acids required for protein synthesis. Proteins are involved in all body functions – From the musculature and immune system to hormones and neurotransmitters. Like vitamins, Essential Amino Acids cannot be made by the human body and must be obtained through diet. Deficiency in one or more of the 9 Essential Amino Acids can lead to loss of muscle mass, fatigue, weight gain and reduced ability to build muscle mass in athletes. Sunshine Biopharma’s Essential 9tm provides all 9 Essential Amino Acids in freeform and in the proportions recommended by Health Canada. Essential 9tm is currently available on Amazon.com and Amazon.ca. Figure 5 below shows our 60-Tablet Essential 9tm product.

Figure 5

In November 2019, we received Health Canada approval for another nutritional supplement, a new Calcium-Vitamin D tablets. Health Canada issued NPN 80093432 through which it authorized us to manufacture and sell the new Calcium-Vitamin D supplement under the brand name Essential Calcium-Vitamin D™.

Vitamin D is a group of steroid-like molecules responsible for increasing intestinal absorption of calcium, magnesium, and phosphate. They are also involved in multiple other biological functions, including proper functioning of the immune system, promoting healthy growth of bone, and reduction of inflammation. The most important compounds in this group are Vitamin D2 (ergocalciferol) and Vitamin D3 (cholecalciferol). Sunshine Biopharma’s Essential Calcium-Vitamin D™ tablets contain both of these compounds as well as Calcium for optimum health benefits. We anticipate that Essential Calcium-Vitamin D™ will be available on Amazon.ca in early 2021.

Discontinued Analytical Chemistry Services Operations

On January 1, 2018, we acquired all of the issued and outstanding shares of Atlas Pharma Inc. (“Atlas”), a privately held Canadian company providing analytical chemistry testing services (“Atlas Business”). The purchase price for the shares was $848,000 Canadian ($676,748 US). The purchase price included cash payment of $100,500 Canadian ($80,289 US), plus the issuance of 50,000 shares of the Company’s Common Stock valued at $238,000, and a promissory note in the principal amount of $450,000 Canadian ($358,407 US), with interest payable at the rate of 3% per annum (“Atlas Note”).

Effective April 1, 2019, we disposed of Atlas by re-assigning all of our stock in Atlas back to the original owner in exchange for the Atlas Note. As a consequence of the sale, the operating results and the assets and liabilities of the discontinued Atlas Business are presented separately in the Company's financial statements as Discontinued Operations. In additions, prior period balances have been reclassified to present the operations of the Atlas Business as Discontinued Operations.

Intellectual Property: Licenses/Patents/Trademarks/Tradenames

We are the exclusive owner of all worldwide rights pertaining to Adva-27a covered by PCT/FR2007/000697 and PCT/CA2014/000029. The patent applications filed under PCT/FR2007/000697 have been issued in Europe, Canada, the United States (US Patent Number 8,236,935) and India. The patent application filed in the U.S. under PCT/CA2014/000029 has recently been issued (US Patent Number 10,272,065). The remaining international patent applications filed under the same PCT are still pending.

In 2016 we signed Licensing Agreements with a major pharmaceutical company for four (4) prescription generic drugs for the treatment of Breast Cancer, Prostate Cancer and Enlarged Prostate. These agreements give us the right to register the four (4) generic products, Anastrozole, Letrozole, Bicalutamide and Finasteride in Canada under our own label and obtain a DIN for each in order to be able to place them on the market.

In 2018 we completed the development of Essential 9tm, our first nutritional supplement. On December 14, 2018, Health Canada issued NPN 80089663 through which it authorized Sunshine Biopharma Inc. to manufacture and sell the Essential 9tm product. We are currently preparing the necessary documents for registration of our Essential 9tm trademark in the United States.

On May 22, 2020, we filed a patent application in the United States for a new treatment for Coronavirus infections, including COVID-19. The patent application covers composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease (Mpro), an enzyme that is essential for viral replication. The United States Patent and Trademark Office publishes patent applications twelve (12) to eighteen (18) months from the date of filing.

On February 1, 2021, we entered an exclusive license agreement with the University of Georgia for two Anti-Coronavirus compounds which the University of Georgia had previously developed and patented. In collaboration with the University of Georgia, we are currently advancing the development of these two compounds in parallel with our own SBFM-PL4 compound.

Government Regulations

All of our business operations, including the Proprietary Drug Development Operations, the Generic Pharmaceutical Operations, and Nutritional Supplements Operations are subject to extensive and frequently changing federal, state, provincial and local laws and regulations.

In the U.S, the Federal Government agency responsible for regulating drugs and nutritional supplements is the U.S. Food and Drug Administration (“FDA”). The Canadian counterpart to the FDA is Health Canada. Both the FDA and Health Canada have similar requirements for drugs and supplements to be approved for marketing. In Canada, drugs and nutritional supplements are authorized through the issuance by Health Canada of a Drug Identification Number (DIN) and a Natural Product Number (NPN) on a per product basis, respectively. In both the U.S. and Canada, the quality standards for brand name drugs and generic drugs are the same. In addition, the ingredients, manufacturing processes and facilities for all drugs and supplements must meet the guidelines for Good Manufacturing Practices (“GMP”). Moreover, all drug manufacturers must perform a series of tests, both during and after production, to show that every drug batch made meets the regulatory requirements for that product.

In connection with our development of the Anti-Coronavirus treatment, SBFM-PL4, and the Anti-Cancer compound, Adva-27a, we will be subject to significant regulations in the U.S. in order to obtain approval of the FDA to offer our product on the market. The approximate procedure for obtaining FDA approval involves an initial filing of an IND application following which the FDA would review and give the go ahead for the drug developer to proceed with Phase I clinical (human) trials. Following completion of Phase I, the results are filed with the FDA and a request is made to proceed to Phase II. Similarly, following completion of Phase II the data are filed with the FDA and a request is made to proceed to Phase III. Following completion of Phase III, a request is made for marketing approval. Depending on various issues and considerations, the FDA could provide limited marketing approval for “compassionate-use” if the drug treats terminally ill patients with limited other treatment options available. As of the date of this Report we have not made any filings with the FDA or other regulatory bodies in other jurisdictions. We have however had discussions with clinicians and as a result we believe that Health Canada is likely to grant us a so-called “fast-track” process on the basis of the ongoing COVID-19 pandemic and the terminal nature of the cancer type we are planning to treat. There are no assurances this will occur.

Employees

As of the date of this Report we have three (3) employees, comprised of our management team. Presently, most of our development and marketing activities are subcontracted out to specialized service providers. As our business activities expand, we anticipate that we will need additional employees in the areas of accounting, regulatory affairs, marketing, sales and laboratory personnel.

Competition

Our Anti-Coronavirus drug development project is in direct competition with over 34 companies working on vaccine or treatment options for COVID-19. Among the companies working on vaccines are Pfizer, Moderna, AstraZeneca, GlaxoSmithKline, Johnson & Johnson, and Sanofi. The companies focused on treatments include AbbVie, Amgen, Bayer, Biogen, Gilead, Eli Lilly, Novartis, Regeneron, Roche, and Takeda. As of December 31, 2020, two (2) vaccines (Pfizer’s and Moderna’s) and three (3) treatments (Regeneron’s, Eli Lilly’s, and Gilead’s) have been approved by the FDA for emergency use. While these vaccines and treatment options are effective, we believe that additional, more convenient treatment options continue to be essential as gaps, lapses, and hospital admissions will likely persist. A treatment such as the one we are developing which can be taken orally at home, will form an important complement for vaccination and the current treatments which must be administered intravenously.

In the area of proprietary anticancer drug development, we are competing with large publicly and privately held companies engaged in developing new cancer therapies. There are numerous other entities engaged in this business that have greater resources, both financial and otherwise, than the resources presently available to us. Nearly all major pharmaceutical companies including Merck, Amgen, Roche, Pfizer, Bristol-Myers Squibb and Novartis, to name a few, have on-going anticancer drug development programs and some of the drugs they may develop could be in direct competition with our own. Also, a number of small companies are also working in the area of cancer therapy and could develop drugs that may be in competition with ours. However, none of these competitor companies can use molecules similar to ours as they would be infringing our patents.

The generic pharmaceuticals business is fairly competitive and there are many players in the field including several multinationals such as Teva (Israel), Novartis - Sandoz (Switzerland), Hospira (USA), Mylan (Netherlands), Sanofi (France), Fresenius Kabi (Germany) and Apotex (Canada) with annual sales in the range of approximately $2 billion to over $10 billion. With our offering of Canadian approved generic products, we believe that we will be able to access a small percentage of the generic pharmaceuticals market.

Similarly, our Essential 9tm and Essential Calcium-Vitamin Dtm together with our other planned line of nutritional supplement products fall directly within a very crowded and highly competitive product sector. As of the date of this Report we believe, Essential 9tm is the only Essential Amino Acid product that comprises all 9 essential amino acids in tablet form. We also believe this may provide us with a competitive advantage, at least for the near future but there are no assurances that this will occur.

ITEM 1A. RISK FACTORS

We are a smaller reporting company and not required to include this disclosure in this Report.

ITEM 1B. UNRESOLVED STAFF COMMENTS

None.

ITEM 2. PROPERTIES

Our principal place of business is located at 6500 Trans-Canada Highway, 4th Floor, Pointe-Claire, Quebec, Canada H9R 0A5. We pay a monthly fee of $261 (Canadian), including applicable taxes for use of the available space and services. We are not party to a lease agreement in connection with this service. Additional office space and conference rooms are available to us on a pay-per-use basis. Our arrangement in connection with this office has no short-term or long-term asset or liability value.

We believe that our existing facilities and equipment are adequate. We continuously review our anticipated requirements for facilities and equipment, and on the basis of such reviews, may from time to time acquire additional facilities or equipment, or dispose of some of the existing space or equipment.

ITEM 3. LEGAL PROCEEDINGS

In June 2018 we filed an action in the Superior Court of the Province of Quebec in the District of Montreal (Canada) against one of our existing shareholders residing in Quebec City (Canada) arising out of a possible equity investment intended to be completed by August 2018. The complaint alleges among other things, claims of misrepresentations and misleading conduct resulting in damages to us in an amount of approximately $200,000 Canadian (approximately $154,000 US). On April 1, 2019, a note payable held by the defendant having a face value of $100,000 Canadian (approximately $76,000 US) became due and payable (the “Subject Note”). We elected not to pay the amount due under the Subject Note and petitioned the courts to link this matter to the ongoing litigation. On March 6, 2020, the Superior Court in the District of Montreal granted our motion and the two proceedings were linked. A date for the hearings to commence was subsequently set for November 16, 2020. On November 10, 2020, we elected to pay off the Subject Note together with accrued interest and terminate the proceedings.

To the best of our management’s knowledge and belief, there are no other material claims that have been brought against us nor any claims threatened.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market Information

Trading of our Common Stock commenced on the OTCBB in September 2007 under the symbol “MWBN.” Effective November 30, 2009, the trading symbol for our Common Stock was changed to “SBFM” as a result of our name change discussed above.

In the third quarter of 2016 our Common Stock began trading on OTC Markets Pink (otcmarkets.com) because the price of our stock had dropped below $0.01 per share.

Effective February 1, 2019 we completed a 20 to 1 reverse split of our $0.001 par value Common Stock, reducing the issued and outstanding shares of Common Stock from 1,713,046,242 to 85,652,400 (the “First Reverse Stock Split”).

The table below sets forth the reported high and low transaction prices for the periods indicated taking into account and giving retroactive effect to the First and Second Reverse Stock Split.

Quarter Ended	High	Low

March 31, 2019	$0.1600	$0.1600
June 30, 2019	$0.0980	$0.0700
September 30, 2019	$0.0460	$0.0360
December 31, 2019	$0.0100	$0.0080

March 31, 2020	$0.0060	$0.0020
June 30, 2020	$0.0110	$0.0070
September 30, 2020	$0.0185	$0.0170
December 31, 2020	$0.0169	$0.0150

As of March 29, 2021, the closing price of our Common Stock was $0.1060 per share.

Trading volume in our Common Stock varies between a few million to several million shares per day. As a result, the trading price of our Common Stock is subject to significant fluctuations.

The Securities Enforcement and Penny Stock Reform Act of 1990

The Securities and Exchange Commission (“Commission” or “SEC”) has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00 (other than securities registered on certain national securities exchanges or quoted on the Nasdaq system, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or system).

As of the date of this Report, our Common Stock is defined as a “penny stock” under the Securities and Exchange Act. It is anticipated that our Common Stock will remain a penny stock for the foreseeable future. The classification of penny stock makes it more difficult for a broker-dealer to sell the stock into a secondary market, which makes it more difficult for a purchaser to liquidate his/her investment. Any broker-dealer engaged by the purchaser for the purpose of selling his or her shares in us will be subject to Rules 15g-1 through 15g-10 of the Securities and Exchange Act. Rather than creating a need to comply with those rules, some broker-dealers will refuse to attempt to sell penny stock.

The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from those rules, to deliver a standardized risk disclosure document prepared by the Commission, which:

●

contains a description of the nature and level of risk in the market for penny stocks in both public offerings and secondary trading;

●

contains a description of the broker's or dealer's duties to the customer and of the rights and remedies available to the customer with respect to a violation to such duties or other requirements of the Securities Act of 1934, as amended;

●

contains a brief, clear, narrative description of a dealer market, including "bid" and "ask" prices for penny stocks and the significance of the spread between the bid and ask price;

●

contains a toll-free telephone number for inquiries on disciplinary actions;

●

defines significant terms in the disclosure document or in the conduct of trading penny stocks; and

●

contains such other information and is in such form (including language, type, size and format) as the Securities and Exchange Commission shall require by rule or regulation;

The broker-dealer also must provide, prior to effecting any transaction in a penny stock, to the customer:

●

the bid and offer quotations for the penny stock;

●

the compensation of the broker-dealer and its salesperson in the transaction;

●

the number of shares to which such bid and ask prices apply, or other comparable information relating to the depth and liquidity of the market for such stock; and

●

monthly account statements showing the market value of each penny stock held in the customer's account.

In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from those rules; the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser's written acknowledgment of the receipt of a risk disclosure statement, a written agreement to transactions involving penny stocks, and a signed and dated copy of a written suitability statement. These disclosure requirements will have the effect of reducing the trading activity in the secondary market for our stock because it will be subject to these penny stock rules. Therefore, stockholders may have difficulty selling their securities.

Holders

We had 147 holders of record of our Common Stock as of the date of this Report, not including those persons who hold their shares in “street name.”

Our CEO, Dr. Steve N. Slilaty, holds all 1,000,000 shares of our Series “B” Preferred Stock issued in 2015 and 2020.

Stock Transfer Agent

The stock transfer agent for our securities is Equiniti Trust Company. Their address is 1110 Centre Pointe Curve, Suite 101, Mendota Heights, Minnesota 55120. Their phone number is (800) 468-9716 and web address is www.shareowneronline.com.

Dividends

We have not paid any dividends since our incorporation and do not anticipate the payment of dividends in the foreseeable future. At present, our policy is to retain earnings, if any, to develop and market our products. The payment of dividends in the future will depend upon, among other factors, our earnings, capital requirements, and operating financial conditions.

Reports

We are subject to certain reporting requirements and furnish annual financial reports to our stockholders, certified by our independent accountants, and furnish unaudited quarterly financial reports in our quarterly reports filed electronically with the SEC. All reports and information filed by us can be found at the SEC website, www.sec.gov. In addition, we are subject to similar reporting requirements in Canada and all reports and information filed by us in Canada can be found at www.sedar.com.

ITEM 6. SELECTED FINANCIAL DATA

Not applicable.

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with our audited financial statements and notes thereto included herein. In connection with, and because we desire to take advantage of, the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, we caution readers regarding certain forward looking statements in the following discussion and elsewhere in this Report and in any other statement made by, or on our behalf, whether or not in future filings with the Securities and Exchange Commission. Forward looking statements are statements not based on historical information and which relate to future operations, strategies, financial results or other developments. Forward looking statements are necessarily based upon estimates and assumptions that are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control and many of which, with respect to future business decisions, are subject to change. These uncertainties and contingencies can affect actual results and could cause actual results to differ materially from those expressed in any forward looking statements made by, or on our behalf. We disclaim any obligation to update forward looking statements.

Overview and History

We have never been subject to any bankruptcy, receivership or similar proceeding.

Going Concern

Our financial statements accompanying this Report have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The financial statements do not include any adjustment that might result from the outcome of this uncertainty. We have minimal revenues and significant losses from operations. We will, in all likelihood, sustain operating losses without corresponding revenues for the immediate future. See “ITEM 8. Financial Statements and Supplementary Data.”

Results Of Operations

Comparison of Results of Operations for the fiscal years ended December 31, 2020 and 2019

During our fiscal year ended December 31, 2020, we generated revenues of $71,410, compared to revenues of $21,121 in 2019. All of these revenues were generated from our Nutritional Supplements operations which we launched in the first quarter of 2019. The cost of sales in 2020 and 2019 for generating these revenues was $25,847 and $11,050, respectively.

General and administrative expenses for our fiscal year ended December 31, 2020 were $622,437, compared to $651,707 during our fiscal year ended December 31, 2019, a decrease of $29,270. The expense categories that saw a decrease included accounting, which decreased by $7,729, legal fees by $17,609, consulting by $58,764, research and development by $13,476, and executive compensation by $5,322. The only general and administrative category that saw an increase was office expenses which increased by $73,338 due to expenses related to expansion of our Nutritional Supplements operations.

We also incurred $168,105 in interest expense and $2,057,513 in losses from debt conversion during the year ended December 31, 2020, compared to $115,901 in interest expense and $314,752 in losses from debt conversion during the similar period in 2019. The increase in interest expense and losses from debt conversion in 2020 was due to an increase in issuance of convertible debt instruments.

As a result, we incurred a net loss of $2,784,091 (approximately $0.01 per share) for the year ended December 31, 2020, compared to a net loss of $1,660,291 (approximately $0.15 per share) during the year ended December 31, 2019.

Liquidity and Capital Resources

As of December 31, 2020, we had cash and cash equivalents of $989,888.

As discussed in Note 3 to the consolidated financial statements included in this Report for going concern, we have incurred significant continuing losses in 2020 and 2019, and the total accumulated deficits were $20.2 million and $17.4 million as of December 31, 2020 and 2019, respectively. We also used cash for operations of $657,299 and $495,798 for the years ended December 31, 2020 and 2019, respectively. Our ability to continue operating is highly dependent upon continued funding from the debt and equity markets. Based on past experience, we believe that we will be able to raise the necessary capital to continue operations. We must continue to rely on proceeds from debt and equity issuances to fund ongoing operating expenses to date, which could raise substantial doubt about our ability to continue as a going concern. The consolidated financial statements included in this Report have been prepared assuming that our Company will continue as a going concern and, accordingly, do not include any adjustments that may result from the outcome of this uncertainty.

Net cash used in operating activities was $657,299 during our fiscal year ended December 31, 2020, compared to $495,798 during our fiscal year ended December 31, 2019. We anticipate that our cash requirements for our operations will increase in the future before we reach profitability levels, of which there is no assurance.

Cash flows used in investing activities were $1,191 during our fiscal year ended December 31, 2020. For the fiscal year ended December 31, 2019, cash flows used in investing activities were $15,276 arising primarily out of the purchase of computer and related equipment. Net cash flows provided by financing activities totaled $1,608,253 in 2020, compared to $442,255 during our fiscal year ended December 31, 2019.

We have issued convertible and non-convertible Notes Payable to both related and unaffiliated parties in order to fund our operations. Our Notes Payable transactions at December 31, 2020 consisted of the following:

●

On April 1, 2017, we received monies in exchange for a Note Payable having a Face Value of $100,000 Canadian (approximately $77,700 US) with interest payable quarterly at 9%, which Note was due April 1, 2019. The Note is convertible any time after issuance into Common Stock at a price of $0.015 Canadian (approximately $0.012 US) per share. In June 2018, we filed an action in the Superior Court of the Province of Quebec in the District of Montreal (Canada) against the holder of this Note. The complaint alleges among other things, claims of misrepresentations and misleading conduct resulting in damages to us in an amount of approximately $200,000 Canadian (approximately $155,400 US). A date for the hearings to commence was set for November 16, 2020. On November 10, 2020, we elected to pay off this Note together with accrued interest of $14,696 Canadian (approximately $11,400 US) and terminate the proceedings. See “ITEM 3 Legal Proceedings.”

●

On September 10, 2018, we issued two Notes Payable having an aggregate Face Value of $36,500 with interest accruing at 8%. The two Notes were issued for services rendered to us and had maturity dates in June 2019. We were unable to pay the Notes and on November 30, 2019 we issued a new Note which included accrued interest and accelerated interest of $7,059 for a total Face Value of $43,559. The new Note accrues interest at 8% and is convertible after 180 days from issuance into Common Stock at a price 35% below market value. The new Note was due August 31, 2020. During the year ended December 31, 2020, the entire principal amount of $43,559 of this Note plus accrued interest of $2,523 was converted into 14,198,048 shares of Common Stock valued at $86,685 resulting in a loss of $40,603.

●

On December 24, 2018, we received monies in exchange for a Note Payable having a Face Value of $87,000 with interest accruing at 8% was due December 24, 2019. The Note was convertible after 180 days from issuance Common Stock at a price 35% below market value. As of December 31, 2020, the entire principal amount of $87,000 of this Note plus accrued interest of $9,639 was converted into 43,986,317 shares of Common Stock valued at $276,396 resulting in a loss of $161,036.

●

On January 8, 2019, we received monies in exchange for a Note Payable having a Face Value of $54,000 with interest accruing at 8% was due January 8, 2020. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. During the year ended December 31, 2020, the entire principal amount of $54,000 of this Note plus accrued interest of $9,814 was converted into 44,931,640 shares of Common Stock valued at $365,787 resulting in a loss of $301,973.

●

On February 5, 2019, we received monies in exchange for a Note Payable having a Face Value of $37,450 with interest accruing at 8% was due October 10, 2019. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. During the year ended December 31, 2020, the entire principal amount of $37,450 of this Note plus accrued interest of $2,996 was converted into 38,263,409 shares of Common Stock valued at $217,971 resulting in a loss of $182,790.

●

On July 2, 2019, we received monies in exchange for a Note Payable having a Face Value of $40,000 with interest accruing at 8% was due April 30, 2020. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. During the year ended December 31, 2020, the entire principal amount of $40,000 of this Note plus accrued interest of $1,600 was converted into 13,099,359 shares of Common Stock valued at $58,684 resulting in a loss of $17,084.

●

On July 26, 2019, we received monies in exchange for a Note Payable having a Face Value of $50,000 with interest accruing at 8%, which became due July 26, 2020. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. During the year ended December 31, 2020, the entire principal of $50,000 of this Note plus accrued interest of $4,909 was converted into 43,522,363 shares of Common Stock valued at $131,370 resulting in a loss of $76,461.

●

On September 12, 2019, we received monies in exchange for a Note Payable having a Face Value of $43,000 with interest accruing at 8% is due July 15, 2020. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. During the year ended December 31, 2020, the entire principal amount of $43,000 of this Note plus accrued interest of $1,720 was converted into 38,855,726 shares of Common Stock valued at $117,177 resulting in a loss of $72,457.

●

On December 14, 2019, we received monies in exchange for a Note Payable having a Face Value of $42,800 with interest accruing at 8% and which is due December 14, 2020. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. During the year ended December 31, 2020, the entire principal amount of $42,800 of this Note plus accrued interest of $1,712 was converted into 18,592,605 shares of Common Stock valued at $81,796 resulting in a loss of $37,284.

●

A Note Payable dated December 31, 2019 having a Face Value of $30,120 and accruing interest at 12% was due December 31, 2020. On December 1, 2020, we paid off the entire principal balance of this Note, together with accrued interest of $3,614 by issuing cash payment of $33,734.

●

A Note Payable dated December 31, 2018 having a Face Value of $136,744 and accruing interest at 12% was due December 31, 2019. On October 1, 2019, the holder of this note requested to convert $30,000 in principal amount into 1,500,000 shares of Common Stock, leaving a principal balance $106,744. On December 31, 2019, we renewed the remaining principal balance of this Note, together with accrued interest of $15,509 for a 12-month period. The new Note has a Face Value of $122,253 and accrues interest at 12%. This Note matures on December 31, 2020. On August 27, 2020, the holder of this Note transferred all of its interest therein to a third party and on September 4, 2020, we agreed to render the Note convertible into Common Stock at $0.001 per share. During the year ended December 31, 2020, an aggregate principal amount of $58,225 of this Note plus accrued interest of $9,775 was converted into $68,000,000 shares of Common Stock valued at $1,286,400 resulting in a loss of $1,218,400. This note is currently past due and we are currently in discussion with the holder to extend the due date.

●

On April 17, 2020, our Canadian subsidiary received a CEBA Loan (Canada Emergency Business Account Loan) from CIBC (Canadian Imperial Bank of Commerce) in the principal amount of $40,000 Canadian ($31,000 US) as part of the Canadian government’s COVID-19 relief program. The CEBA Loan is non-interest bearing if repaid on or before December 31, 2022 (the “Termination Date”). The CEBA Loan is considered repaid in full if the borrower repays 75% of the Principal Amount on or before the Termination Date. If the CEBA Loan is not repaid in full on or before the Termination Date, the lender will automatically extend the term of the loan by three years until December 31, 2025 (the “Extension Period”). During the Extension Period, interest will be charged, and will accrue on the outstanding amount of the CEBA Loan at a fixed rate of 5% per year, calculated daily and compounded monthly. The outstanding balance of the CEBA Loan and all accrued interest will be due at the end of the Extension Period.

●

On April 27, 2020, we received a Paycheck Protection Program loan in the principal amount of $50,655 (“PPP Loan”) from the US Small Business Administration (“SBA”) as part of the US government’s COVID-19 relief program. This loan accrues interest at the rate of 1% per annum. We are obligated to make payments of principal and interest totaling $2,133 each month commencing on November 27, 2020, with any remaining balances due and payable on or before April 27, 2022. The proceeds derived from this loan may only be used for payroll costs, interest on mortgages, rent and utilities (“Admissible Expenses”). In addition, the Paycheck Protection Program provides for conditional loan forgiveness if we utilize at least 75% of the proceeds from the PPP Loan to pay Admissible Expenses. On December 15, 2020, we applied to the funding bank for forgiveness of this loan per SBA guidance. On December 18, 2020, we received notification that the funding bank has approved forgiveness of our PPP Loan in its entirety and that it has submitted a request to the SBA for final approval. As of the date of this Report, no decision has been rendered by the SBA.

●

On June 1, 2020, we received monies in exchange for a Note Payable having a Face Value of $42,000 with interest accruing at 8% is due June 1, 2021. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. On December 2, 2020, we paid off the entire principal balance of this Note, together with accrued interest and prepayment penalties of $13,435 by issuing cash payment of $55,435.

●

On June 9, 2020, we received monies in exchange for a Note Payable having a Face Value of $37,000 with interest accruing at 8% is due June 9, 2021. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. On December 2, 2020, we paid off the entire principal balance of this Note, together with accrued interest and prepayment penalties of $11,779 by issuing a cash payment of $48,779.

●

On July 7, 2020, we received monies in exchange for a Note Payable having a Face Value of $48,000 with interest accruing at 8% is due July 7, 2021. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. We will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on January 3, 2021 which is 180 days after the issuance date.

●

On July 27, 2020, we received monies in exchange for a Note Payable having a Face Value of $102,000 with interest accruing at 8% is due July 27, 2021. The Note is convertible after 180 days from issuance into Common Stock at a price 30% below market value. We will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on January 23, 2021 which is 180 days after the issuance date.

●

On August 14, 2020, we received monies in exchange for a Note Payable having a Face Value of $67,000 with interest accruing at 8% is due August 14, 2021. The Note is convertible after 180 days from issuance into Common Stock at a price 30% below market value. We will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on February 10, 2021 which is 180 days after the issuance date.

●

On September 14, 2020, we received monies in exchange for a Note Payable having a Face Value of $250,000 with interest accruing at 5% is due September 14, 2022. The Note is convertible after 180 days from issuance into Common Stock at a price equal to $0.30 per share. We will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on March 13, 2021 which is 180 days after the issuance date.

●

On September 24, 2020, we received monies in exchange for a Note Payable having a Face Value of $50,000 with interest accruing at 5% is due September 24, 2022. The Note is convertible after 180 days from issuance into Common Stock at a price equal to $0.30 per share. We will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on March 23, 2021 which is 180 days after the issuance date.

●

On October 20, 2020, we received monies in exchange for a Note Payable having a Face Value of $250,000 with interest accruing at 5% is due October 20, 2022. The Note is convertible after 180 days from issuance into Common Stock at a price equal to $0.30 per share. We will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on April 18, 2021 which is 180 days after the issuance date.

●

On November 19, 2020, we received monies in exchange for a Note Payable having a Face Value of $250,000 with interest accruing at 8% is due August 19,2021. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. We will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on May 18, 2021 which is 180 days after the issuance date.

●

On November 24, 2020, We received monies in exchange for a Note Payable having a Face Value of $260,000 with interest accruing at 8% is due November 24, 2021. The Note is convertible after 180 days from issuance into Common Stock at a price 30% below market value. We will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on May 23, 2021 which is 180 days after the issuance date.

●

On November 25, 2020, we received monies in exchange for a Note Payable having a Face Value of $250,000 with interest accruing at 5% is due November 25, 2022. The Note is convertible after 180 days from issuance into Common Stock at a price equal to $0.30 per share. We will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on May 24, 2021 which is 180 days after the issuance date.

●

On December 2, 2020, we received monies in exchange for a Note Payable having a Face Value of $104,215 with interest accruing at 5% is due December 2, 2022. The Note is convertible after 180 days from issuance into Common Stock at a price equal to $0.30 per share. We will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on May 31, 2021 which is 180 days after the issuance date.

●

A Note Payable dated December 31, 2019 held by our CEO having a Face Value of $128,269 and accruing interest at 12% was due December 31, 2020. On December 31, 2020, we renewed the Note together with accrued interest of $15,392 for a 12-month period. The new Note has a face Value of $143,661, accrues interest at 12% per annum, and has a maturity date of December 31, 2021.

During the fiscal year ended December 31, 2020, we issued an aggregate of 311,098,985 shares of our Common Stock valued at $2,515,015 in connection with the conversion of $415,269 in debt and $42,233 in interest resulting in a loss of $2,057,513.

We relied upon the exemption from registration provided by Section 4(2) of the Securities Act of 1933, as amended, to issue the respective shares. We used the proceeds derived from these notes for implementation of our business plan and working capital.

We are not generating significant revenue from our operations, and our ability to implement our business plan as set forth herein will depend on the future availability of financing. Such financing will be required to enable us to further develop our Proprietary Drug Development program, Generic Pharmaceuticals business, and Nutritional Supplements development and sales operations. We intend to raise funds through private placements of our Common Stock and/or debt financing. We estimate that we will require approximately $20 million (approximately $18 million for our Proprietary Drug Development projects and $2 million for our Nutritional Supplements operations) to fully implement our business plan in the future and there are no assurances that we will be able to raise this capital.

Relevant thereto, on September 8, 2020, we executed a financing agreement with RB Capital Partners, Inc., La Jolla, CA, who has agreed to provide us with a minimum of $2 million in convertible debt financing over the next three to six months pursuant to the terms and conditions included in relevant Promissory Notes (the “Promissory Notes”). The Promissory Notes will bear interest at the rate of 5% per annum and will be fully convertible into shares of shares of the Company’s Common Stock at a conversion price equal to the market value of the Company’s Common Stock on the applicable conversion date or $0.30 per share, whichever is greater. The Promissory Notes will have a maturity date of two years from the date of issuance and must be fully converted on or before the maturity date. The Company has the right under these Promissory Notes to pay off all or any part of the Promissory Notes at any time without penalty. As of the date of this Report, we have received a total of $2,054,000 in funding under this agreement.

We are currently in discussion with various investment groups for additional financing. There are no assurances that we will be successful in raising any funds.

Our cost to continue operations are expected to increase as we move forward with implementation of our recently expanded business plan to include the Anti-Coronavirus drug development project. We do not have sufficient funds to cover the anticipated increase in the relevant expenses. We need to raise additional funds in order to continue our existing and expanded operations.

Inflation

Although our operations are influenced by general economic conditions, we do not believe that inflation had a material effect on our results of operations during our fiscal year ended December 31, 2020.

Critical Accounting Policies and Estimates

Critical Accounting Estimates

The discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Leases

We follow the guidance in ASC 842 “Accounting for Leases,” as amended, which requires us to evaluate the lease agreements we enter into to determine whether they represent operating or capital leases at the inception of the lease. Our Company is not party to any lease agreements. Our corporate offices in Pointe-Claire, Quebec (Canada) are on a month-to-month, pay-per-use basis. Our arrangement in connection with this office has no short-term or long-term asset or liability value.

Recently Adopted Accounting Standards

In December 2019, the FASB issued ASU 2019-12 “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.” This guidance removes certain exceptions to the general principles in Topic 740 and provides consistent application of U.S. GAAP by clarifying and amending existing guidance. The effective date of the new guidance for public companies is for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. Early adoption is permitted. We are currently evaluating the timing of adoption and impact of the updated guidance on our financial statements.

Off-Balance Sheet Arrangements

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

Reference is made to the Financial Statements, the notes thereto, and the Report of Independent Public Accountants thereon commencing at page F-1 of this Report, which Financial Statements, notes and report are incorporated herein by reference.

Sunshine Biopharma, Inc.

CONSOLIDATED FINANCIAL STATEMENTS

With Independent Accountant’s Audit Report

At December 31, 2020 and 2019

TABLE OF CONTENTS

	Page

Independent Accountant’s Audit Report	F-1

Consolidated Balance Sheet	F-2

Consolidated Statement of Operations	F-3

Consolidated Statement of Cash Flows	F-4

Consolidated Statement of Shareholders’ Equity	F-5

Notes to Consolidated Financial Statements	F-6

Report of Independent Registered Public Accounting Firm

To the shareholders and the board of directors of Sunshine Biopharma, Inc.:

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Sunshine Biopharma, Inc. (the "Company") as of December 31, 2020 and 2019, the related consolidated statements of operations and comprehensive income (loss), shareholders' equity, and cash flows for each of the two years in the period ended December 31, 2020, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2020, in conformity with accounting principles generally accepted in the United States.

Going Concern Uncertainty

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ B F Borgers CPA PC

We have served as the Company's auditor since 2013.

Lakewood, CO

March 30, 2021

F-1

Sunshine Biopharma, Inc.
Consolidated Balance Sheets

	December 31,	December 31,
	2020	2019
ASSETS
Current Assets:
Cash and cash equivalents	$989,888	$40,501
Accounts receivable	1,916	430
Inventory	23,771	15,910
Prepaid expenses	2,778	1,255
Deposits	7,590	7,590
Total Current Assets	1,025,943	65,686

Equipment (net of $51,485 and $37,109 depreciation, respectively)	19,531	32,456
Patents (net of $58,918 amortization and $556,120 impairment)	-	-

TOTAL ASSETS	$1,045,474	$98,142

LIABILITIES

Current Liabilities:
Notes payable	820,454	586,307
Notes payable - related party	143,661	129,261
Accounts payable & accrued expenses	62,870	96,882
Interest payable	24,320	21,077
Total Current Liabilities	1,051,305	833,527

Long-term portion of notes payable	949,006	-

TOTAL LIABILITIES	2,000,311	833,527

COMMITMENTS AND CONTINGENCIES

SHAREHOLDERS' EQUITY (DEFICIT)

Preferred Stock, Series B $0.10 par value per share; Authorized 1,000,000 Shares;
Issued and outstanding 1,000,000 and 500,000 shares at December 31, 2020 and December 31, 2019, respectively	100,000	50,000

Common Stock, $0.001 value per share; Authorized 3,000,000,000 Shares;
Issued and outstanding 346,419,296 and 35,319,990 at December 31, 2020 and December 31, 2019, respectively	346,418	35,320

Capital paid in excess of par value	18,820,343	16,616,426

Accumulated comprehensive income	(2,871)	(2,495)

Accumulated (Deficit)	(20,218,727)	(17,434,636)

TOTAL SHAREHOLDERS' EQUITY (DEFICIT)	(954,837)	(735,385)

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$1,045,474	$98,142

See Accompanying Notes to These Financial Statements.

F-2

Sunshine Biopharma, Inc.
Consolidated Statement of Operations and Comprehensive Income (Loss)

	December 31,	December 31,
	2020	2019
Sales	$71,410	$21,121
Cost of sales	25,847	11,050
Gross profit	45,563	10,071

General & Administrative Expenses:
Accounting	81,524	89,253
Consulting	15,360	74,124
Legal	89,587	107,196
Office	89,022	74,904
Officer & director remuneration	271,930	277,252
R&D	60,948	15,204
Depreciation	14,066	13,774
Total General & Administrative Expenses	622,437	651,707

Income (Loss) from Operations	(576,874)	(641,636)

Other Income (Expense):
Loss on debt conversions	(2,057,513)	(314,752)
Foreign exchange gain (loss)	4,891	(15,099)
Interest expense	(168,105)	(115,901)
Miscellaneous income	3,000	-
Debt release	7,674	7,967
Interest forgiveness	2,836	1,367
Total Other Income (Expense)	(2,207,217)	(436,418)

Net income (loss) before income taxes	(2,784,091)	(1,078,054)
Provision for income taxes	-	-
Net income (loss) from continuing operations	(2,784,091)	(1,078,054)
Net income (loss) on discontinued operations	-	(582,237)
Net Income (Loss)	(2,784,091)	(1,660,291)

Unrealized gain (loss) from foreign exchange translation	376	1,243
Comprehensive Income (Loss)	(2,783,715)	(1,659,048)


Basic income (loss) from continuing operations per common share	$(0.01)	$(0.10)

Basic income (loss) from discontinued operations per common share	$0.00	$(0.05)

Basic income (loss) per common share	$(0.01)	$(0.15)

Weighted Average Common Shares Outstanding	204,096,338	10,932,813

See Accompanying Notes to These Financial Statements.

F-3

Sunshine Biopharma, Inc.
Consolidated Statement of Cash Flows

	December 31,	December 31,
	2020	2019
Cash Flows from Operating Activities:
Net Income (Loss)	$(2,784,091)	$(1,660,291)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	14,066	13,774
Foreign exchange (gain) loss	(4,891)	15,099
Stock issued for services	50,000	261,690
Stock issued for payment interest	42,233	17,197
Loss on debt conversion	2,057,513	314,752
Gain on interest and debt forgiveness	10,510	(9,334)
Loss on disposition of subsidiary	-	582,237
(Increase) in accounts receivable	(1,486)	(430)
(Increase) decrease in inventory	(7,861)	(15,910)
(Increase) in prepaid expenses	(1,523)	(7,676)
(Increase) in deposits	-	-
(Decrease) in Accounts Payable & accrued expenses	(35,012)	(18,692)
Increase in interest payable	3,243	11,786
Net Cash Flows (Used) in Operations	(657,299)	(495,798)

Cash Flows from Investing Activities:
Advances to discontinued operations	-	(14,416)
Purchase of equipment	(1,191)	(860)
Net Cash Flows (Used) in Investing Activities	(1,191)	(15,276)

Cash Flows from Financing Activities:
Proceeds from notes payable	1,674,246	441,230
Payments of notes payable	(106,600)	(53,000)
Note payable - interest expense	40,607	25,795
Note payable used to pay note origination fees	-	28,230
Net Cash Flows Provided by Financing Activities	1,608,253	442,255

Cash and Cash Equivalents at Beginning of Period	40,501	115,216
Net Increase (Decrease) In Cash and cash equivalents	949,763	(68,819)
Foreign currency translation adjustment	(376)	(5,896)
Cash and Cash Equivalents at End of Period	$989,888	$40,501

Supplementary Disclosure of Cash Flow Information:
Cash paid for interest	$20,963	$-
Cash paid for income taxes	$-	$-
Stock issued for note conversions	$2,515,015	$717,726

See Accompanying Notes to These Financial Statements.

F-4

Sunshine Biopharma, Inc.
Consolidated Statement of Shareholders' Equity

	Number of Common Shares Issued	Common Stock	Capital Paid in Excess of Par Value	Number of Preferred Shares Issued	Preferred Stock	Comprehensive Income	Accumulated Deficit	Total

Balance at December 31, 2018	4,282,620	4,283	15,668,047	500,000	50,000	(3,738)	(15,774,345)	(55,753)

Common stock issued to directors	9,150,000	9,150	195,150					204,300

Common stock issued for services	1,455,000	1,455	55,935					57,390

Common stock issued for the reduction of notes payable	20,432,370	20,432	697,294					717,726
and payment of interest

Net (loss)						1,243	(1,660,291)	(1,659,048)

Balance at December 31, 2019	35,319,990	$35,320	$16,616,426	500,000	$50,000	$(2,495)	$(17,434,636)	(735,385)

Common stock issued for the reduction of notes payable	311,098,985	311,098	2,203,917					2,515,015
and payment of interest

Adjustment for Reverse-Split	321

Preferred stock issued for services				500,000	50,000			50,000

Net (loss)						(376)	(2,784,091)	(2,784,467)
Balance at December 31, 2020	346,419,296	$346,418	$18,820,343	1,000,000	$100,000	$(2,871)	$(20,218,727)	(954,837)

See Accompanying Notes to These Financial Statements.

F-5

Sunshine Biopharma, Inc.

Notes to Consolidated Financial Statements

December 31, 2020 and 2019

Note 1 – Description of Business

Sunshine Biopharma, Inc. (the "Company") was originally incorporated under the name Mountain West Business Solutions, Inc. on August 31, 2006 in the State of Colorado. Until October 2009, the Company was operating as a business consultancy firm.

Effective October 15, 2009, the Company acquired Sunshine Biopharma, Inc. in a transaction classified as a reverse acquisition. Sunshine Biopharma, Inc. was holding an exclusive license to a new anticancer drug bearing the laboratory name, Adva-27a (the “License Agreement”). Upon completion of the reverse acquisition transaction, the Company changed its name to Sunshine Biopharma, Inc. and began operating as a pharmaceutical company focusing on the development of the licensed Adva-27a anticancer drug.

In October 2012, the Company published the results of its initial preclinical studies of Adva-27a in the peer-reviewed journal, ANTICANCER RESEARCH. The preclinical studies were conducted in collaboration with Binghamton University, a State University of New York. The publication is entitled “Adva-27a, a Novel Podophyllotoxin Derivative Found to Be Effective Against Multidrug Resistant Human Cancer Cells” [ANTICANCER RESEARCH Volume 32, Pages 4423-4432 (2012)].

In July 2014, the Company formed a wholly owned Canadian subsidiary, Sunshine Biopharma Canada Inc. (“Sunshine Canada”) for the purposes of offering generic pharmaceutical products in Canada and elsewhere around the world. Sunshine Canada has signed licensing agreements for four (4) generic prescription drugs for treatment of breast cancer, prostate cancer and BPH (Benign Prostatic Hyperplasia).

In December 2015, the Company acquired all worldwide issued (US Patent Number 8,236,935, and 10,272,065) and pending patents under PCT/FR2007/000697 and PCT/CA2014/000029 for the Adva-27a anticancer compound from Advanomics Corporation, a related party, in exchange for an aggregate of 803,264 shares of Common Stock valued at $835,394 and terminated the License Agreement. In 2016, the remaining value of these patents was impaired. The Company is however continuing development of the Adva-27a anticancer drug covered by these patents.

On January 1, 2018, the Company acquired all of the issued and outstanding shares of Atlas Pharma Inc. (“Atlas”), a Canadian privately held analytical chemistry company. The purchase price for the shares was Eight Hundred Forty-Eight Thousand Dollars $848,000 Canadian ($676,748 US). The purchase price included cash payment of $100,500 Canadian ($80,289 US), plus the issuance of 50,000 shares of the Company’s Common Stock valued at $238,000, and a promissory note (“Atlas Debt”) in the principal amount of $450,000 Canadian ($358,407 US), with interest payable at the rate of 3% per annum. Effective April 1, 2019, the Company re-assigned all of its stock in Atlas back to the original owner in exchange for the Atlas Debt. The loss on the disposition was $580,125. See Note 11, below for a more detailed explanation of this disposition.

In March 2018, the Company formed NOX Pharmaceuticals, Inc., a wholly owned Colorado corporation and assigned all of the Company’s interest in the Adva27a anticancer drug to that company. NOX Pharmaceuticals Inc.’s mission is to research, develop and commercialize proprietary drugs including Adva-27a.

In December 2018, the Company launched its first over-the-counter product, Essential 9™, a nutritional supplement comprised of the nine (9) essential amino acids that the human body cannot make. Essential 9tm has been authorized for marketing by Health Canada under NPN 80089663.

Effective February 1, 2019, the Company completed a 20 to 1 reverse split of its Common Stock, reducing the issued and outstanding shares of Common Stock from 1,713,046,242 to 85,652,400 (the “First Reverse Stock Split”). The Company’s authorized capital of Common Stock remained as previously established at 3,000,000,000 shares.

In November 2019, the Company received Health Canada approval for a new Calcium-Vitamin D supplement. Health Canada issued NPN 80093432 through which it authorized the Company to manufacture and sell the new Calcium-Vitamin D supplement under the brand name Essential Calcium-Vitamin Dtm.

Effective April 6, 2020, the Company completed another 20 to 1 reverse split of its Common Stock, reducing the issued and outstanding shares of Common Stock from 1,193,501,925 to 59,675,417 (the “Second Reverse Stock Split”). The Company’s authorized capital of Common Stock remained as previously established at 3,000,000,000 shares.

On May 22, 2020, the Company filed a patent application in the United States for a new treatment for Coronavirus infections. The Company’s patent application covers composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease (Mpro), an enzyme that is essential for viral replication. The patent application has a priority date of May 22, 2020.

On June 17, 2020, the Company filed an amendment to its Articles of Incorporation (the “Amendment”) with the State of Colorado, to eliminate the Series “A” Preferred Shares consisting of Eight Hundred and Fifty Thousand (850,000) shares, par value $0.10 per share, and the designation thereof, which shares were returned to the status of undesignated shares of Preferred Stock. In addition, the Amendment increased the number of authorized Series “B” Preferred Shares from Five Hundred Thousand (500,000) to One Million (1,000,000) shares.

F-6

Also on June 17, 2020, the Company issued Five Hundred Thousand (500,000) shares of Series “B” Preferred Stock in favor of Dr. Steve N. Slilaty, the Company’s CEO, in consideration for the COVID-19 treatment technology he developed. The Series “B” Preferred Stock is non-convertible, non-redeemable, non-retractable and has a superior liquidation value of $0.10 per share. Each share of Series “B” Preferred Stock is entitled to 1,000 votes per share. This issuance brought the total number of Series “B” Preferred Stock held by Dr. Slilaty to 1,000,000 shares.

On September 8, 2020, the Company executed a financing agreement with RB Capital Partners, Inc., La Jolla, CA, who has agreed to provide the Company with a minimum of $2 million in convertible debt financing over the next three to six months pursuant to the terms and conditions included in relevant Promissory Notes (the “Promissory Notes”). The Promissory Notes will bear interest at the rate of 5% per annum and will be fully convertible into shares of shares of the Company’s Common Stock at a conversion price equal to the market value of the Company’s Common Stock on the applicable conversion date or $0.30 per share, whichever is greater. The Promissory Notes will have a maturity date of two years from the date of issuance and must be fully converted on or before the maturity date. The Company has the right under these Promissory Notes to pay off all or any part of the Promissory Notes at any time without penalty. As of December 31, 2020, the Company has received a total of $1,350,000 in funding under this agreement.

Effective October 6, 2020, the Company entered into a Research Agreement (the “Agreement”) with the University of Georgia Research Foundation, Inc. (“UGARF”), representing the University of Georgia (“UGA”). The purpose of the Agreement is to memorialize the terms of the Company working together with UGA to conduct the necessary research and development to advance the Company’s Anti-Coronavirus lead compound, SBFM-PL4 (or derivatives thereof) through various stages of preclinical development, animal studies and clinical trials for Coronavirus infections. The Agreement grants the Company an exclusive worldwide license for all of the intellectual property developed by UGA, whether alone or jointly with the Company.

The Company's financial statements reflect both the First and Second Reverse Stock Split on a retroactive basis and represent the consolidated activity of Sunshine Biopharma, Inc. and its subsidiaries (Sunshine Biopharma Canada Inc. and NOX Pharmaceuticals Inc.) herein collectively referred to as the "Company".

During the last twelve month period the Company has continued to raise money through the issuance of convertible debt. The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding to operationalize the Company’s proprietary drug development program and other business activities.

Note 2 – Summary of Significant Accounting Policies

This summary of significant accounting policies is presented to assist the reader in understanding the Company's financial statements. The consolidated financial statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity. These accounting policies conform to Generally Accepted Accounting Principles and have been consistently applied in the preparation of the financial statements.

IMPACT OF CORONAVIRUS (COVID-19) PANDEMIC

In March 2020, the World Health Organization declared Coronavirus and its associated disease, COVID-19, a global pandemic. Conditions surrounding the Coronavirus outbreak are evolving rapidly and government authorities around the world have implemented emergency measures to mitigate the spread of the virus. The outbreak and related mitigation measures have had and will continue to have a material adverse impact on the world economies and the Company's business activities. It is not possible for the Company to predict the duration or magnitude of the adverse conditions of the outbreak and their effects on the Company’s business or ability to raise funds. No adjustments have been made to the amounts reported in the Company's financial statements as a result of this matter.

PRINCIPLES OF CONSOLIDATION

The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

F-7

USE OF ESTIMATES

The preparation of financial statements in conformity with US Generally Accepted Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant estimates and assumptions made by management are valuation of equity instruments, depreciation of property and equipment, and deferred tax asset valuation. Actual results could differ from those estimates as the current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.

CASH AND CASH EQUIVALENTS

For the Balance Sheets and Statements of Cash Flows, all highly liquid investments with maturity of 90 days or less are considered to be cash equivalents. The Company had a cash balance of $989,888 and $40,501 as of December 31, 2020 and December 31, 2019, respectively. At times such cash balances may be in excess of the FDIC limit of $250,000 or the equivalent in Canada.

PROPERTY AND EQUIPMENT

Property and equipment is reviewed for recoverability when events or changes in circumstances indicate that its carrying value may exceed future undiscounted cash inflows. As of December 31, 2020 and 2019, the Company had not identified any such impairment. Repairs and maintenance are charged to operations when incurred and improvements and renewals are capitalized.

Property and equipment are stated at cost. Depreciation is calculated using the straight-line method for financial reporting purposes and accelerated methods for tax purposes. Their estimated useful lives are as follows:

Office Equipment:	5-7 Years
Laboratory Equipment:	5 Years
Vehicles:	5 Years

EARNINGS PER SHARE

The Company has adopted the Financial Accounting Standards Board (FASB) ASC Topic 260 regarding earnings / loss per share, which provides for calculation of “basic” and “diluted” earnings / loss per share. Basic earnings / loss per share includes no dilution and is computed by dividing net income / loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings / loss per share reflect the potential dilution of securities that could share in the earnings of an entity similar to fully diluted earnings / loss per share.

F-8

INCOME TAXES

In accordance with ASC 740 – Income Taxes, the provision for income taxes is computed using the asset and liability method. The liability method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities have been adjusted to reflect changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized.

The Company expects to recognize the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a "more-likely-than-not" threshold, the amount to be recognized in the financial statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. As of December 31, 2020 the Company had no uncertain tax positions. The Company recognizes interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. The Company currently has no federal or state tax examinations nor has it had any federal or state examinations since its inception. To date, the Company has not incurred any interest or tax penalties.

For Canadian and US tax purposes, the Company’s 2017 through 2019 tax years remain open for examination by the tax authorities under the normal three-year statute of limitations.

FUNCTIONAL CURRENCY

The U.S. dollar is the functional currency of the Company which is operating in the United States. The functional currency for the Company's Canadian subsidiary is the Canadian dollar.

The Company translates its Canadian subsidiary's financial statements into U.S. dollars as follows:

●

Assets and liabilities are translated at the exchange rate in effect as of the financial statement date.

●

Income statement accounts are translated using the weighted average exchange rate for the period.

The Company includes translation adjustments from currency exchange and the effect of exchange rate changes on intercompany transactions of a long-term investment nature as a separate component of shareholders’ equity. There are currently no transactions of a long-term investment nature, nor any gains or losses from non U.S. currency transactions.

CONCENTRATION OF CREDIT RISKS

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents and trade receivables. The Company places its cash equivalents with high credit quality financial institutions.

FINANCIAL INSTRUMENTS AND FAIR VALUE OF FINANCIAL INSTRUMENTS

The Company applies the provisions of accounting guidance, FASB Topic ASC 825, Financial Instruments. ASC 825 requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of December 31, 2020 and 2019, the fair value of cash, accounts receivable and notes receivable, accounts payable, accrued expenses, and other payables approximated carrying value due to the short maturity of the instruments, quoted market prices or interest rates which fluctuate with market rates.

F-9

The Company defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).

●

Level 1 – Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

●

Level 2 – Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability.

●

Level 3 – Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.

The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared.

NOTES PAYABLE

Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently carried at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the income statement over the period of the borrowings using the effective interest method.

ACCOUNTING FOR DERIVATIVES LIABILITIES

The Company evaluates stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of ASC Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity’s Own Equity. The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income or other expense.

Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date. The Company determined that none of the Company’s financial instruments meet the criteria for derivative accounting as of December 31, 2020 and 2019.

EQUITY INSTRUMENTS ISSUED TO EMPLOYEES OR NON-EMPLOYEES FOR AQUIRING GOODS OR SERVICES

The stock-based compensation expense for both employee and non-employee awards is generally recognized on a straight-line basis over the requisite service period of the award. The Company accounts for stock-based compensation to employees in conformity with the provisions of ASC Topic 718, Stock Based Compensation. Stock-based compensation to employees consisting of stock option grants and restricted shares are recognized in the statement of operations based on their fair values at the date of grant. The Company accounts for equity instruments issued to non-employees in accordance with the provisions of ASC Topic 718, based upon the fair-value of the underlying instrument.

F-10

BASIC AND DILUTED NET GAIN (LOSS) PER SHARE

The Company computes loss per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement.

Basic net income (loss) per share is calculated by dividing net (loss) by the weighted-average common shares outstanding. Diluted net income per share is calculated by dividing net income by the weighted-average common shares outstanding during the period using the treasury stock method or the two-class method, whichever is more dilutive. As the Company incurred net losses for the year ended December 31, 2020 no potentially dilutive securities were included in the calculation of diluted earnings per share as the impact would have been anti-dilutive.

Therefore, basic and dilutive net (loss) per share were the same as of December 31, 2020 and 2019.

REVENUE RECOGNITION

As of January 1, 2018, the Company adopted ASU No. 201409, “Revenue from Contracts with Customers” (ASC 606). Under the new guidance, an entity will recognize revenue to depict the transfer of promised goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. A five-step model has been introduced for an entity to apply when recognizing revenue. The new guidance also includes enhanced disclosure requirements. The guidance was effective January 1, 2018 and was applied on a modified retrospective basis. The adoption did not have an impact on the Company's financial statements. All of the revenues of the Company are the Company's wholly owned Canadian subsidiary, which sells nutritional supplements through Amazon.com and Amazon.ca.

In Canada, governmental regulations require that companies recognize revenues upon completion of the work by issuing an invoice and remitting the applicable sales taxes (GST and QST) to the appropriate government agency. The Company’s wholly owned Canadian subsidiary's revenue recognition policy is in compliance with these local regulations.

F-11

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

In December 2019, the FASB issued ASU 2019-12 “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.” This guidance removes certain exceptions to the general principles in Topic 740 and provides consistent application of U.S. GAAP by clarifying and amending existing guidance. The effective date of the new guidance for public companies is for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the timing of adoption and impact of the updated guidance on its financial statements.

LEGAL FEES

During the years ended December 31, 2020 and 2019, the legal fees incurred were related to services provided to the Company to assist with its regulatory requirements with the Securities and Exchange Commission, patenting costs and one ongoing litigation.

DATE OF MANAGEMENT’S REVIEW

Subsequent events have been evaluated through March 29, 2021, which is the date the Financial Statements were available to be issued.

Note 3 – Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. In the course of its life, the Company has had limited operations and Working Capital deficit. This raises substantial doubt about the Company’s ability to continue as a going concern. The Company believes it can raise capital through equity sales and borrowing to fund its operations. Management believes this will contribute toward its subsequent profitability. The accompanying Financial Statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

F-12

Note 4 – Patents

The following is a summary of the patents held by the Company at December 31, 2020 and 2019:

In December 2015, the Company acquired all worldwide issued (US Patent Number 8,236,935, and US Patent Number 10,272,065) and pending patents under PCT/FR2007/000697 and PCT/CA2014/000029 for the Adva-27a anticancer compound from Advanomics Corporation, a related party, in exchange for an aggregate of 803,264 shares of Common Stock valued at $835,394 and terminated the License Agreement. In 2016, the remaining value of these patents was impaired. The Company is however continuing development of the Adva-27a anticancer drug covered by these patents.

Note 5 – Capital Stock

The Company’s authorized capital is comprised of 3,000,000,000 shares of $0.001 par value Common Stock and 30,000,000 shares of $0.10 par value Preferred Stock, to have such rights and preferences as the Directors of the Company have or may assign from time to time. Out of the authorized Preferred Stock, the Company had designated 850,000 shares as Series “A” Preferred Stock (“Series A”). At December 31, 2020 and December 31, 2019, the Company had no issued and outstanding shares of Series A. On June 17, 2020, the Company filed an amendment to its Articles of Incorporation (the “Amendment”) eliminating the Series A shares and the designation thereof, which shares were returned to the status of undesignated shares of Preferred Stock. In addition to eliminating the Series A shares, the Amendment also increased the number of authorized Series B Preferred Shares from Five Hundred Thousand (500,000) to One Million (1,000,000) shares.

During the year ended December 31, 2015, the Company authorized 500,000 shares of $0.10 par value Series “B” Preferred Stock (“Series B”). The Series B Preferred Stock is non-convertible, non-redeemable and non-retractable. It has superior liquidation rights to the Common Stock at $0.10 per share and gives the holder the right to 1,000 votes per share. All shares of the Series B Preferred Stock are held by the CEO of the Company.

On June 17, 2020, the Company issued Five Hundred Thousand (500,000) shares of Series “B” Preferred Stock in favor of the Company’s CEO, in consideration for the COVID-19 treatment technology he developed. This issuance brought the total number of Series B Preferred Stock held by the Company’s CEO to 1,000,000 shares.

Through December 31, 2020 and December 31, 2019, the Company has issued and outstanding a total of 346,419,296 and 35,319,990 shares of Common Stock, respectively. Through the same periods, the Company has issued and outstanding a total of -0- and -0- shares of Series A Preferred Stock and 1,000,000 and 500,000 shares of Series B Preferred Stock, respectively.

During the fiscal year ended December 31, 2020, the Company issued an aggregate of 311,098,985 shares of its Common Stock valued at $2,515,015 in connection with the conversion of $415,269 in debt and interest of $ 42,233 resulting in a $2,057,513 loss on conversion.

During the fiscal year ended December 31, 2019, the Company issued an aggregate of 31,037,370 shares of its Common Stock as follows:

●

9,150,000 shares valued at $204,300 as compensation to the Company’s Directors and Officers

●

1,455,000 shares for services rendered to the Company by third parties valued at $57,390

●

20,432,370 shares valued at $717,726 in connection with the conversion of $385,778 in debt and interest of $6,689 resulting in a $314,751 loss on conversion

The Company has declared no dividends since inception.

F-13

Note 6 – Earnings Per Share

The following table sets forth the computation of basic and diluted net income per share for the years ended December 31:

	2020	2019

Net gain (loss) attributable to Common Stock	$(2,784,091)	$(1,660,291)
Basic weighted average outstanding shares of Common Stock	204,096,338	10,392,813
Dilutive effects of common share equivalents	-0-	-0-
Dilutive weighted average outstanding shares of Common Stock	204,096,338	10,932,813
Net gain (loss) per share attributable to Common Stock	$(0.01)	$(0.15)

Note 7 – Income Taxes

The Company files a United States federal income tax return and a Canadian branch return on a calendar year basis. The Company and its wholly-owned subsidiaries, Sunshine Biopharma Canada Inc., have not generated taxable income since inception.

Deferred income taxes arise from the temporary differences between financial statement and income tax recognition of net operating losses and other items. These loss carryovers are limited under the Internal Revenue Code should a significant change in ownership occur. The Company accounts for income taxes pursuant to ASC 740, “Accounting for Income Taxes”, which requires, among other things, an asset and liability approach to calculating deferred income taxes. The components of the deferred income tax assets and liabilities arising under ASC No. 740 were as follows:

	December 31, 2020		December 31, 2019
	Amount	Tax Effect	Amount	Tax Effect

Deferred tax assets:
Net operating loss	$2,784,091	$683,773	$1,660,291	$407,767
Other differences	$26,786	$6,579	$(686,984)	$(168,723)
Net deferred tax assets	$2,810,877	$690,352	$973,307	$239,044
Valuation allowance	$(2,810,877)	$(690,352)	$(973,307)	$(239,044)

Total deferred tax asset	$-0-	$-0-	$-0-	$-0-

Deferred tax liabilities:	$-0-	$-0-	$-0-	$-0-
Net deferred tax asset	$-0-	$-0-	$-0-	$-0-

Deferred income taxes arise from the temporary differences between financial statement and income tax recognition of net operating losses. These loss carryovers are limited under the Internal Revenue Code should a significant change in ownership occur.

As of December 31, 2020, the Company had net operating loss carry forwards of $10,611,921 that may be available to reduce future years’ taxable income through 2037 and $5,329,161 may be available to reduce future years’ taxable income indefinitely. At December 31, 2020 and December 31, 2019, a deferred tax asset at each date of approximately $690,352 and $239,044, respectively, resulting from the loss carryforwards has been offset by a 100% valuation allowance. The change in the valuation allowance for the period ended December 31, 2020 and December 31, 2019 was approximately $(451,307) and $149,054, respectively.

F-14

A reconciliation of the U.S. statutory federal income tax rate to the effective tax rate is as follows:

	December 31, 2020	December 31, 2019

U.S. Federal statutory graduated income tax rate	21.00%	21.00%
State income tax rate, net of federal benefit	3.56%	3.56%

Net income tax rate	24.56%	24.56%

Net operating loss used	0.00%	0.00%

Net operating loss for which no tax benefit is currently available	0.00%	0.00%

Canada Federal statutory rate	15.00%	15.00%
Canada Provincial rate	11.80%	11.80%

Net Canada rate	26.80%	26.80%

Net operating loss used (Canada)	0.00%	0.00%
Net operating loss for which no tax benefit is currently available (Canada)	-26.80%	-26.80%

The Company’s income tax filings are subject to audit by various taxation authorities. The Company’s open audit periods are 2018, 2019, and 2020, although, the statute of limitations for the 2018 tax year will expire effective October 15, 2020. In evaluating the Company’s provisions and accruals, future taxable income, and reversal of temporary differences, interpretations and tax planning strategies are considered. The Company believes its estimates are appropriate based on current facts and circumstances.

Note 8 – Notes Payable

The Company’s Notes Payable at December 31, 2020 consisted of the following:

On April 1, 2017, the Company received monies in exchange for a Note Payable having a Face Value of $100,000 Canadian ($74,970 US at September 30, 2020) with interest payable quarterly at 9%, which Note was due April 1, 2019. The Note is convertible any time after issuance into $0.001 par value Common Stock at a price of $0.015 Canadian (approximately $0.011 US) per share. The Company estimates that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion. In June 2018, the Company filed an action in the Superior Court of the Province of Quebec in the District of Montreal (Canada) against the holder of this Note. The complaint alleges among other things, claims of misrepresentations and misleading conduct resulting in damages to the Company in an amount of approximately $200,000 Canadian (approximately $143,000 US). A date for the hearings to commence was set for November 16, 2020. On November 10, 2020, the Company elected to pay off the Note together with accrued interest of $14,696 Canadian (approximately $10,500 US) and terminate the proceedings.

F-15

On September 10, 2018, the Company issued two Notes Payable having an aggregate Face Value of $36,500 with interest accruing at 8%. The two Notes were issued for services rendered to the Company and had maturity dates in June 2019. The Company was unable to pay the notes and on November 30, 2019 the Company issued a new Note which included accrued interest and accelerated interest of $7,059 for a total Face Value of $43,559. The new Note accrues interest at 8% and is convertible after 180 days from issuance into Common Stock at a price 35% below market value. The new Note was due August 31, 2020. During the year ended December 31, 2020, the entire principal amount of $43,559 of this Note plus accrued interest of $2,523 was converted into 14,198,048 shares of Common Stock valued at $86,685 resulting in a loss of $40,603.

On December 24, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $87,000 with interest accruing at 8% was due December 24, 2019. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. As of December 31, 2020, the entire principal amount of $87,000 of this Note plus accrued interest of $9,639 was converted into 43,986,317 shares of Common Stock valued at $276,396 resulting in a loss of $161,036.

On January 8, 2019, the Company received monies in exchange for a Note Payable having a Face Value of $54,000 with interest accruing at 8% was due January 8, 2020. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. During the year ended December 31, 2020, the entire principal amount of $54,000 of this Note plus accrued interest of $9,814 was converted into 44,931,640 shares of Common Stock valued at $365,787 resulting in a loss of $301,973.

On February 5, 2019, the Company received monies in exchange for a Note Payable having a Face Value of $37,450 with interest accruing at 8% was due October 10, 2019. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. During the year ended December 31, 2020, the entire principal amount of $37,450 of this Note plus accrued interest of $2,996 was converted into 38,263,409 shares of Common Stock valued at $217,971 resulting in a loss of $182,790.

On July 2, 2019, the Company received monies in exchange for a Note Payable having a Face Value of $40,000 with interest accruing at 8% was due April 30, 2020. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. During the year ended December 31, 2020, the entire principal amount of $40,000 of this Note plus accrued interest of $1,600 was converted into 13,099,359 shares of Common Stock valued at $58,684 resulting in a loss of $17,084.

On July 26, 2019, the Company received monies in exchange for a Note Payable having a Face Value of $50,000 with interest accruing at 8%, which became due July 26, 2020. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. During the year ended December 31, 2020, the entire principal of $50,000 of this Note plus accrued interest of $4,909 was converted into 43,522,363 shares of Common Stock valued at $131,370 resulting in a loss of $76,461.

On September 12, 2019, the Company received monies in exchange for a Note Payable having a Face Value of $43,000 with interest accruing at 8% is due July 15, 2020. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. During the year ended December 31, 2020, the entire principal amount of $43,000 of this Note plus accrued interest of $1,720 was converted into 38,855,726 shares of Common Stock valued at $117,177 resulting in a loss of $72,457.

On December 14, 2019, the Company received monies in exchange for a Note Payable having a Face Value of $42,800 with interest accruing at 8% and which is due December 14, 2020. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. During the year ended December 31, 2020, the entire principal amount of $42,800 of this Note plus accrued interest of $1,712 was converted into 18,592,605 shares of Common Stock valued at $81,796 resulting in a loss of $37,284.

A Note Payable dated December 31, 2019 having a Face Value of $30,120 and accruing interest at 12% was due December 31, 2020. On December 1, 2020, the Company paid off the entire principal balance of this Note, together with accrued interest of $3,614 by issuing cash payment of $33,734.

A Note Payable dated December 31, 2018 having a Face Value of $136,744 and accruing interest at 12% was due December 31, 2019. On October 1, 2019, the holder of this note requested to convert $30,000 in principal amount into 1,500,000 shares of Common Stock, leaving a principal balance $106,744. On December 31, 2019, the Company renewed the remaining principal balance of this Note, together with accrued interest of $15,509 for a 12-month period. The new Note has a Face Value of $122,253 and accrues interest at 12%. This Note matures on December 31, 2020. On August 27, 2020, the holder of this Note transferred all of its interest therein to a third party and on September 4, 2020, the Company agreed to render the Note convertible at $0.001 per share. During the year ended December 31, 2020, an aggregate principal amount of $58,225 of this Note plus accrued interest of $9,775 was converted into 68,000,000 shares of Common Stock valued at $1,286,400 resulting in a loss of $1,218,400. This note is currently past due and the Company is in discussion with the holder to extend the due date.

F-16

On April 17, 2020, the Company’s Canadian subsidiary received a CEBA Loan (Canada Emergency Business Account Loan) from CIBC (Canadian Imperial Bank of Commerce) in the principal amount of $40,000 Canadian ($29,352 US) as part of the Canadian government’s COVID-19 relief program. The CEBA Loan is non-interest bearing if repaid on or before December 31, 2022 (the “Termination Date”). The CEBA Loan is considered repaid in full if the borrower repays 75% of the Principal Amount on or before the Termination Date. If the CEBA Loan is not repaid in full on or before the Termination Date, the lender will automatically extend the term of the loan by three years until December 31, 2025 (the “Extension Period”). During the Extension Period, interest will be charged, and will accrue on the outstanding amount of the CEBA Loan at a fixed rate of 5% per year, calculated daily and compounded monthly. The outstanding balance of the CEBA Loan and all accrued interest will be due at the end of the Extension Period.

On April 27, 2020, the Company received a Paycheck Protection Program loan ("PPP Loan") in the principal amount of $50,655 from the US Small Business Administration (“SBA”) as part of the US government’s COVID-19 relief program. This loan accrues interest at the rate of 1% per annum. The Company is obligated to make payments of principal and interest totaling $2,133 each month commencing on November 27, 2020, with any remaining balances due and payable on or before April 27, 2022. The proceeds derived from this loan may only be used for payroll costs, interest on mortgages, rent and utilities (“Admissible Expenses”). In addition, the Paycheck Protection Program provides for conditional loan forgiveness if the Company utilizes at least 75% of the proceeds from the loan to pay Admissible Expenses. On December 15, 2020, the Company applied to the funding bank for forgiveness of this loan per SBA guidance. On December 18, 2020, the Company received notification that the funding bank has approved forgiveness of the loan in its entirety and that it has submitted a request to the SBA for final approval. On February 22, 2021, the funding bank informed the Company that the SBA has fully forgiven the loan.

On June 1, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $42,000 with interest accruing at 8% is due June 1, 2021. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. On December 2, 2020, the Company paid off the entire principal balance of this Note, together with accrued interest and prepayment penalties of $13,435 by issuing payment of $55,435.

On June 9, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $37,000 with interest accruing at 8% is due June 9, 2021. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. On December 2, 2020, the Company paid off the entire principal balance of this Note, together with accrued interest and prepayment penalties of $11,779 by issuing payment of $48,779.

On July 7, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $48,000 with interest accruing at 8% is due July 7, 2021. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. The Company will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on January 3, 2021 which is 180 days after the issuance date.

On July 27, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $102,000 with interest accruing at 8% is due July 27, 2021. The Note is convertible after 180 days from issuance into Common Stock at a price 30% below market value. The Company will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on January 23, 2021 which is 180 days after the issuance date.

On August 14, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $67,000 with interest accruing at 8% is due August 14, 2021. The Note is convertible after 180 days from issuance into Common Stock at a price 30% below market value. The Company will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on February 10, 2021 which is 180 days after the issuance date.

On September 14, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $250,000 with interest accruing at 5% is due September 14, 2022. The Note is convertible after 180 days from issuance into Common Stock at a price equal to $0.30 per share. The Company will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on March 13, 2021 which is 180 days after the issuance date.

On September 24, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $50,000 with interest accruing at 5% is due September 24, 2022. The Note is convertible after 180 days from issuance into Common Stock at a price equal to $0.30 per share. The Company will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on March 23, 2021 which is 180 days after the issuance date.

F-17

On October 20, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $250,000 with interest accruing at 5% is due October 20, 2022. The Note is convertible after 180 days from issuance into Common Stock at a price equal to $0.30 per share. The Company will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on April 18, 2021 which is 180 days after the issuance date.

On November 19, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $250,000 with interest accruing at 8% is due August 19, 2021. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. The Company will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on May 18, 2021 which is 180 days after the issuance date.

On November 24, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $260,000 with interest accruing at 8% is due November 24, 2021. The Note is convertible after 180 days from issuance into Common Stock at a price 30% below market value. The Company will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on May 23, 2021 which is 180 days after the issuance date.

On November 25, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $250,000 with interest accruing at 5% is due November 25, 2022. The Note is convertible after 180 days from issuance into Common Stock at a price equal to $0.30 per share. The Company will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on May 24, 2021 which is 180 days after the issuance date.

On December 2, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $104,215 with interest accruing at 5% is due December 2, 2022. The Note is convertible after 180 days from issuance into Common Stock at a price equal to $0.30 per share. The Company will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on May 31, 2021 which is 180 days after the issuance date.

At December 31, 2020 and December 31, 2019, total accrued interest on Notes Payable was $24,320 and $21,077, respectively.

Note 9 – Notes Payable - Related Party

Outstanding Notes Payable at December 31, 2020 held by related parties consist of the following:

A Note Payable dated December 31, 2019 held by the CEO of the Company having a Face Value of $128,269 and accruing interest at 12% was due December 31, 2020. On December 31, 2020, the Company renewed the Note together with accrued interest of $15,392 for a 12-month period. The new Note has a face Value of $143,661, accrues interest at 12% per annum, and has a maturity date of December 31, 2021.

Note 10 – Related Party Transactions

In addition to the transactions specified under Note 9 above, during the period ended December 31, 2020, the Directors and Officers of the Company were paid $221,930 in cash. Of this amount, $177,000 was paid to Advanomics Corporation (now known as TRT Pharma Inc.), a company controlled by the CEO of the Company. In addition, during the period ended December 31, 2020, the Company issued to its CEO 500,000 shares of Series B Preferred Stock valued at $50,000.

For the period ended December 31, 2019, the Company issued to the Board of Directors 1,950,000 shares of Common Stock valued at $74,100, 3,300,000 shares of Common Stock valued at $99,000, and 3,900,000 shares of Common Stock valued at $31,200. The Company also issued 550,000 shares of Common Stock valued at $16,500 to the CFO for consulting services rendered to the Company in 2019. During the year ended December 31, 2019 the Directors and officers were paid $72,916 in cash. Of this amount, $28,000 was paid to Advanomics Corporation, a company controlled by the CEO of the Company.

F-18

Note 11 – Acquisition and Disposition of Atlas Pharma Inc.

On January 1, 2018 the Company acquired all of the issued and outstanding shares of Atlas Pharma Inc. (“Atlas”), a privately held Canadian company providing analytical chemistry testing services (“Atlas Business”). The purchase price for the shares was $848,000 Canadian ($676,748 US). The purchase price included cash payment of $100,500 Canadian ($80,289 US), plus the issuance of 50,000 shares of the Company’s Common Stock valued at $238,000, and a promissory note in the principal amount of $450,000 Canadian ($358,407 US), with interest payable at the rate of 3% per annum (“Atlas Note”). The following table summarizes the allocation of the purchase price as of the acquisition date:

Cash	$4,942
Accounts receivable	$79,508
Prepaids	$1,428
Property and equipment	$62,990
Goodwill	$665,697
Liabilities assumed ($172,899 Canadian)	$(137,817)

Total consideration	$676,748

Effective April 1, 2019, the Company disposed of Atlas by re-assigning all of its stock in Atlas back to the original owner in exchange for the Atlas Note. As a consequence of the sale, the operating results and the assets and liabilities of the discontinued Atlas Business are presented separately in the Company's financial statements. Summarized financial information for the discontinued Atlas Business is shown below. Prior period balances have been reclassified to present the operations of the Atlas Business as discontinued operations.

Discontinued Operations Income Statement:

	Audited December 31, 2020	Audited December 31, 2019

Revenues	$0	$119,522
Cost of revenues	0	81,920
Gross profit	0	37,602

General and administrative expenses	0	36,196
Gain (Loss) from operations	0	1,406
Other income (expense) – Interest	0)	(3,518)
Net Income (Loss) from operations	0)	(2,112)

Loss on Disposal	0	(580,125)

Net Income (Loss) from Discontinued Operations	0	(582,237)

F-19

The individual assets and liabilities of the discontinued Atlas Business are in the captions "Assets of Discontinued Operation" and "Liabilities of Discontinued Operation" in the Consolidated Balance Sheet. The carrying amounts of the major classes of assets and liabilities included part of the discontinued business are presented in the following table:

Discontinued Operations Balance Sheets:

	Audited December 31, 2020	Audited December 31, 2019
ASSETS
Current Assets:
Cash and cash equivalents	$-	$-
Accounts receivable	-	-
Total Current Assets	-	-

Equipment (net of $ 0 and $34,959 depreciation)	-	-
Goodwill	-	-

TOTAL ASSETS	$-	$-

LIABILITIES

Current Liabilities:
Notes payable	-	-
Notes payable - related party	-	-
Related party advances	-	-
Accounts payable & accrued expenses	-	-
Total Current Liabilities	-	-

TOTAL LIABILITIES	$-	$-

Discontinued Operations Cash Flows:

Cash flows used in discontinued operations for the period ended December 31, 2020 and 2019 were $-0-and $8,510, respectively. There were no cash flows used in or provided by investing or financing activities during those periods.

Note 12 – Leases

The Company's arrangement in connection with its office space located in Pointe-Claire, Quebec, Canada has no short-term or long-term asset or liability value.

Note 13 – Subsequent Events

On January 5, 2021, the Company paid off a Note Payable dated July 7, 2020 by issuing cash payment in the amount of $63,271 comprised of $48,000 in principal and $15,271 in accrued interest and prepayment penalties.

On January 12, 2021, the Company received monies in exchange for a Note Payable having a Face Value of $150,000 with interest accruing at 5%. The Note is convertible after 180 days from issuance into Common Stock at a price equal to $0.30 per share.

On January 12 and 28, and on March 3, 2021, the holder of a Note Payable dated December 31, 2019 elected to convert a total of $53,000 in principal into 53,000,000 shares of Common Stock leaving a principal balance of $11,028.

On January 27, 2021, the Company received monies in exchange for a Note Payable having a Face Value of $300,000 with interest accruing at 5%. The Note is convertible after 180 days from issuance into Common Stock at a price equal to $0.50 per share.

On January 29, 2021, the holder of a Note Payable dated July 27, 2020 elected to convert the entire principal amount of $102,000 and accrued interest of $4,171 into 5,044,456 shares of Common Stock leaving a balance of $-0-.

On February 12, 2021, the Company received monies in exchange for a Note Payable having a Face Value of $700,000 with interest accruing at 5%. The Note is convertible after 180 days from issuance into Common Stock at a price equal to $0.60 per share.

On February 22, 2021, the holder of a Note Payable dated August 14, 2020 elected to convert the entire principal amount of $67,000 and accrued interest of $2,680 into 542,173 shares of Common Stock leaving a balance of $-0-.

On February 22, 2021, the funding bank informed the Company that the SBA has fully forgiven the Company's PPP Loan dated April 27, 2020 in the amount of $50,655.

F-20

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None

ITEM 9A. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

Disclosure Controls and Procedures – Our management, with the participation of our Chief Executive Officer, Chief Financial Officer, and Chief Operations Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) as of the end of the period covered by this Report.

These controls are designed to ensure that information required to be disclosed in the reports we file or submit pursuant to the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission, and that such information is accumulated and communicated to our management, including our CEO and CFO, to allow timely decisions regarding required disclosure.

Based on this evaluation, our management, including our CEO and CFO, concluded that our disclosure controls and procedures were not effective as of December 31, 2020, at reasonable assurance level, for the following reasons:

●

ineffective control environment and lack of qualified full-time CFO who has SEC experience to focus on our financial affairs;

●

lack of qualified and sufficient personnel, and processes to adequately and timely identify making any and all required public disclosures;

●

deficiencies in the period-end reporting process and accounting policies;

●

inadequate internal controls over the application of new accounting principles or the application of existing accounting principles to new transactions;

●

inadequate internal controls relating to the authorization, recognition, capture, and review of transactions, facts, circumstances, and events that could have a material impact on the company’s financial reporting process;

●

deficient revenue recognition policies;

●

inadequate internal controls with respect to inventory tracking and transactions; and

●

improper and lack of timely accounting for accruals such as prepaid expenses, accounts payable and accrued liabilities.

Our Board of Directors has assigned a priority to the short-term and long-term improvement of our internal control over financial reporting. We are reviewing various potential solutions to remedy the processes that would eliminate the issues that may arise due to the absence of separation of duties within the financial reporting functions. Additionally, the Board of Directors will work with management to continuously review controls and procedures to identified deficiencies and implement remediation within our internal controls over financial reporting and our disclosure controls and procedures.

We believe that our financial statements presented in this annual report on Form 10-K fairly present, in all material respects, our financial position, results of operations, and cash flows for all periods presented herein.

Inherent Limitations – Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdown can occur because of simple error or mistake. In particular, many of our current processes rely upon manual reviews and processes to ensure that neither human error nor system weakness has resulted in erroneous reporting of financial data.

Changes in Internal Control over Financial Reporting – There were no changes in our internal control over financial reporting during our fiscal year ended December 31, 2020, which were identified in conjunction with management’s evaluation required by paragraph (d) of Rules 13a-15 and 15d-15 under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

This Annual Report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit us to provide only management’s report in this Annual Report.

Management Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Exchange Act. Those rules define internal control over financial reporting as a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:

●

Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company;

●

Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and the receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the Company; and

●

Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisitions, use or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal controls over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Management assessed the effectiveness of our internal control over financial reporting as of December 31, 2020. In making this assessment, our management used the criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

Based on an assessment carried out in December 2019, management believes that, as of December 31, 2020, our internal control over financial reporting were ineffective based in part on the issues discussed above.

ITEM 9B. OTHER INFORMATION

None.

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

Following is a list of our officers and directors:

Name	Age	Position(s)

Dr. Steve N. Slilaty	68	President, Chief Executive Officer and Chairman

Dr. Abderrazzak Merzouki	57	Chief Operating Officer and Director

Camille Sebaaly	60	Chief Financial Officer, Secretary and Director

Our directors serve as directors until our next Annual Meeting of Stockholders and the election and qualification of the director’s respective successor or until the director’s earlier death, removal or resignation.

Following is biographical information of our current management:

Dr. Steve N. Slilaty was appointed as our CEO and Chairman of our Board of Directors on October 15, 2009. Dr. Slilaty is an accomplished scientist and business executive. His scientific publications are widely cited. Sunshine Biopharma is the third in a line of biotechnology companies that Dr. Slilaty founded and managed. The first, Quantum Biotechnologies Inc. later known as Qbiogene Inc., was founded in 1991 and is now a member of a family of companies owned by MP Biomedicals, one of the largest international suppliers of biotechnology reagents and other research products. The second company which Dr. Slilaty founded, Genomics One Corporation, conducted an initial public offering of its capital stock in 1999 and, on the basis of its ownership of Dr. Slilaty’s patented TrueBlue® Technology, Genomics One became one of the key participants in the Human Genome Project and reached a market cap of $1 billion in 2000. Formerly, Dr. Slilaty was a research team leader at the Biotechnology Research Institute (Montreal), a division of the National Research Council of Canada. Dr. Slilaty is one of the pioneers of Gene Therapy having developed the first gene delivery system applicable to humans in 1983 [Science 220: 725-727 (1983)]. Dr. Slilaty's other distinguished scientific career accomplishments was the discovery of a new class of enzymes, the S24 Family of Proteases (IUBMB Enzyme: EC 3.4.21.88) [Proc. Natl. Acad. Sci. U.S.A. 84: 3987-3991 (1987)]. In addition, Dr. Slilaty (i) developed the first site-directed mutagenesis system applicable to double-stranded DNA [Analyt. Biochem. 185: 194-200 (1990)], (ii) cloned the gene for the first yeast-lytic enzyme (lytic b-1,3-glucanase) [J. Biol. Chem. 266: 1058-1063 (1991)], (iii) developed a new molecular strategy for increasing the rate of enzyme reactions [Protein Engineering 4: 919-922 (1991)], and (iv) constructed a powerful new cloning system for genomic sequencing (TrueBlue® Technology) [Gene 213: 83-91 (1998)]. Most recently, Dr. Slilaty, in collaboration with Institut National des Sciences Appliquée (France), State University of New York at Binghamton (USA) and École Polytechnique, Université de Montréal (Canada), designed, patented, and advanced the development the first, and currently the only known anticancer compound (Adva-27a) capable of destroying multidrug resistant cancer cells [Anticancer Res. 32: 4423 (2011) and US Patent Numbers: 8,236,935 and 10,272,065]. These and other works of Dr. Slilaty are cited in research papers, editorials, review articles and textbooks. Dr. Slilaty is the author of 18 original research papers and 10 issued and pending. These and other works of Dr. Slilaty are cited in research papers, editorials, review articles and textbooks. Dr. Slilaty received his Ph.D. degree in Molecular Biology from the University of Arizona in 1983 and Bachelor of Science degree in Genetics and Biochemistry from Cornell University in 1976. Dr. Slilaty has received research grants from the NIH and NSF and he is the recipient of the 1981 University of Arizona Foundation award for Meritorious Performance in Teaching. He devotes approximately 50% of his time to our business affairs.

Dr. Abderrazzak Merzouki was appointed as a Director and our Chief Operating Officer in February 2016. In addition to his new positions with our Company, since January 2016 he has been self-employed as a consultant in the fields of biotechnology and pharmacology. From July 2007 through December 2016, Dr. Merzouki worked at the Institute of Biomedical Engineering in the Department of Chemical Engineering at Ecole Polytechnique de Montreal, where he taught and acted as a senior scientist involved in the research and development of plasmid and siRNA-based therapies. Dr. Merzouki is a molecular biologist and an immunologist with extensive experience in the area of gene therapy where he performed several preclinical studies for pharmaceutical companies involving the use of adenoviral vectors for cancer therapy and plasmid vectors for the treatment of peripheral arterial occlusions. Dr. Merzouki also has extensive expertise in the design of expression vectors, and production and purification of recombinant proteins. He developed technologies for production of biogeneric therapeutic proteins for the treatment of various diseases including cancer, diabetes, hepatitis and multiple sclerosis. Dr. Merzouki obtained his Ph.D. in Virology and Immunology from Institut Armand-Frappier in Quebec and received his post-doctoral training at the University of British Columbia and the BC Center for Excellence in HIV/AIDS research. Dr. Merzouki has over 30 publications and 70 communications in various, highly respected scientific journals in the field of cellular and molecular biology. He will devote approximately 50% of his time to our business affairs.

Camille Sebaaly was appointed as our Chief Financial Officer, Secretary and a Director of our Company on October 15, 2009. Since 2001, Mr. Sebaaly has been self-employed as a business consultant, primarily in the biotechnology and biopharmaceutical sectors. He held a number of senior executive positions in various areas including, financial management, business development, project management and finance. As an executive and an entrepreneur, he combines expertise in strategic planning and finance with strong skills in business development and deal structure and negotiations. In addition, Mr. Sebaaly worked in operations, general management, investor relations, marketing and business development with emphasis on international business and marketing of advanced technologies including hydrogen generation and energy saving. In the area of marketing, Mr. Sebaaly has evaluated market demands and opportunities, created strategic marketing and business development plans, designed marketing communications and launched market penetration programs. Mr. Sebaaly graduated from State University of New York at Buffalo with an Electrical and Computer Engineering Degree in 1987. He devotes approximately 50% of his time to our business affairs.

There are no family relationships between any of our officers and directors.

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Securities Exchange Act of 1934 (the “34 Act”) requires our officers and directors and persons owning more than ten percent of the Common Stock, to file initial reports of ownership and changes in ownership with the Securities and Exchange Commission (“SEC”). Additionally, Item 405 of Regulation S-K under the 34 Act requires us to identify in our Form 10-K and proxy statement those individuals for whom one of the above referenced reports was not filed on a timely basis during the most recent year or prior years. To our best knowledge, all reports that were required to be filed were filed, though some were filed late.

Code of Ethics

Our board of directors adopted a code of ethics on April 15, 2020. A copy of the same is available on our website at www.sunshinebiopharma.com.

Committees of the Board of Directors

There are no committees of the Board of Directors but it is anticipated that we will establish an audit committee, nominating committee and governance committee once independent directors are appointed, which is expected to occur at such time as financing for our drug development program is secured, of which there are no assurances.

ITEM 11. EXECUTIVE COMPENSATION

The following table sets forth information concerning all cash and non-cash compensation awarded to, earned by or paid to our executive officers. We do not currently have an established policy to provide compensation to members of our Board of Directors for their services in that capacity, although we may choose to adopt a policy in the future.

SUMMARY COMPENSATION TABLE

Name and Principal Position	Year		Salary ($)		Bonus ($)		Stock Awards ($)		All Other Compensation ($)		Total ($)

Dr. Steve N. Slilaty
Chief Executive Officer and Director
		2018		85,000(4)		-		200,100(1)		-		285,100
		2019		28,000(4)		-		68,100(2)		-		96,100
		2020		177,000(4)		-		50,000(3)		-		227,000

Camille Sebaaly(6)
Chief Financial Officer and Director		2018		37,500		-		200,100(1)		-		237,600
		2019		25,000		-		68,100(2)		-		93,100
		2020		20,000		-		-		-		20,000

Dr. Abderrazzak Merzouki
Chief Operating Officer and Director		2018		32,415		-		200,100(1)		-		232,515
		2019		19,916		-		68,100(2)		-		88,016
		2020		24,930		-		-		-		24,930

(1)

In 2018, each member of our Board of Directors was issued 67,500 and 95,000 shares of our Common Stock valued at $143,100 and $57,000, respectively.

(2)

In 2019, each member of our Board of Directors was issued 650,000, 1,100,000 and 1,300,000 shares of our Common Stock valued at $24,700, $33,000 and $10,400, respectively.

(3)

In consideration for services valued at $50,000, our CEO was issued 500,000 shares of Series “B” Preferred Stock having 1,000 votes per share. The Series “B” Preferred Stock is non-convertible, non-redeemable, non-retractable and has a stated value of $0.10 per share. This issuance brought the total of Series “B” Preferred Stock held by our CEO to 1,000,000 shares.

(4)

These amounts were paid to Advanomics Corporation (now known as TRT Pharma Inc.), a company controlled by our CEO.

Executive compensation and salaries are established by our Board of Directors. We currently do not have a Compensation Committee but expect to have one in place in the future once we are able to secure adequate funding for our operations.

Employment Agreements

None of our executive officers is party to an employment agreement with us.

Stock Plan

We have not adopted any stock option or other employee compensation plans as of the date of this Report. We may adopt such plans in the future.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The following table sets forth certain information regarding the ownership of Common Stock and Preferred Stock voting with the Common Stock as of the date of this Report by (i) each person known to us to own more than 5% of our outstanding Common Stock as of the date of this Report, (ii) each of our directors, (iii) each of our executive officers, and (iv) all of our directors and executive officers as a group. Unless otherwise indicated, all shares are owned directly and the indicated person has sole voting and investment power. The information provided is based upon 465,005,925 Common Shares and 1,000,000 Series B Preferred Shares issued and outstanding as of the date of this Report.

Title of Class	Name and Address of Beneficial Owner	Amount and Nature of Beneficial Ownership	Percent of Common Class	Percent of Voting Shares

Common	Dr. Steve N. Slilaty(1) 579 Rue Lajeunesse Laval, Quebec Canada H7X 3K4	24,204,670(2)	5.21%	1.65%
Series B Preferred		1,000,000(3)	100%	68.26%

Common	Camille Sebaaly(1) 14464 Gouin West, #B Montreal, Quebec Canada H9H 1B1	23,893,086	5.14%	1.63%

Common	Dr. Abderrazzak Merzouki(1) 731 Place de l’Eeau Vive Laval, Quebec Canada H7Y 2E1	23,343,975	5.02%	1.59%

Common	All Officers and Directors As Group (3 persons)	71,441,731	15.36%	73.14%

Series B Preferred		1,000,000(3)	100%	68.26%

(1)

Officer and Director.

(2)

Includes 861,209 shares held in the name of Advanomics Corporation (now known as TRT Pharma Inc.). Dr. Slilaty is an officer, director and principal shareholder of TRT Pharma Inc. and, as a result, controls the disposition of these shares.

(3)

The Series B Preferred shares entitle the holder to 1,000 votes per share. The Series “B” Preferred Stock is non-convertible, non-redeemable, non-retractable and has a superior liquidation value of $0.10 per share.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE

Related Party Transactions

A Note Payable dated December 31, 2019 held by our CEO having a Face Value of $128,269 and accruing interest at 12% was due December 31, 2020. On December 31, 2020, we renewed this Note together with accrued interest of $15,392 for a 12-month period. The new Note has a Face Value of $143,661, accrues interest at 12% per annum, and has a maturity date of December 31, 2021.

On January 1, 2018, as part of the acquisition of Atlas Pharma Inc., we issued a Note Payable in the amount of $450,000 Canadian (approximately $358,407 US). The Note was nonconvertible and accrued interest at the rate of 3% per annum. Payments on this note were $10,000 Canadian (approximately $7,800 US) per quarter. Post-acquisition, the holder of this Note stayed on as a director and officer of Atlas Pharma Inc. We disposed of Atlas Pharma Inc. on April 1, 2019 in exchange for this Note.

During the period ended December 31, 2020, our Directors and Officers were paid $221,930 in cash. Of this amount, $177,000 was paid to Advanomics Corporation (now known as TRT Pharma Inc.), a company controlled by our CEO. In addition, during the period ended December 31, 2020, we issued to our CEO 500,000 shares of Series B Preferred Stock valued at $50,000. This issuance brought the total number of Series B Preferred Stock held by our CEO to 1,000,000 shares.

During the year ended December 31, 2019, we issued to our Board of Directors 1,950,000 shares of Common Stock valued at $74,100, 3,300,000 shares of Common Stock valued at $99,000, and 3,900,000 shares of Common Stock valued at $31,200. We also issued 550,000 shares of Common Stock valued at $16,500 to our CFO for consulting services rendered to us in 2019. During the year ended December 31, 2019, our Directors and Officers were paid $72,916 in cash. Of this amount, $28,000 was paid to Advanomics Corporation, a company controlled by our CEO.

There are no other related party transactions that are required to be disclosed pursuant to Regulation S-K promulgated under the Securities Act of 1933, as amended.

Director Independence

None of our current directors are deemed “independent” pursuant to SEC rules.

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

Fees Paid to Independent Registered Public Accounting Firms

The following table presents fees for professional audit services rendered by B F Borgers CPA PC, our independent auditors, during our fiscal years ended December 31, 2020 and 2019:

	December 31, 2020	December 31, 2019
Audit Fees	$64,800	$64,800
Tax Fees	-	-
All Other Fees	-	-
Total	$64,800	$64,800

Audit Fees. Consist of amounts billed for professional services rendered for the audit of our annual financial statements included in our Annual Reports on Forms 10-K for our fiscal years ended December 31, 2020 and 2019 and for reviews of our interim financial statements included in our Quarterly Reports on Form 10-Q.

Tax Fees. Consists of amounts billed for professional services rendered for tax return preparation, tax planning and tax advice.

All Other Fees. Consists of amounts billed for services other than Audit Fees.

We do not have an audit committee and as a result our entire Board of Directors performs the duties of an audit committee. Our Board of Directors evaluates the scope and cost of the engagement of an auditor before the auditor renders audit and non-audit services.

PART IV

ITEM 15. EXHIBITS, FINANCIAL STATEMENTS SCHEDULES

The following exhibits are included herewith:

Exhibit No.		Description

14		Code of Ethics

31.1		Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2		Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350

101.INS	XBRL Instances Document

101.SCH	XBRL Taxonomy Extension Schema Document

101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF	XBRL Taxonomy Extension Definition Linkbase Document

101.LAB	XBRL Taxonomy Extension Label Linkbase Document

101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

Following are a list of exhibits which we previously filed in other reports which we filed with the SEC, including the Exhibit No., description of the exhibit and the identity of the Report where the exhibit was filed.

No.	Description	Filed With	Date
3.1	Articles of Incorporation	Form SB-2 Registration Statement	October 19, 2007
3.2	Bylaws	Form SB-2 Registration Statement	October 19, 2007
3.3	Articles of Amendment (Name Change)	Form 8-K Dated November 2, 2009	November 6, 2009
3.4	Statement of Share and Equity Capital Exchange	Form 10-Q For Quarter Ended 06/30/10	August 4, 2010
3.5	Articles of Amendment (Add Preferred and Series A Preferred to Authorized)	Form 10-Q For Quarter Ended 06/30/10	August 4, 2010
10.1	Share Exchange Agreement with Sunshine Biopharma, Inc.	Form 8-K Dated October 15, 2009	October 20, 2009
10.2	License Agreement with Advanomics, Inc.	Form 8-K/A1 Dated October 15, 2009	January 19, 2010
10.3	Amendment No. 1 to License Agreement with Advanomics, Inc.	Form 8-K/A1 Dated October 15, 2009	January 19, 2010
10.4	Research Agreement with The Research Foundation of the State University of New York	Form 8-K Dated January 17, 2011	January 19, 2011
10.5	Research Agreement with Jewish General Hospital	Form 8-K Dated June 14, 2011	June 17, 2011
10.6	Amendment No. 2 to License Agreement with Advanomics	Form 8-K Dated December 21, 2011	December 27, 2011
10.7	Investment Agreement with Dutchess Investment Group II	Form 8-K dated April 28, 2014	April 28, 2014
10.8	Registration Rights Agreement with Dutchess Investment Group II	“	“
10.9	Patent Purchase Agreement with Advanomics Corporation	Form 8-K dated October 8, 2016	October 9, 2016
10.10	Second Patent Purchase Agreement with Advanomics Corporation	Form 8-K dated December 28, 2015	December 28, 2015
10.11	Amendment No. 1 to Patent Purchase Agreement with Advanomics Corporation dated October 8, 2016, including Secured Convertible Promissory Note.	Form 8-K dated March 14, 2016	March 14, 2016
10.12	Amendment No. 1 to Patent Purchase Agreement with Advanomics Corporation dated December 28, 2016, including Secured Convertible Promissory Note	Form 8-K dated March 14, 2016	March 14, 2016

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Annual Report to be signed on its behalf by the undersigned thereunder duly authorized.

	SUNSHINE BIOPHARMA, INC.

Dated: March 30, 2021	By:	/s/ Dr. Steve N. Slilaty
		Dr. Steve N. Slilaty, Principal Executive Officer


		/s/ Camille Sebaaly
		Camille Sebaaly, Principal Financial and Accounting Officer

In accordance with the Exchange Act, this Annual Report has been signed below by the following persons on behalf of the registrant and in the capacities indicated on March 30, 2021.

s/ Dr. Steve N. Slilaty

Dr. Steve N. Slilaty, Director

s/ Camille Sebaaly

Camille Sebaaly, Director

s/ Dr. Abderrazzak Merzouki

Dr. Abderrazzak Merzouki, Director

EX-31.1 2 sbfm_ex311.htm CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF THE SARBANES-OXLY ACT OF 2002 sbfm_ex311

Exhibit 31.1

CERTIFICATION PURSUANT TO

18 USC, SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

I, Steve N. Slilaty, certify that:

1. I have reviewed this annual report on Form 10-K of Sunshine Biopharma, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedure to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: March 30, 2021	s/ Steve N. Slilaty
	Steve N. Slilaty, Chief Executive Officer

EX-31.2 3 sbfm_ex312.htm CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF THE SARBANES-OXLY ACT OF 2002 sbfm_ex312

Exhibit 31.2

CERTIFICATION PURSUANT TO

18 USC, SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

I, Camille Sebaaly, certify that:

1. I have reviewed this annual report on Form 10-K of Sunshine Biopharma, Inc.;

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: March 30, 2021	s/ Camille Sebaaly
	Camille Sebaaly, Chief Financial Officer

EX-32.1 4 sbfm_ex32.htm CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 sbfm_ex32

Exhibit 32

CERTIFICATION PURSUANT TO

18 USC, SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this annual report of Sunshine Biopharma, Inc. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2020 as filed with the Securities and Exchange Commission on March 30, 2021, (the “Report”), we, the undersigned, in the capacities and on the date indicated below, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:

The Report fully complies with the requirements of Rule 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: March 30, 2021	s/ Steve N. Slilaty
	Steve N. Slilaty, Chief Executive Officer

Dated: March 30, 2021	/s/ Camille Sebaaly
	Camille Sebaaly, Chief Financial Officer

GRAPHIC 5 sbfm_10k1.jpg IMAGE begin 644 sbfm_10k1.jpg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end GRAPHIC 6 sbfm_10k2.jpg IMAGE begin 644 sbfm_10k2.jpg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end GRAPHIC 7 sbfm_10k3.jpg IMAGE begin 644 sbfm_10k3.jpg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sbfm_10k4.jpg IMAGE begin 644 sbfm_10k4.jpg M_]C_X 02D9)1@ ! 0$ E@"6 #_VP!# ," @," @,# P,$ P,$!0@%!00$ M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_ MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04%!3_P 1" #) 6D# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#J?V"OV"O@ M3\:?V3_ WC+QEX&_MCQ)J7V[[7>_VO?P>9Y=_<1)\D4ZH,)&@X49QD\DFOH# M_AUQ^S%_T3/_ ,K^J?\ R31_P2X_Y,3^&7_<3_\ 3I=U]54 ?*O_ ZX_9B_ MZ)G_ .5_5/\ Y)H_X=A>(/VE;/PKXE\2:1J&BL[:3: M?:EDL+Z*X9V,RPQQ2JO^I=V==H8GC).,5N:7\7=0UCPGXGO8/#!77_#MT]I? MZ/+?HJ@JBR%DF"D,"C CY1Z<5M[&:7,UH8JM!RY4]3R'_AUQ^S%_T3/_ ,K^ MJ?\ R31_PZX_9B_Z)G_Y7]4_^2:]5\,?M :3=>!]$\2^*K=?"5OK4:3V<;RM M=CRG"[7D=(]L?+ ?-P/6LI?VG-%72/&7F+%%K^A2:HMOI;.X%XMF"Q*R;=NX MJ Q4$D YQ3]A4NU;82KTVD[[_KL>?_\ #KC]F+_HF?\ Y7]4_P#DFC_AUQ^S M%_T3/_ROZI_\DUZS=?M&>#-.T>>>[U)3JEMIIU";3;='D?*P"9X48+M:0*0= MH.0.2 *V/!_QH\*^-I-(M]/O91J.I6,>H)8RVTJR11N"5\SY<(3M;&2-V"5R M.:3HU$KN+&JU.5DI(\._X=RL=)_M'4KQF.Z%Y)-L$:CIE@DK'/91ZUA^&?CC! MKNAW'BF\THZ-X%Q(;;7;N[3=.%D\L'R -P#MG;R2>.!D4O9RM>P_:1O:YY+_ M ,.N/V8O^B9_^5_5/_DFC_AUQ^S%_P!$S_\ *_JG_P DU[-=?M"?#ZQT^WO9 M_$<44,WG[5:WF\Q?)V^<'CV;D*;E)# 8!STYIX^/O@!K*2Z7Q'"T,=U'9_+# M*6:62,R1JJ[,MO525*@AL<$T>RJ?RO[@]K3_ )E]YXM_PZX_9B_Z)G_Y7]4_ M^2:/^'7'[,7_ $3/_P K^J?_ "37J7B3]I3P1INDF33/$.GWNIS6!U&TMIVE MC22(%@6=Q&WE@%'!R,@KC&:T;S]H;X?Z;>365WXBACO8&DCEACMYGQ)&H:1% M(3YF4$':,G'.,4_8U/Y6+VU/^9'CG_#KC]F+_HF?_E?U3_Y)H_X=*M TBSU;3IX=1B^T37DDY5(HVB,D(!V[2\@RP4 MD':I/I78>$?&>C^/-'35=#NS>Z>[;4F\IXPW .0'4$@@@@C@YX-3*G.*NT5& MI"3LF?.'_#KC]F+_ *)G_P"5_5/_ ))H_P"'7'[,7_1,_P#ROZI_\DU]545F M:'RK_P .N/V8O^B9_P#E?U3_ .2:/^'7'[,7_1,__*_JG_R37U510!\J_P## MKC]F+_HF?_E?U3_Y)H_X=!F@#Y6_X=6R3>&$\0V\[3J4ED:%IOL><<2;$8@]#M/I71]7JZZ;?\ !_R9S?6* M3MKO_P #_-'&_P##KC]F+_HF?_E?U3_Y)H_X=P M^./C98?#_P '>'/%FK6$T7AS4O*-[?*X/]FK+'NC=UQEE+;4)'0L*YC5/VFF MT%?#T6J>#]0L]1\2V45QH=D9U9[R=Y0OV8D+B.14=)#G@*6_NFE&A4ELO+YC MEB*<=WTO\CA?^'7'[,7_ $3/_P K^J?_ "31_P .N/V8O^B9_P#E?U3_ .2: M].C^/WVCXD7/@&'PW7C=LF=61/?;G[PJ;4?V MCGT/6M#T+5?"-]8^(=?MK2XTC3_M"N;II6Q-&6 PC0*0SY['BG]7J[6_K_@= M>W47UBE:_-_7_!Z=^AY]_P .N/V8O^B9_P#E?U3_ .2:/^'7'[,7_1,__*_J MG_R37JGAWX\1^(?B9<> TT"Z@\06-Q.-1C:4%+6T55,-UNQ\RS;U"@-/#>D^&K/2KFVU'3Y+J9M0B=V#+)M &UAQBNBA1GB)JG#/-61XQ'E44;5"HJ@ >E?GDO_ 4R M^*C?\POPW_X#2_\ QRIT_P""EGQ2;KI?AS_P&E_^.5Z[R[&./([6/&CFF"4N M=7N?9?BK]E/2?%/A7PSH$NOZA'9:)I8TI5:*.59$!0B4*P(27* ;UYP2.]/O MOV6].U.;45N_$>I36%Q+J5U!9^7$%MKB]C:*20,%W-A&.U2<9)-?'$?_ 4F M^*#?\PSP[_X#2_\ QRID_P""D'Q/;_F&>'O_ 'E_P#CE5]1QW==?QW)^OX" M][/I^&Q]B:/^RKX;T;5=3N([CS;;4()8Y5ELH&N$DEM_(D>.X*^8@*\[0<9) M[<5J^'_@*FC^)/"FLS^(KN[N/#]D+*,Q6T5N]TBH419G0 N@4CY#QN&[BOBQ M?^"C/Q-;_F&>'O\ P'E_^+J9?^"BGQ,;_F&^'_\ P'E_^+I/ XU[M?U_PY4< M=@8JR3/NGX:^";_0;[Q?K&N&&35=?U1[@B)RZQVJ*(K>+) Z(N3[NU3PO%XJU*/PU;SK=Z58^3"6T^9)Q/&PD*[I%1QPK<8X.:^1%_X*'?$IO^ M8;H'_@/)_P#%U,O_ 4(^)#8_P")=H/_ (#R?_%U*R_%IW5NGX;?<5_:.#:L M[]?QW/K6+]FW3FFO+R[UR^N]4U"VU*&^O#'&GGO>QQQNX4#";%B4*HX] M*/V<;S^UM!OO#NMRVMU;WVEM/<3*A,,-G;30JZ*5(9F\P94\=>E?,Z?\% OB M.W73M!_\!Y/_ (NIH_V_/B*W73]"_P"_$G_Q=4L#C4[W1#QV"::LSZAL?V7- M$T_P]K^E1ZQ?N-:TA-+NKB14,A(GFF>8<8W,\S<= *U[7X Z9:ZE;7BZI>% MX-3U#4U7:N"]U;^0Z].BCD>]?)\?[>OQ#;KI^A_]^)/_ (NIX_V[OB$W73]# M_P"_$G_Q=)X#&RO=K4I8_!::/3R/HKPS^R?X>\*:U8ZA:7OGM#;V\ MXD:2&'RDE21T+1';C(7@D=LFN\^%/PQ@^%>AWFG0:C/J"W-V]V5=%BAA+ #9 M#$ORQI\N=J\9)/>OD!/VZ/'[8S8:)_WXD_\ BZGC_;@\>M_RX:+_ -^)/_BZ M)8#&S34F@AC\%3LXIJQ]W45\,1_MM>/&ZV.C?]^9/_BZL1_MI>.6ZV.C_P#? ME_\ XNL/[*Q/E]YO_:V&\_N/M^BOBB/]LOQNW6RT?_OR_P#\75B/]L3QLW6R MTC_OR_\ \51_96)\OO%_:^&\_N/L^BOCA/VO/&C#_CRTG_OT_P#\54\?[6WC M%NMGI7_?I_\ XJG_ &3B?+[Q?VQA?/[C[ HKY'C_ &KO&#?\N>E_]^G_ /BJ MLQ_M2^+6ZVFF?]^G_P#BJ/[)Q/E]XO[8PO=_*R.;33?^_;__ M !5+_P -.^*_^?33?^_;_P#Q5/\ LC$^7WB_MG"]W]Q]345\L_\ #3OBO_GT MTW_OV_\ \51_PT[XK_Y]--_[]O\ _%4?V1B?+[P_MK"=W]Q]345\L_\ #3OB MO_GTTW_OV_\ \51_PT[XK_Y]--_[]O\ _%4?V1B?+[P_MK"=W]Q]345\L_\ M#3OBO_GTTW_OV_\ \51_PT[XK_Y]--_[]O\ _%4?V1B?+[P_MK"=W]Q]34AY MXKY:_P"&G?%?_/IIO_?M_P#XJC_AIWQ7_P ^FF_]^W_^*I?V1B?+[P_MK"=W M]QW_ (?_ &:[;2[&QL=0\2ZAJ^GZ7'>)I5J\,426C7(=7D.T9D<+(P4L>,GB MHM2_97T'5/!NH>'YM5OE6XTS3].AO$"":V:T1T29#C&YA(P8=""1WKA?^&G? M%?\ SZ:;_P!^W_\ BJ/^&G?%?_/IIO\ W[?_ .*KH^H8[NCG_M+ =G]Q[-XN M^#.D^./#_AOP]J]Q-=>'M)V^?IK >7?[(O+C$OLI^? ZL!Z5R5Y^R_8ZK8Z7 M'J?B?5M0O=$LH;30[^38)M-:*42"=#CYI"%1&8]53'(+Z'Q?)=RRR:J(T)>V>'RA:%#QY285U'9AGN:R[']E?1M'TF_TK3==U2Q MTW5[6WM]:A0J3J4D';R_N[ MKP;;7MU>VWAU@HMX3,A"(".=D3,[QC^$L/[HHN?V:;34[C3=0U/Q/JFHZ]H\ M%E!I.K2*@EL?L[;F90!AFFZ2$_>'%\GVZLZ#]K#_DUGXR?]B9K/_I#-7\UE?TI_M8?\FL_&3_L3-9_](9J_FLK MQCW#]_O^"7'_ "8G\,O^XG_Z=+NOG_\ X*G M\5/ P'4Z/,!_P!_Z^@/^"7' M_)B?PR_[B?\ Z=+NO ?^"I7_ "5CP%_V"9/_ $H%>OE7^]+T?Y'BYQ_NDO5? MF>!0?LM?%62-9%\&W11E#*WGP\@\C^.L#Q?\+/%?P]N;"W\0Z+/IL]_N%K&S M([2D$ @!">0ZI)J,X8P);1L]NEMCR MW5^1N)[GTKSKXT^-M7TS4O@SXP\3"&^N8WFOWM8(/)VQAXODP>K<$YXYK\SR M?CW.LPS*CA&J%12BVXP4HSYG2G4C%/VDXZ\MFY6:_E5T98S)<+A\/.JN=-.R M;LU9246]D^O2_KN>;WG[,_Q&TGP[-K-UH'EVL,)N)8_M,9FCC R6,>J_ [Q?\ $#Q;XHU;1+.UGL?[7NHM MTUY'$VY9#D;6.>]?09%Q]3QLHSS2=.A3=&G-MRLE.4ZD'&[=M.3X?B3NFW8Y M,9DKHIK#J4Y*;5K=.5.^GKOLS@O!_@G7/'>H26.@:=)J5U%'YKQQE5VID#)+ M$#J14&HZ7=Z'J=SI]_ UK>VLABFA?JC#J#7O'PGT_6?AM\&=;\2:9IES>^(- M3U&.SMX[2%IG6&*3YS\H/RDAQGZ5)\=/!=O>?&+PAJ\EHZ:9XG>V%Q"X*'?N M574]P2I7WZUT4..'+/:^!J1C]7BJB@T_?E.C&,JB:O:VLE'17<):F!1U:AZBOIFS\(_#B'XMWGP\3PFTS31M(VHS7#%H6V M!@D8[*!WSG-<=\._#%I;_P!M6D'P\N/&M]9ZA+ U[//Y5LD2MA5';?PLHNW,[.- MKJRC=_)'D<57[&VFO+B."WB>>>0[4CC4LS'T '6OH/4OA#X1M?B[H5K/:#3] M.U'3GNO[+>;"&X4C]WNSTYZ \XI=-MM*\/\ Q4\-V][\/I/#NH23O%#)!<[K M=CQLE4_Q$#.1_M5P2\2,'6H.I@]O+3?2]KG@\UK-8W#P7$,D$\;;7BD4JRGT(/2IH:]WO=+\ M,>./CM-HTNAO')&]P;Z=K@D73A 58 ?=Q4&A>&?!7C+Q5+IUAI4UGIOAZ*:2 M\G9_GOMI &>XY#5U1X_H4Z*GBL)5BU2C5G90:BI\R@KJ>KG*-HI:^\G*UI64 MLCFYN-*K%^\X+>[:M?IT3U]':^E_&H:N0UZMI>G^%/B?X=\1?V9X?7P_J&EP MFXMY8I2PD7!QN'X<_6KOA_3_ 7J7@.^U^[\,R:=;6L?E1S273,;F;;CY!G^ M]_GBNFKQS2PZ<:V"JJI&I&G*'[MRC*:BX?\ +RTE)2NN3F:M+F2L8PR>51KD MJQ<6FT_>LU'?[.EO.VZL>4P]*Z/PGX7O?%M^]G8>7YR1M*?-;:-HQ^O-=C)I M_ASX=^&="FU+1%UW4=4C\^0RR%5B3@X7\Q78^&_"UAX;^(:3:6&CL-0TE[A( M6.?+.1D#VZ5XV;^($:6!K5<%1E%N,W2G)1<*GLY*,[)2YE:]US*-UJCHPN2. M=:$:LD]8\R5[I2VZ6^YNQXF@VY!Z@XJU#7I/A3P7;6_A.'5SH?\ PD5_>3-M M@>4(D488C/7KQ^M9/Q)\,V?AW5+)[*(VT5Y!YK6I;=Y3 X(S^-?2Y;QMEN9Y MO+)Z*?,G-)WA9NF[37*I.<>MG*,5*SLV>=B,GKX?"_6I/31VUVEMK:S\TG=7 MU.:AZU>A[51AZU>A[5^AGSS+B_=I:1?NTM42PHHHH$%%%% !1110 4444 %% M%% !1110 4444 %%%% !7IG[.?\ R5.S_P"O6?\ ]!%>9UZ9^SG_ ,E3L_\ MKUG_ /017'C/]WJ>C.[ _P"]4_5?F>Q?M8?\FL_&3_L3-9_](9J_FLK^E/\ M:P_Y-9^,G_8F:S_Z0S5_-97YV?II^_W_ 2X_P"3$_AE_P!Q/_TZ7=?/_P#P M5.)7XJ>!B.HT>4C_ +_U] ?\$N/^3$_AE_W$_P#TZ7=?/_\ P5._Y*EX'_[ MTW_H^O7RK_>H_/\ (\7./]SEZK\SPN#]K#XJQQHB^*G"(H51]D@X &!_!5&Z M^,VK>./%GA_4/B Y\5Z9IDC;[(HD)>-\;U!0#G@'GTKS*.M?0=(N?$&LV&EV M:&2[O9TMXE'=F8 ?SKL_U;R'!*6(HX2G2:4O?A",)1334FIQ2E'1O5-,^3_M M#&U;0G5E)::-MI]M'HSZ'\-__"6WUK4? .E:]/X@U*V-LBZJRB"V4\]0 M26 .#Z\5!IOQD^'^M_"WPSX3\7Z!K6H2:/N?S+&=(T=R6R>N<8;I5GXC? O0 MKZ\\,6_A*VFTB.36'\-W]QH? N&QCLKFW\5VE_ M9/JDFCW=Q;V4S&VN$4MM" %I <8!4=?SK\OP=#A7'4X8FI6KJO.7/S2E4]JG M"-2G%.4+I>ZIJ,;WE?JV?557F=%NG&$.1*UDERZV;T>^J5WTMV.VC_::T_\ MX6%X3OH=!FL/"GANWEM[73X9 TQW1[ Q)XX Q]>:\@\4>(#KOBC6=3M6GMH M+Z[EN$C+D%0S$@'!QGFO1U_9FOO[3@3^VU&GRZ<^HK(VGRK=%5<(R"V/SE@2 M#]*LK\&?#MYX.\+M9>("=;U36)=-$[6DHCE(8+MV-@IM!SD]>E>QE>.X1R:I M"MESD^:*IMJ-2227M*MYW6]^=R;O*^ZMJN;$4"+C4/#MCI=F(9\LNZ>3C)XSQU/XUH'X^6^O>#O#=IXBM[ M[4?$.C:K%?+J&4Q)&KY93WW%>.G4"L*\^"%AI/\ :%Q>>-M.72M/G2QN+Z&V MEDVW;$CR0G4X R6ZN.H]:V-)^+GA+6/!VH^ M'_$=KJ]O;MJ(I=-EAT;2(]2:RLX8[=Y5W!5)SC M[B G[QK@QCX,O2=2M.FJ<*:C-.<7%4OX=M.9MQJMJ2BU*+:BF MY2=T[.[DGS7Z*W+JKIID7B7XJ>#/'NNZ,^L:/J=OI=EI[6H6"4>;#)N!5U(/ MS8 QSZU=UWXT:1')X/M-$@U"]L-!NAQ/7T%&U>9IY%,)7<#LVD Y([UI:3X)L/B)KUU!IR1>'/(G^R):VU MO<72N=Q D=^0@Z Y/X5TU\JX=R^M]6Q5.JL/AJ?,FYN=)1JJ<.9*,I5+M.:; MY;+=]&90Q&.K1EI7C9VNTHVT77R\CJ3\4O!VE_$Z#Q;I=IJLSSB9 MKV.8*OS,H"[!GV.>:YWX>_$:/P?XRU'4I;5KG3M1\V.X@!&_RV8L,=LC_&MS M_A5-A?>'_"^G/?6>D:_<7-Y:%FC=S>2HY"C(Z 8ZGU%33?"5M:M?#T=I%'IS MPZ29]1FCB:1Y)/.9.%'+,I?$3P5KGA_3=)N=&U5+2PBVQ0P3*B;L8W'GDYSS M[FLR;X3Z?H7A_7SJFJ*NHVDMN()DC;8$D'RAE]6Z<_=Q6!XP\$GP5-;P2WPN MKB09=5@=%' .5<\.O/4>E=67X#AC-<536'KUI5U.4HU'*HI3?LX7ESI)-*G* M,5>UDVDO>URKULQPU-N<(*%K.-HV2YGI;S:;ZWMY:=A;^./"_B;P_I-CXHM+ MY;K3%\N*:SP1(GH>>. /RK1MOB]:GQD=3>QF338;(V5M;QD;U&0OPWBQV\K26]S9'Y@"2<'GWK%U^;1YKR+^Q1=BV6/#->-EV;/7V&,5SL?W:M MPU]AE_#V%RW%U,5AIS2FY2<.9^SYI.\FH]&WKO:[=DCR:^/JXBE&E42=DE>W MO66RN7H>M7H>U48>M7H>U?4GDLN+]VEI%^[2U1+"BBB@04444 %%%% !1110 M 4444 %6+"PGU.Z2VMTWROT!( XY))/057I0KOE8U9F(/RH"2?RK&MSNE)4I M*,K:-JZ3[M75TNUUZHN%N9(/#L_AR:WCGEBE,T?F Q$D 9Q65 M78_$2)\Z,VQMJV* MM. ?0T>$+IK'PKX@N42-Y8O+9/,4, S*V$C7RCSE@\TE=H M)7: <#.:\"MXC5<+2C/$8-1<[\O[QR5XU'3G?EI.22<6X\L9-K5J.MNZ'#\: MDK4ZU[6O[MM''F6\K;;W:2?5GDE>F?LY_P#)4[/_ *]9_P#T$5R?CC5O[6\0 M2LJND,2B.-9$V''L__ *"*_3J.)K8W*8XG$4_9SG!2 M<;WY6U>U[*[771:GBTZ4*.8*E3ES*,K7VO9_,]B_:P_Y-9^,G_8F:S_Z0S5_ M-97]*?[6'_)K/QD_[$S6?_2&:OYK*^-/T0_?[_@EQ_R8G\,O^XG_ .G2[KY_ M_P""IW_)4O __8&F_P#1]?0'_!+C_DQ/X9?]Q/\ ].EW7S__ ,%3O^2I>!_^ MP--_Z/KU\J_WJ/S_ "/%SC_J_,^,(ZZOX>>,9?A_XNL/$%O9P7UU8EGAC MN"=@* M=$CN(]2G/BD-=P7L/]JW,DAMI8GW H<\ ]"/2K'A/]H#6?"9?[)IUE(7UB?5 MV\TM]Z6,HT8P>!ACAAR*V=*N+SXU>-M6\.Z[9V>E:'HSW5ZRZ7IL<-Q;Q0!O M]'1@!]X ?>SR,UJ:%\&?!7B'P[;>*X)=:M-"GTJ\O39221MG6OS#%5.',+STLRP*A.IR\T87E&\HRY(W7*N9Q4G912T=W=IOZNG',*C3P] M:ZC>S>CT:3[Z)R77KMO;&F_:"FOM0T>YG\+Z?(-(B:.S7[5<;XR9 ^[S-^XG M(PA@E8@NH ."IQCGFNCG^#?@F\A6+ M3IM;@OK[PV_B*T^T21M';JBY\I\#+D\\\8JUJ7P3\(C4->T:PFU>/5=+TRUU M8W%PZ&W9)-FZ(<9S\QPWX=JXH8[@_P!V#PTUIU4_=BY*+=^;1.52TK?%=WNM M35TJW_P#:5R< MZ:T;YO=E/;W1X;,*<6O:JRO>]K?:NMG>R4O35+?7G9/C5JVJ_:#!HEBFMZA% M%;WNI6R.9[N.,@[=N<+G:,D#M4]Q\;+K6)-135M"T_4K6ZOFU".WD>1!;RE0 MK;64@E2!T-=YI/PET+X=:EJM_=^)GTNWDO'TNVNI+A('BA:-69LE&W/AL8&W M@'GFN*U3X=Z!;^ ;K5=&O)O$%[:LWVJYM[A%2V EVJ7A(W%67!W@]31@<9PK MC*L8X?#/D$[6XMTTZWN MHI;[^T4\UI$V2_\ 2-R^QXKJ/@_X1T31]2\"ZE>_;;G5]:DGEM_*V_9X5CR MN'!&6)Y^G%9UC]E^(6I)82:5PKTLPS+* M,SQ&(I8G"<]&G&//-RY;J,ZL(J*;5[5%**=U?FE?1+FYJ&'Q-"G"<*MI2;LD MK[J+U_[==]GLNNR6WQLO$>TE?1-.GN;.XGNK6>3>6@EE8L6'/.,]#3;3XN:C MY$%MV@L38W$,I8?:%\PR;R0]7]+^"^F?\ "17VEW2WQ@%\UI;WYN8HEQL# !#\ MTC#/(%>0\RX+C1EB?8/EMSIZJ^TVX7DFG'VG-:-GS2;BG*]NOZOFSFH<^NWY MK739\MM>BUT.1L_B +>'5K4:)8MINH>46LV:0I&T?W6!SDGUR>:EUOQH_B33 M=/TO[)!IFG6LID"PL\F"V Q!8D@8_A'%=)H7@/08;72[Q!<:U)%=QQW_ ),Z M*MNQEV;'B(W;3Q\W>KFL>&?"KWGB[49X+ZT@T[4%M%M[5DPSONZ#'RKG'T K MTH9OD-/'%QKHVG4BD^GEK-ZI M;:/1/?0YCQMKEMKNO;K L=,M8([6TW*5/EHN,X[9.363#7>77@#1;.35],22 M^?5-)LTO)IV*B&8':611C(X; /K5R;P/H$1,XV1@XP M&YR?2O6P'%&48+"T<+AXU'!12C[NK7+!Q;UO[_/"SM\4DI%K./P_J#Z>TBV^KV$+QI=8+PDS!2 M"1U'O67XL\*Z)H-K,EGJ*R:A;SB)[=I@[..[%0!L(/;FNS <9X#'8SZE",N9 MRY5[K?V8-N6GNVE+DZJZO>QSULIK4:/MFU:U]_6UN]TK].VYS4/6KT/:J,/6 MKT/:OT ^?9<7[M+2+]VEJB6%%%% @HHHH **** "BBB@ HHHH *GLKZXTZX6 MXM96@F7.V1.HS4%%95:5.O3E2JQ4HR5FFKII[IIZ-%1E*#4HNS1I7GB75=1M MVM[J_FGA8@F-B,'%58=0N;>UGMHIF2"?'FQ@\/CIFJ]%<='+<%AJ2H4*$(P3 MYN51BES*S3LE:Z:33WND;3Q%:I+GG-M[7;=[=O0M-JEW)':QM<.4M3F!<\1\ MYXKI--\:1?V:UMJ!OA<--YK75G*$>3MAOPKD:*\K,^&\LS:E&CB*22B[IQ]U MIZMZKHVVVG=-ZVOJ=.'S#$86;G"6ZMKK_7EY:;&SXJ\0#Q)J27"PF%(XQ$H8 MY8@=V/F?LY_\E3L_P#KUG_]!%=<,#A\LRQ8 M+"QY:=.'+%:NR2TU>OWFE&O4Q..C6JN\I23?WGL7[6'_ ":S\9/^Q,UG_P!( M9J_FLK^E/]K#_DUGXR?]B9K/_I#-7\UE?%'Z,?O]_P $N/\ DQ/X9?\ <3_] M.EW7S_\ \%3O^2I>!_\ L#3?^CZ^@/\ @EQ_R8G\,O\ N)_^G2[K1_:L_9U\ M+_&CQ5H>HZ]<:E#/963V\0L9EC4J7W'.5/.:X\7G^"X9I/,LPO[..CLKO71: M>IR8K ULPI/#T+/'A',UK:/W_\ ^6)OCQX]OKRTNI/$,J7-K)YR20PQ1EWV[=TFU1YAVDC MYL\&FWGQ@\7ZK=7$USK#,9[)].:-88TC%NYRR*@4*N3W !KZL7]B+P O2]UW M_P "H_\ XW4B_L4> EZ7FN?^!2?_ !NO$AXG>'M)IT\-9I65J$597O9?/7U/ M0_U?SR7Q5/\ R=GR=;_$KQ+#+;2)J;![?36TB(^6GRVAX,?3T[]?>NU^(OQX MUCQ=>RP:3=W.G:"\-LGV.1(]Y:)5R"P!)7O[&?@5?^7S6O_ I/_B*QJ>)7A_5Q%/%3H2U]TXJSW6M MMV7'(<[C3E34U9[^]\ORW^78^6?^%C>(I-2UJ_;46-WK.T7\GEI^^VL&7C&! M@J#QCI4]Y\0/$&JKJZW6H-*-8N([J^_=J/.EC^XW XQ[8KZC7]CKP,O_ "]Z MU_X%)_\ $5(O['_@A>EWK/\ X$I_\17;'Q6X$BU*-%W5O^72^SRVZ].6-NW+ M&VR,O]7,X::<]_[SZWO]]W][[GSG:_&+QA!=7MP-8+R7DBRS++!'(AD50H<* MRD*P R .E13?$;Q%?:&^CS:D6T^3B2-8D5I!NW;6<# MEWK'_@2G_P 14B_LF>"UZ76L?^!*?_$5C#Q0\/Z MX'!J/P[XNU?PW>75SIUWY$MTI6<-&KK("Q?[WX_W,?>UO[W\VNNM]=2? M]7>GIV/G[4OB!K^NQ3QW^H-<)<212R@QJ-S1C"'@=A6Q:_%CQ M7#<33+JS>;--]H9FAC.), %ERORY .,9KVU?V8?"*]+G5?_ (3_P"(J1?V M9_":]+G5/^_Z_P#Q%82\3O#ZI35*>&O%;+V,;+9;>B2^2[%K(,[4N95-?\;\ M_P#-_>SPM_'VOW6G+8OJ#"W#*V(XT1F*MN7+ 9(!Y )JSJ7C?6M>@NH;Z\\Z M.Z:-YAY2+O9,[2< <\GZU[>O[-WA5>EQJ?\ W_7_ .)J5?V=O#"]+C4O^_R_ M_$UK#Q2X"IR4X4&FG=-48IIMIW];I._=+LB'P]G4E:4[K;XGM_3?WL\;_P"$ M_P#$%Q8QVLFI.\,>SJB[F"G*AFQE@,=":OM\0_$%Q>QW;WX%RNX>8D$:E@V M0V%^8<=#FO65_9]\-+TGU'_O\O\ \34B_ 3PXO2?4/\ O\O_ ,36'_$3/#S_ M *!>_P#RXC]KXOOZ]^I7]@9Y_P _.WVWTV^[H>22>,-8O#'EZ3W_\ MW^7_ .)J1?@GH*])K[_OZO\ \3733\5. J4X5*=!J4/A:HQ36B6CZ:)+3HDN MB,I<.9U)-.>CW]]Z_P!7/'(>M7H>U>M+\&]#7I->_P#?U?\ XFI5^$>BKTEO M/^_B_P#Q->M_Q&OA/^:I_P" ?\$X_P#5',^T?O\ ^ >6+]VEKUK_\ "K-'_P">MW_W\'^%'_"K-'_YZW?_ '\'^%'_ !&OA/\ FJ?^ ?\ M!#_5#,^T?O\ ^ >445ZO_P *LT?_ )ZW?_?P?X4?\*LT?_GK=_\ ?P?X4?\ M$:^$_P":I_X!_P $/]4,S[1^_P#X!Y117J__ JS1_\ GK=_]_!_A1_PJS1_ M^>MW_P!_!_A1_P 1KX3_ )JG_@'_ 0_U0S/M'[_ /@'E%%>K_\ "K-'_P"> MMW_W\'^%'_"K-'_YZW?_ '\'^%'_ !&OA/\ FJ?^ ?\ !#_5#,^T?O\ ^ >4 M45ZO_P *LT?_ )ZW?_?P?X4?\*LT?_GK=_\ ?P?X4?\ $:^$_P":I_X!_P $ M/]4,S[1^_P#X!Y117J__ JS1_\ GK=_]_!_A1_PJS1_^>MW_P!_!_A1_P 1 MKX3_ )JG_@'_ 0_U0S/M'[_ /@'E%%>K_\ "K-'_P">MW_W\'^%'_"K-'_Y MZW?_ '\'^%'_ !&OA/\ FJ?^ ?\ !#_5#,^T?O\ ^ >445ZO_P *LT?_ )ZW M?_?P?X4?\*LT?_GK=_\ ?P?X4?\ $:^$_P":I_X!_P $/]4,S[1^_P#X!Y17 MIG[.?_)4[/\ Z]9__015O_A5FC_\];O_ +^#_"NI^&/@VQ\+^-;"]M'F:5MT M)$K C:PY[#FG_P 1@X7Q[6$HRJ<]2T5>&EY:+KW9M0X6S'#U8UIJ-HN[U['7 M?M8?\FL_&3_L3-9_](9J_FLK^E/]K#_DUGXR?]B9K/\ Z0S5_-97U)[Y^_W_ M 2X_P"3$_AE_P!Q/_TZ7=>Q?% _\32R_P"N)_\ 0J\=_P""7'_)B?PR_P"X MG_Z=+NOJ66UAN&!EACD(X!90:^1XJR*7$>5SRZ%3D(_P"@ MZ/\ X __ )(]S^V8_P GX_\ /"]P]:-P]:]T_L^U_Y]H?\ OV/\*/[/M?\ MGVA_[]C_ H_X@WB/^@Z/_@#_P#D@_MF/\GX_P# /"]P]:-P]:]T_L^U_P"? M:'_OV/\ "C^S[7_GVA_[]C_"C_B#>(_Z#H_^ /\ ^2#^V8_R?C_P#PO(_P"@Z/\ MX __ )(/[9C_ "?C_P \+W#UHW#UKW3^S[7_GVA_P"_8_PH_L^U_P"?:'_O MV/\ "C_B#>(_Z#H_^ /_ .2#^V8_R?C_ , \+W#UHW#UKW3^S[7_ )]H?^_8 M_P */[/M?^?:'_OV/\*/^(-XC_H.C_X _P#Y(/[9C_)^/_ /"]P]:-P]:]T_ ML^U_Y]H?^_8_PH_L^U_Y]H?^_8_PH_X@WB/^@Z/_ ( __D@_MF/\GX_\ \+W M#UHW#UKW3^S[7_GVA_[]C_"C^S[7_GVA_P"_8_PH_P"(-XC_ *#H_P#@#_\ MD@_MF/\ )^/_ #PO(_Z#H_\ @#_^2#^V8_R?C_P#PO(_Z#H_^ /\ ^2#^V8_R?C_P#PO(_P"@Z/\ X __ )(/[9C_ "?C M_P \+W#UHW#UKW3^S[7_GVA_P"_8_PH_L^U_P"?:'_OV/\ "C_B#>(_Z#H_ M^ /_ .2#^V8_R?C_ , \+W#UHW#UKW3^S[7_ )]H?^_8_P */[/M?^?:'_OV M/\*/^(-XC_H.C_X _P#Y(/[9C_)^/_ /"]P]:-P]:]T_L^U_Y]H?^_8_PH_L M^U_Y]H?^_8_PH_X@WB/^@Z/_ ( __D@_MF/\GX_\ \+W#UK5\)D?\))IW_74 M5Z__ &?:_P#/M#_W['^%*EC;1L&6WB5AT94 (KNP'A)7P>+HXEXQ/DE&5N1Z MV:=OB\C.IF\9P<>3==SS']K#_DUGXR?]B9K/_I#-7\UE?TI_M8?\FL_&3_L3 M-9_](9J_FLK^DCYL_?[_ ()18L[VB5_E+CT) (&:XKQ)\% M?$\UC87NE16R:LOB&9KV%Y@JW&F2:B+D$M_?3:KJ#ZL.]7KCP+XT7P?J?PWB MT6W?1;R]GV>)#>ILCLYK@S,&A^^90'9 !\I.#N[5WJ%'1K\_3^O^&.&4ZJ;7 MZ>MOZ_S.HL_C[I%U#XQSI]Y#<>&M06RE@DV@W"-*(EGB.>4+%AZ@H171>//' MS>#[K1=/L]+DUG6-8FDAM+19T@5MD9DNS^)'@6:[T6XM#H5]X^@OK@S^ M3=:I';R:=( ?+>W3^7X_P!?B6+_ M .*GB"Q\9:5X?_X06Y:74H7N(9FU*W4+''Y?FEAG(*F4#'?!Q5&'XY7K>"=6 M\6R^$+J'0[5)&MI?ML+27;+/Y(4(#E,G)RW058\->!_$MGKWP\O=9N5U*XTC M1+JSU*],N6:>3R-O7EO]6V6QSC)ZUYKH_P &=;C^&?BKPO\ \(2NG:MJ*2"3 M5_[4C>.]S>>8!M#Y3*$G.!C&*TC&D[)V_IOS[6_R,W.JKM7_ *2?;O?_ #/3 M/^%WK%:W=K<>'+Z'Q1!J,6E+H2RQ.TT\D7G(5E!V;/+RY8D;0IR,XS+8_&A/ M[072M5T*[TG7%U.VTV:Q:5)0@N%=HIUD4X>,B-AQR"""*Y%OA+KW@W6&NO#> MG0WUEI&NC6M.M9[O;)=1SVSPW,!D?)#(6W(SDC!"Y '%F3P#XJ\5>+8/%FH: M5#I,\FKZ:PTTW22O!9VRSEG=U^4NSS'Y5)P .>M+EI?+3KZ?\'_,;E62??7I MZ_\ _R-[PA\F:[,]OI>HRS13132KOQ&X0YC9@C%=PP<8 MSGBIH_CII8L+L?\ "*1M,Q8J!?1J&#O"<]!)')&<]UKA_#G@;QU)X2\+ M:%>>';?3H_"]U)J:S2:A'(;^>/S3;QH%^XK-(I9G(P!C!S696D\<-NL1G0S!E=0"^+CCYB>')]:;IT;O5+Y_P!?TPC4JZ:- M]]/O[>OR/HR'4(I--2^<^5 T(F)<_=7;GGZ"O--/^/MIJ_P]E\366A7TDZZG M%I::7,Z1S/)+*B0L6)VJKK+&X)_A:I=6M_&'C#X2ZGHJZ$WAK6;F&/34\Z]A MGVPOM268%"1\J%R%/)('K7#ZM\"/$T5QJ6FF_P#^$ET759=(GFEF$5FT!M+A M R!8MO!@4?,.E1"G3NU-K==>G7\"IU*G*G!/9].O3\3N(?C@EU916UOX M=OI?%,FI3:5_8/FQ;EFB022,9L[/+",K;_\ : QGBJ6H?M$V.APV:ZOH-_I] M_P#VRNC:C:,\;FP9HQ()BP.'B*%6W+V)XX-8>G_#'Q-\/]2L+W0])AU:TT#4 M[XV=FUVL\ ML([A939VO]GO;1 L.'D+'<=O R.3C-5RT=^GKKZ?=^.ER>:MMU].G?[_ ,.A MZ#J?Q0LM.^*.C>"!:7%Q>ZA:RW3W497RK<*"55^<[G"OC']VL[P_\8/^$RC\ M3QZ!H5S?7VBW@MDMIIXX1>1DD">-V.-A*R 9YRAKS_1?AG\0--L=+UV\BM+W MQE&;YIW2X 08M#;68#'J#M5V]"[5O?#GX0^)/AOXPT&Z.NMX@TO^QFTF]66" M&W,&PB2%UV &0EC*"3D_/GUI2A2BGKK;[WK_ ,,5[2JVG9ZO[EHO^"7['XZS MS?"^Z\;7GA.]M;7:GV"QCNHIKB^9G*!$"G"MN[&M2X^+RWFIZ%8>']%GUZXU M334U@A+B* 16K,JAAO/SMEONCTY(R*Y#3_A3XNF$_#G0!?+H T1YKZ]O(5B MN2)UW"&-4<%6!\UF)QQM'>N?O/A/XMM/!MMX6'A]=6U+2;J== \7PZC':3V* M-)OCD95PP4!L&-) MH]0CVF)U7 ,&[<"2N/N\5+J'PLU35/'%_=W5G;W&CW?B-;Z1))%.^U_LMK9\ MKZ[SC'IS4O,-#^ .O3S1Z9XGM[?5]&M?$R7$L[: M=?\ /^KF_IW[0D3Z+<7VJ>&K[295TZUU:W@,\4WGVMQ*L:.&4X5@S#*M@^F: MN6_QDU*'Q#K=AJ_A*72+#1+=;O4=1?489$AA99&5PB_,V1&>!R,BO*/#?P'\ M36OA>>TLO#47AAFT6TL+RU?5%N/[1NHIX7$XP2L:JJ2XY!/F8QQ7K'B3X9W_ M (HU+XDPR,EK9^(=)MK&UN-VXB1$F#%E'( +K]>:JI&C%^[_ %MY_P!?@33E M6DES?U^']?B,A^-\UG]FDUWPGJ.A6FH6<]YILTTT4AN/*B:8Q.JG,4AC4L%; MT(SD8K5^'?Q4;QO?-I][H5UH&HG3X-5AAFFCF66VER$<,A(!RI!4X/UKC-:\ M-^.OB/:Z9:ZOX=MM!&C6ETYD^WQSB^NWM)((Q$%&4CS(S$O@]!CK6O\ !_X6 MWGPPUHI!:(FEW^C68NV:X,LD-]"NQT4L2QC93D ':"IP!NJ91I*+[^OK_7_# MCC*JY1[==/3^O^&/6J***XCN"BBB@ HHHH **** "BBB@ HHHH **** "BBB M@#RK]K#_ )-9^,G_ &)FL_\ I#-7\UE?TI_M8?\ )K/QD_[$S6?_ $AFK^:R M@#]_O^"7'_)B?PR_[B?_ *=+NOJJOE7_ ()01S$1?#75O$FJ&(6=Q87MO-KM[IU]+$56 M"Z&I1RVSY(Z-C_@2EJ9X$$^(O&6H>"[V]C\0>"KA_[?N;LV:)'+ \MY&RQ, M9(W7:V&9>.0H(-=WL863OW_6WY?U$K6QN+R M35,06]K<7DC"&0D103>1*0 N3B0[<#D]J2R^,7A:_L_/CO)U<78L&M9K.:.X M6>+[6]M$U[6]&E\1Z==_VQKEB8+QW6VG21678G[E!Y M>&*#EV&3UJO84[7O_5[?D0J]32Z_JU_S/4H?VA/!\UKJ=QYFJ10Z:PCNGFTB MZ01R$H!'S'RY,B84<_-72:)\0M'UZYL;:$W=O=7JS/!;WMG+;R,L14.=KJ" M-Z]>N>*\?\;:%JC?#WXI(+34X6G\4074+V5NSSF%6M"TL*[3NVA&(P#]T\&M M+^WH='U;P7XH#^)-=T*RBU#3[O4;_3)3>QO*8F1I(5A1BG[LKN5,=/K4>R@U M=?U[M^W?0KVTT[2_KWK=^VIW&M?&SPEH/E?:;VXD,DUU!MM;*:&.TELX7N#<-+_ *L(J EMWL*\'/@' MQ5XBN-(FTV75/#%S?CQ%?0W @4/$MQ+$T$^& MEY!H&H:?;:9J>ES7&F6]I+--9QQG:XV*"Y"GO@Y'-/V,/=5]6U?[W_D'MJGO M-K1)V^Y?YG<3?&SPC'HEOJB7UQ<13WO]G+;P64SW(N=A22'^P[2.]OKAHSY4<;AV ##JP6,DC&<%?6LR\^,7A:T\,Z%KZW MD]WIVN8_L]K.SFGDGRA?B-%+#"JQ.1Q@US?Q,N;OQGX%L+7PCI9>X\2:A"DS M7]K-:HL*'?*UQ\F] 4B\OD9.X 5Y[9^#?&4FJ:7X:N?/\/W.G^);R\M]4T.$ MRVUO;W-I-(OEM*F"JRNZ$$<9 [BE"E&4;RT?]7_']1SK2B[1UO\ TOP_-'LM M]\9/"EIIFDWT6H2:DFK1M-90Z;:RW,TT:_??RT4L IX)(&#QUXJ73_B]X1U; M5/#VGVFLQSW7B""6XTU51\3K'_K!DC"L.1M;!R",<5Y!\/+F;X8ZIHVK:YH& MJ6MB=#;1II+6RFNFBO8KR5Y6945GVSE_,5L;3TSTK&'@7Q$TTNOPZ)>6NHPP M7_B/3K5XB'BD.HI.EL<<"22(."G_ $T([5?L:=[-Z:Z_?_7_ Z(5:HUHM=- M/N_X*_X9GT5;^.]#N_&&H>%XK]7US3[5+VYMMK?NHG)"L6QM[=,YY'K6!)\< MO""^"X_%D-] M(_%FA.&$D;8M;B[NT5(Y& ^7R82N[T\LUIP^&/%7AOPO\5/#-[HULD.HZ-]N MTR/0Q+-;[_L_D21 NH/F$QQMMQSO)I>Q@E=O\?O&J\Y2LEIZ>6AZS)\7O#%K MH6F:O>W=QIMEJ5]'I]JU]:2P/),_W!L90P!_O$8]ZO77Q&T2U\6+X<,MQ+JG MR"006LLD4!<$H))%4JA8 X#$?J*\H^)W@_Q9\1M3MM%TG3;$V.G^'F1I]8>: M%!=W "JT113N>-8\\]-XJA8ZYJLWB+PQK6D6?B#3/&NJ"QAU_1[C3I?[/NXE M 2:9Y&79&\:[]KJP)VJI4Y%+V,&M'_73^O0/;33U7]=?S_,]A\&_$S1/'TTJ MZ-]NFB1687,UA-##( VT[)'4*W(/0TS3_BOX5U33]4O;75DFM],U'^R;PA'S M#<[UC$9&,\LRX/0YSFO/OV9V&FZ'_9-S?>)GU&&-S+I^L6+PVMIB9^(7,*@Y MR/XVXKB=3\$Z_H=A9:GIFC7DZ:SX@-GK%I%"=ZJFJ&:WO"O]U5#*6_NNIZ"C MV,/:.%P=:?L^=*^Y[;*LV?Q9\*WUGK5U!JR21:+J/]E7^(WW07.]4"$8SRSJ 1P<]:\;<7O\ MPJV^^%S:)JK>*IM0EB$OV&3[*T;WIF%Y]HQY>T(=WWMVX8QFL?Q1X'\0Z387 M&K:5HU[=?VQXDDL=6M8H3YC0C4_-MKS;_=0;P6_N2 ]!5QH4VTF[7?\ EK\] M?ZN1/$5(IM*]E_GI\M/ZL?0OB3XBZ)X5U>TTN^FN'O[E/-6"UM9;ADBW!?,? M8IV)N(&XX'Y&L-?CKX5;6+[3';5(;JQB:>Z\[2;E$AC 8[V8I@*0C8.><<5S M'QQD?2]>L]7\/?VY:^.X;3RM/-C827%GJ*&3/V6X(4H%W<[B5*;BP/45-XFT M?5+OQ!\49!87#?;/"=O!!Y:%EEF"768T/\1!9>!_>'K6,:<.12?F;NI/VG*N MZ-32_CEIC:7=:QJ:7=KIDU]%::9&FEW7GW ="R':4RY;:Q^4848RJ1:A)>Q:F\D=G;V=K+-<3-&2)%$*KO!0@AL@;>^*\>L--N_$W@?P-I MFE:QXNGO;/6[%[F]U33C%/8 6TBG8'@12BG@DANO)Y%2^"8[WX9ZYHNL:_I& MIRVUG;ZGH^H7UO92W#F\:[6;[6412Q2X4;MR@@$;>!BMY4:=VEO_ ,#TZF$: M]1I/I;]?7I^AZ3<_&;3&@M=2LKW3Y=%N(9;E9IC,LPCMR3>[H]F5>-=N%."3 MD<8J_IWQL\(ZEI^I7:ZA-:C3K9;RYAO+2:"9(#TE$;J&9#_>4$5XAKWA37=4 MM=6U:+0M0ABUJ+Q+>6]HUNPEC26UACA#I_ \IC+!3S\V.M7_ !Y#??$O0UO= M%T35D@TCPO=6'_B MAX9\4Z3X?U/2]42[LM>=H]/E1&'G,JLS+@C*D!&^]CI7DFDQR:?X\^(=K<7? MB>&ZU"YN&M-+CL';3+A6LHU$GF"$C<2I'^L'*@8K.\'>"]<\(^,OAC:P:1=' MP_?1IJMPRQ$+IMZNGF*9''\ D)1AG^,/ZU'L86WZ)_@V_P"OD4JT][=6OQLC MZ6HHHKA.X**** "BBB@ HHHH **** "BBB@#RK]K#_DUGXR?]B9K/_I#-7\U ME?TI_M8?\FL_&3_L3-9_](9J_FLH _?[_@EQ_P F)_#+_N)_^G2[KZJKY5_X M)%+'2/#93_A,-;#?9Y9$#BTA7AI M<'@MD@*#QG)/2L/X#_!'_A'-'MO%/BV]7Q'\0-5C%U>ZIJ4TTLD&\!O*CRN$ M &,[<*Q+P])?#K)] M%V]7_5SZTMKR"\7=!,DP_P!A@:FKR5;$(V5GA4]'6<[IZ?,[6BO.?#?QBA\4>(=:M+/3E&EZ+J-QIFHWLMVBR6LD2;C(\ M1Y$3= V??&*ZB3Q[X:AM4NI-?TV.V>'[0LS72!#$3CS V<;<\;NE?H'H?-\S M7-.3RK=;N3==(-D!QB4\\(YM45AS>.O#EMYPFU[38O)B2>7 MS+I%V1OC8[9/"MD8)X-/OO&6@Z6THO-:L+4Q,BR>=U'++ ML'-'N;-%9QR.U>3Q3EU3,L)AJ] M"S5-.+TO9NWYV_(\W+:BPN,KTJF\]5YK_@'I^U?^?T_^!TO_ ,37+WTR0_%C MP8(YO-G=;I7Q.TA\O9WW 8&17<:Q=6OA_3Y;[4;^2TM8E+-))>GMV'')]A7! M?#"SN_'GCBZ\<744T.EPQ&TTM+ARSL,_,_/;K^?M7S_#V2UL/BGC*ME""E]F MUVTTDG\[^B/3S#$QFHT(:R;3]$G=O\+&+XD^#,FI?%*P\4ZG?:)X>OY+74-- MN[RTE,%=:NO#-ZMEHT/AO:;H MM!>+$Z++ORN4RJ %.<,Q!/2NS^+WPIN/B9>>'98+^&Q72Y;AW,D;,Q\R(Q@J M01RN=V#D' !XKFH_V?;Y;/Q-:R:S;RQ^(UOK>\+6YS#%<3R2AX1G"RCS6!/0 MD*>,8K]'C54H1YI?\#<\N5)QG+EA^.^B.:_X4/!8Z'KWAV'Q1;W]F^J6;Z+Y MFH^1?:3Y*,(H8Y@K9>*0XC#*H/$'P#UOQG:W\LOBW2[B[O?!B^&C=6 MDQA2XNHY&:61T12/+&X@J.00>!GCMY_V?XK@V M23NX1'L.CAIZ_P!=V8.J?"!O%NK>(I/[3\.ZA9Z]X>TS01:?:2XD M-K+)+-G"\JR2G '(P">O$%Y\ ;^?P+/X7T;Q7::GI[:U97VCR7MP?.MK.TD1 MS;"50Q&_V>;[P_I]O:KK%GYL-W%J$6H+:M]IBF6)8F4,6^ M9"@91GD*^.<"M'1O@?>Z/=>%KJ+5HH)O#MU(]I%;JZPFWF>4SQLF>2P= &[> M6#BE[91VG^';_AD/V+E\4-_/OO\ F_P/1/!NEWVB^'X++4'CDGB9P&CD:0E- MQ*EG*J6?'4X&3GBMNBBO-;N[GJ)65CRK]K#_ )-9^,G_ &)FL_\ I#-7\UE? MTI_M8?\ )K/QD_[$S6?_ $AFK^:RD,_?[_@EQ_R8G\,O^XG_ .G2[KZJKY5_ MX)9,Q\J]SU+6X!\M6[KT[XS7 MV%J&GKJ/V=)?FA202,AZ-CE0?49P?P%7*ZZ.(>'3Y-WWV^[K\SBKX98EI3V7 M;>_KT^1\M^!=-U>TOK:/XU^&]:N-8CDVQ:M;2F_TB7G@XCRT7;_6+CWKZ?M5 MA6WB6W54@"C8L8PH7M@>E2T5-:O*LTW_ ,#Y+H7A\/'#IJ.OGU^;ZA1117,= M04444 %%%% !1110!Y5^UA_R:S\9/^Q,UG_TAFK^:ROZ4_VL/^36?C)_V)FL M_P#I#-7\UE '[??\$X?VA/A9X'_8Q^'FB>)/B7X/\/ZU:_VCY^G:IKUK;7$. M[4;IUWQO(&7*LK#(Y# ]#7TK_P -8_!#_HLGP_\ _"HL?_CM?S744 ?TH_\ M#6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM?S744 ?TH_\-8_ M!#_HLGP__P#"HL?_ ([1_P -8_!#_HLGP_\ _"HL?_CM?S744 ?TH_\ #6/P M0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM?S744 ?TH_\-8_!#_H MLGP__P#"HL?_ ([1_P -8_!#_HLGP_\ _"HL?_CM?S744 ?TH_\ #6/P0_Z+ M)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM?S744 ?TH_\-8_!#_HLGP_ M_P#"HL?_ ([1_P -8_!#_HLGP_\ _"HL?_CM?S744 ?TH_\ #6/P0_Z+)\/_ M /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM?S744 ?TH_\-8_!#_HLGP__P#" MHL?_ ([1_P -8_!#_HLGP_\ _"HL?_CM?S744 ?TH_\ #6/P0_Z+)\/_ /PJ M+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM?S744 ?TH_\-8_!#_HLGP__P#"HL?_ M ([1_P -8_!#_HLGP_\ _"HL?_CM?S744 ?TH_\ #6/P0_Z+)\/_ /PJ+'_X M[1_PUC\$/^BR?#__ ,*BQ_\ CM?S744 ?TH_\-8_!#_HLGP__P#"HL?_ ([1 M_P -8_!#_HLGP_\ _"HL?_CM?S744 ?TH_\ #6/P0_Z+)\/_ /PJ+'_X[1_P MUC\$/^BR?#__ ,*BQ_\ CM?S744 ?TH_\-8_!#_HLGP__P#"HL?_ ([1_P - M8_!#_HLGP_\ _"HL?_CM?S744 ?TH_\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$ M/^BR?#__ ,*BQ_\ CM?S744 ?TH_\-8_!#_HLGP__P#"HL?_ ([1_P -8_!# M_HLGP_\ _"HL?_CM?S744 ?TH_\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR M?#__ ,*BQ_\ CM?S744 ?TH_\-8_!#_HLGP__P#"HL?_ ([1_P -8_!#_HLG MP_\ _"HL?_CM?S744 ?TH_\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ M ,*BQ_\ CM?S744 ?TH_\-8_!#_HLGP__P#"HL?_ ([1_P -8_!#_HLGP_\ M_"HL?_CM?S744 ?TH_\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*B MQ_\ CM?S744 ?T#_ +37[3?P>U[]F[XKZ9IGQ7\#ZCJ5[X3U:VM;.T\1V GRAPHIC 9 sbfm_10k5.jpg IMAGE begin 644 sbfm_10k5.jpg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end EX-101.INS 10 sbfm-20201231.xml XBRL INSTANCE DOCUMENT 0001402328 2020-01-01 2020-12-31 0001402328 2020-12-31 0001402328 2019-12-31 0001402328 2019-01-01 2019-12-31 0001402328 2018-12-31 0001402328 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001402328 us-gaap:CommonStockMember 2018-12-31 0001402328 us-gaap:CommonStockMember 2019-12-31 0001402328 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001402328 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001402328 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001402328 us-gaap:PreferredStockMember 2018-12-31 0001402328 us-gaap:PreferredStockMember 2019-12-31 0001402328 us-gaap:ComprehensiveIncomeMember 2019-01-01 2019-12-31 0001402328 us-gaap:ComprehensiveIncomeMember 2018-12-31 0001402328 us-gaap:ComprehensiveIncomeMember 2019-12-31 0001402328 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001402328 us-gaap:RetainedEarningsMember 2018-12-31 0001402328 us-gaap:RetainedEarningsMember 2019-12-31 0001402328 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001402328 us-gaap:CommonStockMember 2020-12-31 0001402328 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001402328 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001402328 us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001402328 us-gaap:PreferredStockMember 2020-12-31 0001402328 us-gaap:ComprehensiveIncomeMember 2020-01-01 2020-12-31 0001402328 us-gaap:ComprehensiveIncomeMember 2020-12-31 0001402328 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001402328 us-gaap:RetainedEarningsMember 2020-12-31 0001402328 SBFM:TemporaryDifferenceMember 2020-12-31 0001402328 SBFM:TemporaryDifferenceMember 2019-12-31 0001402328 SBFM:TaxEffectMember 2020-12-31 0001402328 SBFM:TaxEffectMember 2019-12-31 0001402328 us-gaap:OfficeEquipmentMember 2020-01-01 2020-12-31 0001402328 us-gaap:EquipmentMember 2020-01-01 2020-12-31 0001402328 us-gaap:VehiclesMember 2020-01-01 2020-12-31 0001402328 us-gaap:SeriesAPreferredStockMember 2020-12-31 0001402328 us-gaap:SeriesAPreferredStockMember 2019-12-31 0001402328 us-gaap:SeriesBPreferredStockMember 2020-12-31 0001402328 us-gaap:SeriesBPreferredStockMember 2019-12-31 0001402328 SBFM:Note1Member 2020-12-31 0001402328 SBFM:Note1Member 2019-12-31 0001402328 2020-06-30 0001402328 2021-03-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure Sunshine Biopharma, Inc 0001402328 10-K 2020-12-31 false --12-31 No No Yes Non-accelerated Filer true true true false FY 2020 Yes CO 000-52898 989888 40501 1916 430 23771 15910 2778 1255 7590 7590 0 0 1025943 65686 19531 32456 0 0 1045474 98142 820454 586307 143661 129261 62870 96882 24320 21077 15392 0 0 1051305 833527 949006 0 2000311 833527 346418 35320 18820343 16616426 -2871 -2495 -20218727 -17434636 -954837 -735385 -55753 4283 35320 15668047 16616426 50000 50000 -3738 -2495 -15774345 -17434636 346418 18820343 100000 -2871 -20218727 1045474 98142 0 0 100000 50000 51485 37109 58918 58918 0.001 0.001 3000000000 3000000000 346419296 35319990 346419296 35319990 0.10 0.10 1000000 500000 1000000 500000 1000000 500000 71410 21121 25847 11050 45563 10071 81524 89253 89587 107196 15360 74124 89022 74904 271930 277252 60948 15204 14066 13774 622437 651707 -576874 -641636 168105 115901 2057513 314752 4891 -15099 2836 1367 -7674 -7967 -2207217 -436418 -2784091 -1078054 0 0 -2784091 -1078054 0 -582237 -2784091 -1660291 376 1243 -2783715 -1659048 -0.01 -0.10 0 -0.05 -0.01 -0.15 204096338 10932813 4282620 35319990 500000 500000 346419296 1000000 204300 9150 195150 1455000 57390 1455 55935 0 20432370 311099306 2515015 717726 20432 697294 311098 2203917 -2784467 -1659048 1243 -1660291 -376 -2784091 -2784091 -1660291 14066 13774 4891 -15099 50000 261690 42233 17197 2057513 314752 10510 -9334 0 -582237 1486 430 7861 15910 1523 7676 -35012 -18692 3243 11786 -657299 -495798 0 -14416 1191 860 -1191 -15276 1674246 441230 106600 53000 40607 25795 0 28230 1608253 442255 989888 40501 115216 949763 -68819 -376 -5896 20963 0 2515015 717726 -1660291 0 0 0 10932813 0 1660291 0 407767 0 -235633 0 -57872 690352 239044 0 1424658 0 349896 0 1424658 0 349896 0 0 0 0 0 0 0 0 0.2100 0.2100 0.0356 0.0356 0.2456 .2512 0.0000 0.0000 0.0000 0.0000 0.1500 0.1500 0.1180 0.1180 0.2680 0.2680 0.0000 0.0000 -0.2680 -0.2680 10611921 451307 -149054 0 119522 0 81920 0 37602 0 36196 0 1406 0 3518 0 -2112 0 -580125 0 -582237 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 8510 2790475 556120 3000 0 500000 50000 50000 0 0 Sunshine Biopharma, Inc. (the "Company") was originally incorporated under the name Mountain West Business Solutions, Inc. on August 31, 2006 in the State of Colorado. Until October 2009, the Company was operating as a business consultancy firm.   Effective October 15, 2009, the Company acquired Sunshine Biopharma, Inc. in a transaction classified as a reverse acquisition. Sunshine Biopharma, Inc. was holding an exclusive license to a new anticancer drug bearing the laboratory name, Adva-27a (the “License Agreement”). Upon completion of the reverse acquisition transaction, the Company changed its name to Sunshine Biopharma, Inc. and began operating as a pharmaceutical company focusing on the development of the licensed Adva-27a anticancer drug.   In October 2012, the Company published the results of its initial preclinical studies of Adva-27a in the peer-reviewed journal, ANTICANCER RESEARCH. The preclinical studies were conducted in collaboration with Binghamton University, a State University of New York. The publication is entitled “Adva-27a, a Novel Podophyllotoxin Derivative Found to Be Effective Against Multidrug Resistant Human Cancer Cells” [ANTICANCER RESEARCH Volume 32, Pages 4423-4432 (2012)].   In July 2014, the Company formed a wholly owned Canadian subsidiary, Sunshine Biopharma Canada Inc. (“Sunshine Canada”) for the purposes of offering generic pharmaceutical products in Canada and elsewhere around the world. Sunshine Canada has signed licensing agreements for four (4) generic prescription drugs for treatment of breast cancer, prostate cancer and BPH (Benign Prostatic Hyperplasia).   In December 2015, the Company acquired all worldwide issued (US Patent Number 8,236,935, and 10,272,065) and pending patents under PCT/FR2007/000697 and PCT/CA2014/000029 for the Adva-27a anticancer compound from Advanomics Corporation, a related party, in exchange for an aggregate of 803,264 shares of Common Stock valued at $835,394 and terminated the License Agreement. In 2016, the remaining value of these patents was impaired. The Company is however continuing development of the Adva-27a anticancer drug covered by these patents.   On January 1, 2018, the Company acquired all of the issued and outstanding shares of Atlas Pharma Inc. (“Atlas”), a Canadian privately held analytical chemistry company. The purchase price for the shares was Eight Hundred Forty-Eight Thousand Dollars $848,000 Canadian ($676,748 US). The purchase price included a cash payment of $100,500 Canadian ($80,289 US), plus the issuance of 50,000 shares of the Company’s Common Stock valued at $238,000, and a promissory note (“Atlas Debt”) in the principal amount of $450,000 Canadian ($358,407 US), with interest payable at the rate of 3% per annum. Effective April 1, 2019, the Company re-assigned all of its stock in Atlas back to the original owner in exchange for the Atlas Debt. The loss on the disposition was $580,125. See Note 11, below for a more detailed explanation of this disposition.   In March 2018, the Company formed NOX Pharmaceuticals, Inc., a wholly owned Colorado corporation and assigned all of the Company’s interest in the Adva27a anticancer drug to that company. NOX Pharmaceuticals Inc.’s mission is to research, develop and commercialize proprietary drugs including Adva-27a.   In December 2018, the Company launched its first over-the-counter product, Essential 9™, a nutritional supplement comprised of the nine (9) essential amino acids that the human body cannot make. Essential 9tm has been authorized for marketing by Health Canada under NPN 80089663.   Effective February 1, 2019, the Company completed a 20 to 1 reverse split of its Common Stock, reducing the issued and outstanding shares of Common Stock from 1,713,046,242 to 85,652,400 (the “First Reverse Stock Split”). The Company’s authorized capital of Common Stock remained as previously established at 3,000,000,000 shares.   In November 2019, the Company received Health Canada approval for a new Calcium-Vitamin D supplement. Health Canada issued NPN 80093432 through which it authorized the Company to manufacture and sell the new Calcium-Vitamin D supplement under the brand name Essential Calcium-Vitamin Dtm.   Effective April 6, 2020, the Company completed another 20 to 1 reverse split of its Common Stock, reducing the issued and outstanding shares of Common Stock from 1,193,501,925 to 59,675,417 (the “Second Reverse Stock Split”). The Company’s authorized capital of Common Stock remained as previously established at 3,000,000,000 shares.   On May 22, 2020, the Company filed a patent application in the United States for a new treatment for Coronavirus infections. The Company’s patent application covers composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease (Mpro), an enzyme that is essential for viral replication. The patent application has a priority date of May 22, 2020.   On June 17, 2020, the Company filed an amendment to its Articles of Incorporation (the “Amendment”) with the State of Colorado, to eliminate the Series “A” Preferred Shares consisting of Eight Hundred and Fifty Thousand (850,000) shares, par value $0.10 per share, and the designation thereof, which shares were returned to the status of undesignated shares of Preferred Stock. In addition, the Amendment increased the number of authorized Series “B” Preferred Shares from Five Hundred Thousand (500,000) to One Million (1,000,000) shares.   Also on June 17, 2020, the Company issued Five Hundred Thousand (500,000) shares of Series “B” Preferred Stock in favor of Dr. Steve N. Slilaty, the Company’s CEO, in consideration for the COVID-19 treatment technology he developed. The Series “B” Preferred Stock is non-convertible, non-redeemable, non-retractable and has a superior liquidation value of $0.10 per share. Each share of Series “B” Preferred Stock is entitled to 1,000 votes per share. This issuance brought the total number of Series “B” Preferred Stock held by Dr. Slilaty to 1,000,000 shares.   On September 8, 2020, the Company executed a financing agreement with RB Capital Partners, Inc., La Jolla, CA, who has agreed to provide the Company with a minimum of $2 million in convertible debt financing over the next three to six months pursuant to the terms and conditions included in relevant Promissory Notes (the “Promissory Notes”). The Promissory Notes will bear interest at the rate of 5% per annum and will be fully convertible into shares of shares of the Company’s Common Stock at a conversion price equal to the market value of the Company’s Common Stock on the applicable conversion date or $0.30 per share, whichever is greater. The Promissory Notes will have a maturity date of two years from the date of issuance and must be fully converted on or before the maturity date. The Company has the right under these Promissory Notes to pay off all or any part of the Promissory Notes at any time without penalty. As of December 31, 2020, the Company has received a total of $1,350,000 in funding under this agreement.   Effective October 6, 2020, the Company entered into a Research Agreement (the “Agreement”) with the University of Georgia Research Foundation, Inc. (“UGARF”), representing the University of Georgia (“UGA”). The purpose of the Agreement is to memorialize the terms of the Company working together with UGA to conduct the necessary research and development to advance the Company’s Anti-Coronavirus lead compound, SBFM-PL4 (or derivatives thereof) through various stages of preclinical development, animal studies and clinical trials for Coronavirus infections. The Agreement grants the Company an exclusive worldwide license for all of the intellectual property developed by UGA, whether alone or jointly with the Company.   The Company's financial statements reflect both the First and Second Reverse Stock Split on a retroactive basis and represent the consolidated activity of Sunshine Biopharma, Inc. and its subsidiaries (Sunshine Biopharma Canada Inc. and NOX Pharmaceuticals Inc.) herein collectively referred to as the "Company".   During the last twelve month period the Company has continued to raise money through the issuance of convertible debt. The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding to operationalize the Company’s proprietary drug development program and other business activities.   This summary of significant accounting policies is presented to assist the reader in understanding the Company's financial statements. The consolidated financial statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity. These accounting policies conform to Generally Accepted Accounting Principles and have been consistently applied in the preparation of the financial statements.   IMPACT OF CORONAVIRUS (COVID-19) PANDEMIC   In March 2020, the World Health Organization declared Coronavirus and its associated disease, COVID-19, a global pandemic. Conditions surrounding the Coronavirus outbreak are evolving rapidly and government authorities around the world have implemented emergency measures to mitigate the spread of the virus. The outbreak and related mitigation measures have had and will continue to have a material adverse impact on the world economies and the Company's business activities. It is not possible for the Company to predict the duration or magnitude of the adverse conditions of the outbreak and their effects on the Company’s business or ability to raise funds. No adjustments have been made to the amounts reported in the Company's financial statements as a result of this matter.   PRINCIPLES OF CONSOLIDATION   The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.   USE OF ESTIMATES   The preparation of financial statements in conformity with US Generally Accepted Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant estimates and assumptions made by management are valuation of equity instruments, depreciation of property and equipment, and deferred tax asset valuation. Actual results could differ from those estimates as the current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.   CASH AND CASH EQUIVALENTS   For the Balance Sheets and Statements of Cash Flows, all highly liquid investments with maturity of 90 days or less are considered to be cash equivalents. The Company had a cash balance of $989,888 and $40,501 as of December 31, 2020 and December 31, 2019, respectively. At times such cash balances may be in excess of the FDIC limit of $250,000 or the equivalent in Canada.   PROPERTY AND EQUIPMENT   Property and equipment is reviewed for recoverability when events or changes in circumstances indicate that its carrying value may exceed future undiscounted cash inflows. As of December 31, 2020 and 2019, the Company had not identified any such impairment. Repairs and maintenance are charged to operations when incurred and improvements and renewals are capitalized.   Property and equipment are stated at cost. Depreciation is calculated using the straight-line method for financial reporting purposes and accelerated methods for tax purposes. Their estimated useful lives are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="padding-left: 20pt; width: 48%; text-align: justify">Office Equipment:</td> <td style="width: 52%; text-align: justify">5-7 Years</td></tr> <tr style="vertical-align: top"> <td style="padding-left: 20pt; text-align: justify">Laboratory Equipment:</td> <td style="text-align: justify">5 Years</td></tr> <tr style="vertical-align: top"> <td style="padding-left: 20pt; text-align: justify">Vehicles:</td> <td style="text-align: justify">5 Years</td></tr> </table>    EARNINGS PER SHARE   The Company has adopted the Financial Accounting Standards Board (FASB) ASC Topic 260 regarding earnings / loss per share, which provides for calculation of “basic” and “diluted” earnings / loss per share. Basic earnings / loss per share includes no dilution and is computed by dividing net income / loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings / loss per share reflect the potential dilution of securities that could share in the earnings of an entity similar to fully diluted earnings / loss per share.   INCOME TAXES   In accordance with ASC 740 – Income Taxes, the provision for income taxes is computed using the asset and liability method. The liability method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities have been adjusted to reflect changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized.   The Company expects to recognize the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a "more-likely-than-not" threshold, the amount to be recognized in the financial statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. As of December 31, 2020 the Company had no uncertain tax positions. The Company recognizes interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. The Company currently has no federal or state tax examinations nor has it had any federal or state examinations since its inception. To date, the Company has not incurred any interest or tax penalties.   For Canadian and US tax purposes, the Company’s 2017 through 2019 tax years remain open for examination by the tax authorities under the normal three-year statute of limitations.   FUNCTIONAL CURRENCY   The U.S. dollar is the functional currency of the Company which is operating in the United States. The functional currency for the Company's Canadian subsidiary is the Canadian dollar.   The Company translates its Canadian subsidiary's financial statements into U.S. dollars as follows:   <table cellspacing="3" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="vertical-align: top; width: 60px; padding-left: 27pt">●</td> <td style="text-align: justify">Assets and liabilities are translated at the exchange rate in effect as of the financial statement date.</td></tr> </table>   <table cellspacing="3" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="vertical-align: top; width: 60px; padding-left: 27pt">●</td> <td style="text-align: justify">Income statement accounts are translated using the weighted average exchange rate for the period.</td></tr> </table>   The Company includes translation adjustments from currency exchange and the effect of exchange rate changes on intercompany transactions of a long-term investment nature as a separate component of shareholders’ equity. There are currently no transactions of a long-term investment nature, nor any gains or losses from non U.S. currency transactions.   CONCENTRATION OF CREDIT RISKS   Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents and trade receivables. The Company places its cash equivalents with high credit quality financial institutions.   FINANCIAL INSTRUMENTS AND FAIR VALUE OF FINANCIAL INSTRUMENTS   The Company applies the provisions of accounting guidance, FASB Topic ASC 825, Financial Instruments. ASC 825 requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of December 31, 2020 and 2019, the fair value of cash, accounts receivable and notes receivable, accounts payable, accrued expenses, and other payables approximated carrying value due to the short maturity of the instruments, quoted market prices or interest rates which fluctuate with market rates.   The Company defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).   <table cellspacing="3" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="vertical-align: top; width: 60px; padding-left: 27pt">●</td> <td style="text-align: justify">Level 1 – Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</td></tr> </table>   <table cellspacing="3" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="vertical-align: top; width: 60px; padding-left: 27pt">●</td> <td style="text-align: justify">Level 2 – Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability.</td></tr> </table>   <table cellspacing="3" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="vertical-align: top; width: 60px; padding-left: 27pt">●</td> <td style="text-align: justify">Level 3 – Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</td></tr> </table>   The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared.   NOTES PAYABLE   Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently carried at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the income statement over the period of the borrowings using the effective interest method.   ACCOUNTING FOR DERIVATIVES LIABILITIES   The Company evaluates stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of ASC Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity’s Own Equity. The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income or other expense.   Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date. The Company determined that none of the Company’s financial instruments meet the criteria for derivative accounting as of December 31, 2020 and 2019.   EQUITY INSTRUMENTS ISSUED TO EMPLOYEES OR NON-EMPLOYEES FOR ACQUIRING GOODS OR SERVICES   The stock-based compensation expense for both employee and non-employee awards is generally recognized on a straight-line basis over the requisite service period of the award. The Company accounts for stock-based compensation to employees in conformity with the provisions of ASC Topic 718, Stock Based Compensation. Stock-based compensation to employees consisting of stock option grants and restricted shares are recognized in the statement of operations based on their fair values at the date of grant. The Company accounts for equity instruments issued to non-employees in accordance with the provisions of ASC Topic 718, based upon the fair-value of the underlying instrument.   BASIC AND DILUTED NET GAIN (LOSS) PER SHARE   The Company computes loss per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement.   Basic net income (loss) per share is calculated by dividing net (loss) by the weighted-average common shares outstanding. Diluted net income per share is calculated by dividing net income by the weighted-average common shares outstanding during the period using the treasury stock method or the two-class method, whichever is more dilutive. As the Company incurred net losses for the year ended December 31, 2020 no potentially dilutive securities were included in the calculation of diluted earnings per share as the impact would have been anti-dilutive.   Therefore, basic and dilutive net (loss) per share were the same as of December 31, 2020 and 2019.   REVENUE RECOGNITION   As of January 1, 2018, the Company adopted ASU No. 201409, “Revenue from Contracts with Customers” (ASC 606). Under the new guidance, an entity will recognize revenue to depict the transfer of promised goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. A five-step model has been introduced for an entity to apply when recognizing revenue. The new guidance also includes enhanced disclosure requirements. The guidance was effective January 1, 2018 and was applied on a modified retrospective basis. The adoption did not have an impact on the Company's financial statements. All of the revenues of the Company are the Company's wholly owned Canadian subsidiary, which sells nutritional supplements through Amazon.com and Amazon.ca.   In Canada, governmental regulations require that companies recognize revenues upon completion of the work by issuing an invoice and remitting the applicable sales taxes (GST and QST) to the appropriate government agency. The Company’s wholly owned Canadian subsidiary's revenue recognition policy is in compliance with these local regulations.   RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS   In December 2019, the FASB issued ASU 2019-12 “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.” This guidance removes certain exceptions to the general principles in Topic 740 and provides consistent application of U.S. GAAP by clarifying and amending existing guidance. The effective date of the new guidance for public companies is for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the timing of adoption and impact of the updated guidance on its financial statements.   LEGAL FEES   During the years ended December 31, 2020 and 2019, the legal fees incurred were related to services provided to the Company to assist with its regulatory requirements with the Securities and Exchange Commission, patenting costs and one ongoing litigation.   DATE OF MANAGEMENT’S REVIEW   Subsequent events have been evaluated through March 29, 2021, which is the date the Financial Statements were available to be issued.   The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. In the course of its life, the Company has had limited operations and Working Capital deficit. This raises substantial doubt about the Company’s ability to continue as a going concern. The Company believes it can raise capital through equity sales and borrowing to fund its operations. Management believes this will contribute toward its subsequent profitability. The accompanying Financial Statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.   The following is a summary of the patents held by the Company at December 31, 2020 and 2019:   In December 2015, the Company acquired all worldwide issued (US Patent Number 8,236,935, and US Patent Number 10,272,065) and pending patents under PCT/FR2007/000697 and PCT/CA2014/000029 for the Adva-27a anticancer compound from Advanomics Corporation, a related party, in exchange for an aggregate of 803,264 shares of Common Stock valued at $835,394 and terminated the License Agreement. In 2016, the remaining value of these patents was impaired. The Company is however continuing development of the Adva-27a anticancer drug covered by these patents.   On May 22, 2020, the Company filed a patent application in the United States for a new treatment for Coronavirus infections. The Company’s patent application covers composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease (Mpro), an enzyme that is essential for viral replication. The patent application has a priority date of May 22, 2020.   The Company’s authorized capital is comprised of 3,000,000,000 shares of $0.001 par value Common Stock and 30,000,000 shares of $0.10 par value Preferred Stock, to have such rights and preferences as the Directors of the Company have or may assign from time to time. Out of the authorized Preferred Stock, the Company had designated 850,000 shares as Series “A” Preferred Stock (“Series A”). At December 31, 2020 and December 31, 2019, the Company had no issued and outstanding shares of Series A. On June 17, 2020, the Company filed an amendment to its Articles of Incorporation (the “Amendment”) eliminating the Series A shares and the designation thereof, which shares were returned to the status of undesignated shares of Preferred Stock. In addition to eliminating the Series A shares, the Amendment also increased the number of authorized Series B Preferred Shares from Five Hundred Thousand (500,000) to One Million (1,000,000) shares.   During the year ended December 31, 2015, the Company authorized 500,000 shares of $0.10 par value Series “B” Preferred Stock (“Series B”). The Series B Preferred Stock is non-convertible, non-redeemable and non-retractable. It has superior liquidation rights to the Common Stock at $0.10 per share and gives the holder the right to 1,000 votes per share. All shares of the Series B Preferred Stock are held by the CEO of the Company.   On June 17, 2020, the Company issued Five Hundred Thousand (500,000) shares of Series “B” Preferred Stock in favor of the Company’s CEO, in consideration for the COVID-19 treatment technology he developed. This issuance brought the total number of Series B Preferred Stock held by the Company’s CEO to 1,000,000 shares.   Through December 31, 2020 and December 31, 2019, the Company has issued and outstanding a total of 346,419,296 and 35,319,990 shares of Common Stock, respectively. Through the same periods, the Company has issued and outstanding a total of -0- and -0- shares of Series A Preferred Stock and 1,000,000 and 500,000 shares of Series B Preferred Stock, respectively.   During the fiscal year ended December 31, 2020, the Company issued an aggregate of 311,099,306 shares of its Common Stock in connection with the conversion of $373,269 in debt and interest of $ 42,233 resulting in a $1,416,313 loss on conversion.   During the fiscal year ended December 31, 2019, the Company issued an aggregate of 31,037,370 shares of its Common Stock as follows:   <table cellspacing="3" cellpadding="0" style="width: 100%"> <tr> <td style="font: 12pt Times New Roman, Times, Serif; vertical-align: top; width: 72px; padding-left: 0.5in">●</td> <td style="font: 12pt Times New Roman, Times, Serif; padding: 0.75pt; text-align: justify">9,150,000 shares valued at $204,300 as compensation to the Company’s Directors and Officers</td></tr> </table>   <table cellspacing="3" cellpadding="0" style="width: 100%"> <tr> <td style="font: 12pt Times New Roman, Times, Serif; vertical-align: top; width: 72px; padding-left: 0.5in">●</td> <td style="font: 12pt Times New Roman, Times, Serif; padding: 0.75pt; text-align: justify">1,455,000 shares for services rendered to the Company by third parties valued at $57,390</td></tr> </table>   <table cellspacing="3" cellpadding="0" style="width: 100%"> <tr> <td style="font: 12pt Times New Roman, Times, Serif; vertical-align: top; width: 72px; padding-left: 0.5in">●</td> <td style="font: 12pt Times New Roman, Times, Serif; padding: 0.75pt; text-align: justify">20,432,370 shares valued at $717,726 in connection with the conversion of $385,778 in debt and interest of $6,689 resulting in a $314,751 loss on conversion</td></tr> </table>   The Company has declared no dividends since inception.     The following table sets forth the computation of basic and diluted net income per share for the years ended December 31:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 76%; text-align: justify">Net gain (loss) attributable to Common Stock</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">(-)</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">(1,660,291</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Basic weighted average outstanding shares of Common Stock</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10,392,813</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Dilutive effects of common share equivalents</td> <td> </td> <td> </td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-0-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Dilutive weighted average outstanding shares of Common Stock</td> <td> </td> <td> </td> <td style="text-align: right">- </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10,932,813</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Net gain (loss) per share attributable to Common Stock</td> <td> </td> <td>$</td> <td style="text-align: right">(0</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(0.15</td> <td>)</td></tr> </table>   The Company files a United States federal income tax return and a Canadian branch return on a calendar year basis. The Company and its wholly-owned subsidiaries, Sunshine Biopharma Canada Inc., have not generated taxable income since inception.   Deferred income taxes arise from the temporary differences between financial statement and income tax recognition of net operating losses and other items. These loss carryovers are limited under the Internal Revenue Code should a significant change in ownership occur. The Company accounts for income taxes pursuant to ASC 740, “Accounting for Income Taxes”, which requires, among other things, an asset and liability approach to calculating deferred income taxes. The components of the deferred income tax assets and liabilities arising under ASC No. 740 were as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">December 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Amount</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> Tax Effect</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Amount</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Tax Effect</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Deferred tax assets:</td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 50%; text-align: justify">Net operating loss</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">- </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">- </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">1,660,291</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">407,767</td> <td style="width: 2%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Other differences</td> <td> </td> <td>$</td> <td style="text-align: right">(-)</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">(-)</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">(235,633</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(57,871</td> <td>)</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Net deferred tax assets</td> <td> </td> <td>$</td> <td style="text-align: right">- </td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">- </td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1,424,658</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">349,896</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Valuation allowance</td> <td> </td> <td>$</td> <td style="text-align: right">(-)</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">(-)</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">(1,424,658</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(349,896</td> <td>)</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Total deferred tax asset</td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Deferred tax liabilities: </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Net deferred tax asset</td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td></tr> </table>     Deferred income taxes arise from the temporary differences between financial statement and income tax recognition of net operating losses. These loss carryovers are limited under the Internal Revenue Code should a significant change in ownership occur.   As of December 31, 2020, the Company had net operating loss carry forwards of $10,611,921 that may be available to reduce future years’ taxable income through 2037 and $5,329,161 may be available to reduce future years’ taxable income indefinitely. At December 31, 2020 and December 31, 2019, a deferred tax asset at each date of approximately $690,352 and $239,044, respectively, resulting from the loss carryforwards has been offset by a 100% valuation allowance. The change in the valuation allowance for the period ended December 31, 2020 and December 31, 2019 was approximately $(451,307) and $149,054, respectively.   A reconciliation of the U.S. statutory federal income tax rate to the effective tax rate is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> December 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 76%; text-align: justify">U.S. Federal statutory graduated income tax rate</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">21.00</td> <td style="width: 1%">%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">21.00</td> <td style="width: 1%">%</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">State income tax rate, net of federal benefit</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3.56</td> <td style="padding-bottom: 1.5pt">%</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">4.12</td> <td style="padding-bottom: 1.5pt">%</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Net income tax rate</td> <td> </td> <td> </td> <td style="text-align: right">24.56</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">25.12</td> <td>%</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Net operating loss used</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td>%</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Net operating loss for which no tax benefit is currently available</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td>%</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Canada Federal statutory rate</td> <td> </td> <td> </td> <td style="text-align: right">15.00</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">15.00</td> <td>%</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Canada Provincial rate</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">11.80</td> <td style="padding-bottom: 1.5pt">%</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">11.80</td> <td style="padding-bottom: 1.5pt">%</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Net Canada rate</td> <td> </td> <td> </td> <td style="text-align: right">26.80</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">26.80</td> <td>%</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Net operating loss used (Canada)</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td>%</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Net operating loss for which no tax benefit is currently available (Canada)</td> <td> </td> <td> </td> <td style="text-align: right">-26.80</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">-26.80</td> <td>%</td></tr> </table>   The Company’s income tax filings are subject to audit by various taxation authorities. The Company’s open audit periods are 2018, 2019, and 2020, although, the statute of limitations for the 2018 tax year will expire effective October 15, 2020. In evaluating the Company’s provisions and accruals, future taxable income, and reversal of temporary differences, interpretations and tax planning strategies are considered. The Company believes its estimates are appropriate based on current facts and circumstances.   Outstanding Notes Payable at December 31, 2020 held by related parties consist of the following:   A Note Payable dated December 31, 2019 held by the CEO of the Company having a Face Value of $128,269 and accruing interest at 12% was due December 31, 2020. On December 31, 2020, the Company renewed the Note together with accrued interest of $15,392 for a 12-month period. The new Note has a face Value of $143,661, accrues interest at 12% per annum, and has a maturity date of December 31, 2021.   In addition to the transactions specified under Note 9 above, during the period ended December 31, 2020, the Directors and Officers of the Company were paid $271,930 in cash. Of this amount, $177,000 was paid to Advanomics Corporation (now known as TRT Pharma Inc.), a company controlled by the CEO of the Company. During the period ended December 31, 2020, the Company issued to its CEO 500,000 shares of Series B Preferred Stock valued at $50,000.   For the period ended December 31, 2019, the Company issued to the Board of Directors 1,950,000 shares of Common Stock valued at $74,100, 3,300,000 shares of Common Stock valued at $99,000, and 3,900,000 shares of Common Stock valued at $31,200. The Company also issued 550,000 shares of Common Stock valued at $16,500 to the CFO for consulting services rendered to the Company in 2019. During the year ended December 31, 2019 the Directors and officers were paid $72,916 in cash. Of this amount, $28,000 was paid to Advanomics Corporation, a company controlled by the CEO of the Company.   On January 1, 2018 the Company acquired all of the issued and outstanding shares of Atlas Pharma Inc. (“Atlas”), a privately held Canadian company providing analytical chemistry testing services (“Atlas Business”). The purchase price for the shares was $848,000 Canadian ($676,748 US). The purchase price included cash payment of $100,500 Canadian ($80,289 US), plus the issuance of 50,000 shares of the Company’s Common Stock valued at $238,000, and a promissory note in the principal amount of $450,000 Canadian ($358,407 US), with interest payable at the rate of 3% per annum (“Atlas Note”). The following table summarizes the allocation of the purchase price as of the acquisition date:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="width: 88%; text-align: justify">Cash</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">4,942</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Accounts receivable</td> <td> </td> <td>$</td> <td style="text-align: right">79,508</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Prepaids</td> <td> </td> <td>$</td> <td style="text-align: right">1,428</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Property and equipment</td> <td> </td> <td>$</td> <td style="text-align: right">62,990</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Goodwill</td> <td> </td> <td>$</td> <td style="text-align: right">665,697</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Liabilities assumed ($172,899 Canadian)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">(137,817</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Total consideration</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">676,748</td> <td style="padding-bottom: 3pt"> </td></tr> </table>   Effective April 1, 2019, the Company disposed of Atlas by re-assigning all of its stock in Atlas back to the original owner in exchange for the Atlas Note. As a consequence of the sale, the operating results and the assets and liabilities of the discontinued Atlas Business are presented separately in the Company's financial statements. Summarized financial information for the discontinued Atlas Business is shown below. Prior period balances have been reclassified to present the operations of the Atlas Business as discontinued operations.   Discontinued Operations Income Statement:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> Audited December 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> Audited December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 76%; text-align: justify">Revenues</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">0</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">119,522</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Cost of revenues</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">0</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">81,920</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Gross profit</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">0</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">37,602</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">General and administrative expenses</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">36,196</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Gain (Loss) from operations</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,406</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Other income (expense) – Interest</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">0</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(3,518</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Net Income (Loss) from operations</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">0</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(2,112</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Loss on Disposal</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(580,125</td> <td>)</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Net Income (Loss) from Discontinued Operations</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">0</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(582,237</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> </table>   The individual assets and liabilities of the discontinued Atlas Business are in the captions "Assets of Discontinued Operation" and "Liabilities of Discontinued Operation" in the Consolidated Balance Sheet. The carrying amounts of the major classes of assets and liabilities included part of the discontinued business are presented in the following table:   Discontinued Operations Balance Sheets:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> Audited December 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> Audited December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">ASSETS</td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Current Assets:</td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 76%; text-align: justify">Cash and cash equivalents</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Accounts receivable</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Total Current Assets</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Equipment (net of $ 0 and $34,959 depreciation)</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Goodwill</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">TOTAL ASSETS</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">-</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">-</td> <td style="padding-bottom: 3pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">LIABILITIES</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Current Liabilities:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Notes payable</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Notes payable - related party</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Related party advances</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Accounts payable & accrued expenses</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Total Current Liabilities</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">TOTAL LIABILITIES</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">-</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">-</td> <td style="padding-bottom: 3pt"> </td></tr> </table>   Discontinued Operations Cash Flows:   Cash flows used in discontinued operations for the period ended December 31, 2020 and 2019 were $-0-and $8,510, respectively. There were no cash flows used in or provided by investing or financing activities during those periods.   The Company's arrangement in connection with its office space located in Pointe-Claire, Quebec, Canada has no short-term or long-term asset or liability value. In March 2020, the World Health Organization declared Coronavirus and its associated disease, COVID-19, a global pandemic. Conditions surrounding the Coronavirus outbreak are evolving rapidly and government authorities around the world have implemented emergency measures to mitigate the spread of the virus. The outbreak and related mitigation measures have had and will continue to have a material adverse impact on the world economies and the Company's business activities. It is not possible for the Company to predict the duration or magnitude of the adverse conditions of the outbreak and their effects on the Company’s business or ability to raise funds. No adjustments have been made to the amounts reported in the Company's financial statements as a result of this matter.   The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.   The preparation of financial statements in conformity with US Generally Accepted Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant estimates and assumptions made by management are valuation of equity instruments, depreciation of property and equipment, and deferred tax asset valuation. Actual results could differ from those estimates as the current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.   For the Balance Sheets and Statements of Cash Flows, all highly liquid investments with maturity of 90 days or less are considered to be cash equivalents. The Company had a cash balance of $989,888 and $40,501 as of December 31, 2020 and December 31, 2019, respectively. At times such cash balances may be in excess of the FDIC limit of $250,000 or the equivalent in Canada.   Property and equipment is reviewed for recoverability when events or changes in circumstances indicate that its carrying value may exceed future undiscounted cash inflows. As of December 31, 2020 and 2019, the Company had not identified any such impairment. Repairs and maintenance are charged to operations when incurred and improvements and renewals are capitalized.   Property and equipment are stated at cost. Depreciation is calculated using the straight-line method for financial reporting purposes and accelerated methods for tax purposes. Their estimated useful lives are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="padding-left: 20pt; width: 48%; text-align: justify">Office Equipment:</td> <td style="width: 52%; text-align: justify">5-7 Years</td></tr> <tr style="vertical-align: top"> <td style="padding-left: 20pt; text-align: justify">Laboratory Equipment:</td> <td style="text-align: justify">5 Years</td></tr> <tr style="vertical-align: top"> <td style="padding-left: 20pt; text-align: justify">Vehicles:</td> <td style="text-align: justify">5 Years</td></tr> </table>   The Company has adopted the Financial Accounting Standards Board (FASB) ASC Topic 260 regarding earnings / loss per share, which provides for calculation of “basic” and “diluted” earnings / loss per share. Basic earnings / loss per share includes no dilution and is computed by dividing net income / loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings / loss per share reflect the potential dilution of securities that could share in the earnings of an entity similar to fully diluted earnings / loss per share.   In accordance with ASC 740 – Income Taxes, the provision for income taxes is computed using the asset and liability method. The liability method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities have been adjusted to reflect changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized.   The Company expects to recognize the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a "more-likely-than-not" threshold, the amount to be recognized in the financial statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. As of December 31, 2020 the Company had no uncertain tax positions. The Company recognizes interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. The Company currently has no federal or state tax examinations nor has it had any federal or state examinations since its inception. To date, the Company has not incurred any interest or tax penalties.   For Canadian and US tax purposes, the Company’s 2017 through 2019 tax years remain open for examination by the tax authorities under the normal three-year statute of limitations.   The U.S. dollar is the functional currency of the Company which is operating in the United States. The functional currency for the Company's Canadian subsidiary is the Canadian dollar.   The Company translates its Canadian subsidiary's financial statements into U.S. dollars as follows:   <table cellspacing="3" cellpadding="0" style="width: 100%"> <tr> <td style="font: 12pt Times New Roman, Times, Serif; vertical-align: top; width: 60px; padding-left: 27pt">●</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">Assets and liabilities are translated at the exchange rate in effect as of the financial statement date.</td></tr> </table>   <table cellspacing="3" cellpadding="0" style="width: 100%"> <tr> <td style="font: 12pt Times New Roman, Times, Serif; vertical-align: top; width: 60px; padding-left: 27pt">●</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">Income statement accounts are translated using the weighted average exchange rate for the period.</td></tr> </table>   The Company includes translation adjustments from currency exchange and the effect of exchange rate changes on intercompany transactions of a long-term investment nature as a separate component of shareholders’ equity. There are currently no transactions of a long-term investment nature, nor any gains or losses from non U.S. currency transactions.   Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents and trade receivables. The Company places its cash equivalents with high credit quality financial institutions.   The Company applies the provisions of accounting guidance, FASB Topic ASC 825, Financial Instruments. ASC 825 requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of December 31, 2020 and 2019, the fair value of cash, accounts receivable and notes receivable, accounts payable, accrued expenses, and other payables approximated carrying value due to the short maturity of the instruments, quoted market prices or interest rates which fluctuate with market rates.   The Company defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).   <table cellspacing="3" cellpadding="0" style="width: 100%"> <tr> <td style="font: 12pt Times New Roman, Times, Serif; vertical-align: top; width: 60px; padding-left: 27pt">●</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">Level 1 – Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</td></tr> </table>   <table cellspacing="3" cellpadding="0" style="width: 100%"> <tr> <td style="font: 12pt Times New Roman, Times, Serif; vertical-align: top; width: 60px; padding-left: 27pt">●</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">Level 2 – Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability.</td></tr> </table>   <table cellspacing="3" cellpadding="0" style="width: 100%"> <tr> <td style="font: 12pt Times New Roman, Times, Serif; vertical-align: top; width: 60px; padding-left: 27pt">●</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">Level 3 – Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</td></tr> </table>   The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared.   Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently carried at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the income statement over the period of the borrowings using the effective interest method.   The Company evaluates stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of ASC Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity’s Own Equity. The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income or other expense.   Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date. The Company determined that none of the Company’s financial instruments meet the criteria for derivative accounting as of December 31, 2020 and 2019.   As of January 1, 2018, the Company adopted ASU No. 201409, “Revenue from Contracts with Customers” (ASC 606). Under the new guidance, an entity will recognize revenue to depict the transfer of promised goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. A five-step model has been introduced for an entity to apply when recognizing revenue. The new guidance also includes enhanced disclosure requirements. The guidance was effective January 1, 2018 and was applied on a modified retrospective basis. The adoption did not have an impact on the Company's financial statements. All of the revenues of the Company are the Company's wholly owned Canadian subsidiary, which sells nutritional supplements through Amazon.com and Amazon.ca.   In Canada, governmental regulations require that companies recognize revenues upon completion of the work by issuing an invoice and remitting the applicable sales taxes (GST and QST) to the appropriate government agency. The Company’s wholly owned Canadian subsidiary's revenue recognition policy is in compliance with these local regulations.   In December 2019, the FASB issued ASU 2019-12 “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.” This guidance removes certain exceptions to the general principles in Topic 740 and provides consistent application of U.S. GAAP by clarifying and amending existing guidance. The effective date of the new guidance for public companies is for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the timing of adoption and impact of the updated guidance on its financial statements.   Subsequent events have been evaluated through March 29, 2021, which is the date the Financial Statements were available to be issued. <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48%; text-align: justify">Office Equipment:</td> <td style="width: 52%; text-align: justify">5-7 Years</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">Laboratory Equipment:</td> <td style="text-align: justify">5 Years</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">Vehicles:</td> <td style="text-align: justify">5 Years</td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 76%; text-align: justify">Net gain (loss) attributable to Common Stock</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">(-)</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">(1,660,291</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Basic weighted average outstanding shares of Common Stock</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10,392,813</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Dilutive effects of common share equivalents</td> <td> </td> <td> </td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-0-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Dilutive weighted average outstanding shares of Common Stock</td> <td> </td> <td> </td> <td style="text-align: right">- </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10,932,813</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Net gain (loss) per share attributable to Common Stock</td> <td> </td> <td>$</td> <td style="text-align: right">(0</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(0.15</td> <td>)</td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">December 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Amount</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> Tax Effect</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Amount</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Tax Effect</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Deferred tax assets:</td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 50%; text-align: justify">Net operating loss</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">- </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">- </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">1,660,291</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">407,767</td> <td style="width: 2%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Other differences</td> <td> </td> <td>$</td> <td style="text-align: right">(-)</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">(-)</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">(235,633</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(57,871</td> <td>)</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Net deferred tax assets</td> <td> </td> <td>$</td> <td style="text-align: right">- </td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">- </td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1,424,658</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">349,896</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Valuation allowance</td> <td> </td> <td>$</td> <td style="text-align: right">(-)</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">(-)</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">(1,424,658</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(349,896</td> <td>)</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Total deferred tax asset</td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Deferred tax liabilities: </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Net deferred tax asset</td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-0-</td> <td> </td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> December 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 76%; text-align: justify">U.S. Federal statutory graduated income tax rate</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">21.00</td> <td style="width: 1%">%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">21.00</td> <td style="width: 1%">%</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">State income tax rate, net of federal benefit</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3.56</td> <td style="padding-bottom: 1.5pt">%</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">4.12</td> <td style="padding-bottom: 1.5pt">%</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Net income tax rate</td> <td> </td> <td> </td> <td style="text-align: right">24.56</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">25.12</td> <td>%</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Net operating loss used</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td>%</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Net operating loss for which no tax benefit is currently available</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td>%</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Canada Federal statutory rate</td> <td> </td> <td> </td> <td style="text-align: right">15.00</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">15.00</td> <td>%</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Canada Provincial rate</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">11.80</td> <td style="padding-bottom: 1.5pt">%</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">11.80</td> <td style="padding-bottom: 1.5pt">%</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Net Canada rate</td> <td> </td> <td> </td> <td style="text-align: right">26.80</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">26.80</td> <td>%</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Net operating loss used (Canada)</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td>%</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Net operating loss for which no tax benefit is currently available (Canada)</td> <td> </td> <td> </td> <td style="text-align: right">-26.80</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">-26.80</td> <td>%</td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="width: 88%; text-align: justify">Cash</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">4,942</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Accounts receivable</td> <td> </td> <td>$</td> <td style="text-align: right">79,508</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Prepaids</td> <td> </td> <td>$</td> <td style="text-align: right">1,428</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Property and equipment</td> <td> </td> <td>$</td> <td style="text-align: right">62,990</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Goodwill</td> <td> </td> <td>$</td> <td style="text-align: right">665,697</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Liabilities assumed ($172,899 Canadian)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">(137,817</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Total consideration</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">676,748</td> <td style="padding-bottom: 3pt"> </td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> Audited December 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> Audited December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 76%; text-align: justify">Revenues</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">0</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">119,522</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Cost of revenues</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">0</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">81,920</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Gross profit</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">0</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">37,602</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">General and administrative expenses</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">36,196</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Gain (Loss) from operations</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,406</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Other income (expense) – Interest</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">0</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(3,518</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Net Income (Loss) from operations</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">0</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(2,112</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Loss on Disposal</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(580,125</td> <td>)</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Net Income (Loss) from Discontinued Operations</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">0</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(582,237</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> Audited December 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> Audited December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">ASSETS</td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Current Assets:</td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 76%; text-align: justify">Cash and cash equivalents</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Accounts receivable</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Total Current Assets</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Equipment (net of $ 0 and $34,959 depreciation)</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Goodwill</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">TOTAL ASSETS</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">-</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">-</td> <td style="padding-bottom: 3pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">LIABILITIES</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Current Liabilities:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Notes payable</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Notes payable - related party</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Related party advances</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Accounts payable & accrued expenses</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Total Current Liabilities</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">TOTAL LIABILITIES</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">-</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">-</td> <td style="padding-bottom: 3pt"> </td></tr> </table> 5-7 Years 5 Years 5 Years 24320 21077 137817 665697 62990 1428 79508 4942 676748 On January 5, 2021, the Company paid off a Note Payable dated July 7, 2020 by issuing cash payment in the amount of $63,271 comprised of $48,000 in principal and $15,271 in accrued interest and prepayment penalties.   On January 12, 2021, the Company received monies in exchange for a Note Payable having a Face Value of $150,000 with interest accruing at 5%. The Note is convertible after 180 days from issuance into Common Stock at a price equal to $0.30 per share.   On January 12 and 28, and on March 3, 2021, the holder of a Note Payable dated December 31, 2019 elected to convert a total of $53,000 in principal into 53,000,000 shares of Common Stock leaving a principal balance of $11,028.   On January 27, 2021, the Company received monies in exchange for a Note Payable having a Face Value of $300,000 with interest accruing at 5%. The Note is convertible after 180 days from issuance into Common Stock at a price equal to $0.50 per share.   On January 29, 2021, the holder of a Note Payable dated July 27, 2020 elected to convert the entire principal amount of $102,000 and accrued interest of $4,171 into 5,044,456 shares of Common Stock leaving a balance of $-0-.   On February 12, 2021, the Company received monies in exchange for a Note Payable having a Face Value of $700,000 with interest accruing at 5%. The Note is convertible after 180 days from issuance into Common Stock at a price equal to $0.60 per share.   On February 22, 2021, the holder of a Note Payable dated August 14, 2020 elected to convert the entire principal amount of $67,000 and accrued interest of $2,680 into 542,173 shares of Common Stock leaving a balance of $-0-.   On February 22, 2021, the funding bank informed the Company that the SBA has fully forgiven the Company's PPP Loan dated April 27, 2020 in the amount of $50,655.   The Company computes loss per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement.   Basic net income (loss) per share is calculated by dividing net (loss) by the weighted-average common shares outstanding. Diluted net income per share is calculated by dividing net income by the weighted-average common shares outstanding during the period using the treasury stock method or the two-class method, whichever is more dilutive. As the Company incurred net losses for the year ended December 31, 2020 no potentially dilutive securities were included in the calculation of diluted earnings per share as the impact would have been anti-dilutive.   Therefore, basic and dilutive net (loss) per share were the same as of December 31, 2020 and 2019.   During the years ended December 31, 2020 and 2019, the legal fees incurred were related to services provided to the Company to assist with its regulatory requirements with the Securities and Exchange Commission, patenting costs and one ongoing litigation.   The Company’s Notes Payable at December 31, 2020 consisted of the following:   On April 1, 2017, the Company received monies in exchange for a Note Payable having a Face Value of $100,000 Canadian ($74,970 US at September 30, 2020) with interest payable quarterly at 9%, which Note was due April 1, 2019. The Note is convertible any time after issuance into $0.001 par value Common Stock at a price of $0.015 Canadian (approximately $0.011 US) per share. The Company estimates that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion. In June 2018, the Company filed an action in the Superior Court of the Province of Quebec in the District of Montreal (Canada) against the holder of this Note. The complaint alleges among other things, claims of misrepresentations and misleading conduct resulting in damages to the Company in an amount of approximately $200,000 Canadian (approximately $143,000 US). A date for the hearings to commence was set for November 16, 2020. On November 10, 2020, the Company elected to pay off the Note together with accrued interest of $14,696 Canadian (approximately $10,500 US) and terminate the proceedings.   On September 10, 2018, the Company issued two Notes Payable having an aggregate Face Value of $36,500 with interest accruing at 8%. The two Notes were issued for services rendered to the Company and had maturity dates in June 2019. The Company was unable to pay the notes and on November 30, 2019 the Company issued a new Note which included accrued interest and accelerated interest of $7,059 for a total Face Value of $43,559. The new Note accrues interest at 8% and is convertible after 180 days from issuance into Common Stock at a price 35% below market value. The new Note was due August 31, 2020. During the year ended December 31, 2020, the entire principal amount of $43,559 of this Note plus accrued interest of $2,523 was converted into 14,198,048 shares of Common Stock valued at $86,685 resulting in a loss of $40,603.   On December 24, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $87,000 with interest accruing at 8% was due December 24, 2019. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. As of December 31, 2020, the entire principal amount of $87,000 of this Note plus accrued interest of $9,639 was converted into 43,986,317 shares of Common Stock valued at $276,396 resulting in a loss of $161,036.   On January 8, 2019, the Company received monies in exchange for a Note Payable having a Face Value of $54,000 with interest accruing at 8% was due January 8, 2020. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. During the year ended December 31, 2020, the entire principal amount of $54,000 of this Note plus accrued interest of $9,814 was converted into 44,931,640 shares of Common Stock valued at $365,787 resulting in a loss of $301,973.   On February 5, 2019, the Company received monies in exchange for a Note Payable having a Face Value of $37,450 with interest accruing at 8% was due October 10, 2019. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. During the year ended December 31, 2020, the entire principal amount of $37,450 of this Note plus accrued interest of $2,996 was converted into 38,263,409 shares of Common Stock valued at $217,971 resulting in a loss of $182,790.   On July 2, 2019, the Company received monies in exchange for a Note Payable having a Face Value of $40,000 with interest accruing at 8% was due April 30, 2020. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. During the year ended December 31, 2020, the entire principal amount of $40,000 of this Note plus accrued interest of $1,600 was converted into 13,099,359 shares of Common Stock valued at $58,684 resulting in a loss of $17,084.   On July 26, 2019, the Company received monies in exchange for a Note Payable having a Face Value of $50,000 with interest accruing at 8%, which became due July 26, 2020. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. During the year ended December 31, 2020, the entire principal of $50,000 of this Note plus accrued interest of $4,909 was converted into 43,522,363 shares of Common Stock valued at $131,370 resulting in a loss of $76,461.   On September 12, 2019, the Company received monies in exchange for a Note Payable having a Face Value of $43,000 with interest accruing at 8% is due July 15, 2020. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. During the year ended December 31, 2020, the entire principal amount of $43,000 of this Note plus accrued interest of $1,720 was converted into 38,855,726 shares of Common Stock valued at $117,177 resulting in a loss of $72,457.   On December 14, 2019, the Company received monies in exchange for a Note Payable having a Face Value of $42,800 with interest accruing at 8% and which is due December 14, 2020. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. During the year ended December 31, 2020, the entire principal amount of $42,800 of this Note plus accrued interest of $1,712 was converted into 18,592,605 shares of Common Stock valued at $81,796 resulting in a loss of $37,284.   A Note Payable dated December 31, 2019 having a Face Value of $30,120 and accruing interest at 12% was due December 31, 2020. On December 1, 2020, the Company paid off the entire principal balance of this Note, together with accrued interest of $3,614 by issuing cash payment of $33,734.   A Note Payable dated December 31, 2018 having a Face Value of $136,744 and accruing interest at 12% was due December 31, 2019. On October 1, 2019, the holder of this note requested to convert $30,000 in principal amount into 1,500,000 shares of Common Stock, leaving a principal balance $106,744. On December 31, 2019, the Company renewed the remaining principal balance of this Note, together with accrued interest of $15,509 for a 12-month period. The new Note has a Face Value of $122,253 and accrues interest at 12%. This Note matures on December 31, 2020. On August 27, 2020, the holder of this Note transferred all of its interest therein to a third party and on September 4, 2020, the Company agreed to render the Note convertible at $0.001 per share. During the year ended December 31, 2020, an aggregate principal amount of $58,225 of this Note plus accrued interest of $9,775 was converted into 68,000,000 shares of Common Stock valued at $1,286,400 resulting in a loss of $1,218,400. This note is currently past due and the Company is in discussion with the holder to extend the due date.   On April 17, 2020, the Company’s Canadian subsidiary received a CEBA Loan (Canada Emergency Business Account Loan) from CIBC (Canadian Imperial Bank of Commerce) in the principal amount of $40,000 Canadian ($29,352 US) as part of the Canadian government’s COVID-19 relief program. The CEBA Loan is non-interest bearing if repaid on or before December 31, 2022 (the “Termination Date”). The CEBA Loan is considered repaid in full if the borrower repays 75% of the Principal Amount on or before the Termination Date. If the CEBA Loan is not repaid in full on or before the Termination Date, the lender will automatically extend the term of the loan by three years until December 31, 2025 (the “Extension Period”). During the Extension Period, interest will be charged, and will accrue on the outstanding amount of the CEBA Loan at a fixed rate of 5% per year, calculated daily and compounded monthly. The outstanding balance of the CEBA Loan and all accrued interest will be due at the end of the Extension Period.   On April 27, 2020, the Company received a Paycheck Protection Program loan ("PPP Loan") in the principal amount of $50,655 from the US Small Business Administration (“SBA”) as part of the US government’s COVID-19 relief program. This loan accrues interest at the rate of 1% per annum. The Company is obligated to make payments of principal and interest totaling $2,133 each month commencing on November 27, 2020, with any remaining balances due and payable on or before April 27, 2022. The proceeds derived from this loan may only be used for payroll costs, interest on mortgages, rent and utilities (“Admissible Expenses”). In addition, the Paycheck Protection Program provides for conditional loan forgiveness if the Company utilizes at least 75% of the proceeds from the loan to pay Admissible Expenses. On December 15, 2020, the Company applied to the funding bank for forgiveness of this loan per SBA guidance. On December 18, 2020, the Company received notification that the funding bank has approved forgiveness of the loan in its entirety and that it has submitted a request to the SBA for final approval. On February 22, 2021, the funding bank informed the Company that the SBA has fully forgiven the loan.   On June 1, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $42,000 with interest accruing at 8% is due June 1, 2021. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. On December 2, 2020, the Company paid off the entire principal balance of this Note, together with accrued interest and prepayment penalties of $13,435 by issuing payment of $55,435.   On June 9, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $37,000 with interest accruing at 8% is due June 9, 2021. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. On December 2, 2020, the Company paid off the entire principal balance of this Note, together with accrued interest and prepayment penalties of $11,779 by issuing payment of $48,779.   On July 7, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $48,000 with interest accruing at 8% is due July 7, 2021. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. The Company will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on January 3, 2021 which is 180 days after the issuance date.    On July 27, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $102,000 with interest accruing at 8% is due July 27, 2021. The Note is convertible after 180 days from issuance into Common Stock at a price 30% below market value. The Company will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on January 23, 2021 which is 180 days after the issuance date.    On August 14, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $67,000 with interest accruing at 8% is due August 14, 2021. The Note is convertible after 180 days from issuance into Common Stock at a price 30% below market value. The Company will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on February 10, 2021 which is 180 days after the issuance date.    On September 14, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $250,000 with interest accruing at 5% is due September 14, 2022. The Note is convertible after 180 days from issuance into Common Stock at a price equal to $0.30 per share. The Company will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on March 13, 2021 which is 180 days after the issuance date.    On September 24, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $50,000 with interest accruing at 5% is due September 24, 2022. The Note is convertible after 180 days from issuance into Common Stock at a price equal to $0.30 per share. The Company will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on March 23, 2021 which is 180 days after the issuance date.    On October 20, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $250,000 with interest accruing at 5% is due October 20, 2022. The Note is convertible after 180 days from issuance into Common Stock at a price equal to $0.30 per share. The Company will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on April 18, 2021 which is 180 days after the issuance date.    On November 19, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $250,000 with interest accruing at 8% is due August 19, 2021. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. The Company will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on May 18, 2021 which is 180 days after the issuance date.    On November 24, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $260,000 with interest accruing at 8% is due November 24, 2021. The Note is convertible after 180 days from issuance into Common Stock at a price 30% below market value. The Company will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on May 23, 2021 which is 180 days after the issuance date.    On November 25, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $250,000 with interest accruing at 5% is due November 25, 2022. The Note is convertible after 180 days from issuance into Common Stock at a price equal to $0.30 per share. The Company will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on May 24, 2021 which is 180 days after the issuance date.    On December 2, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $104,215 with interest accruing at 5% is due December 2, 2022. The Note is convertible after 180 days from issuance into Common Stock at a price equal to $0.30 per share. The Company will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on May 31, 2021 which is 180 days after the issuance date.    At December 31, 2020 and December 31, 2019, total accrued interest on Notes Payable was $24,320 and $21,077, respectively.   143661 128269 The stock-based compensation expense for both employee and non-employee awards is generally recognized on a straight-line basis over the requisite service period of the award. The Company accounts for stock-based compensation to employees in conformity with the provisions of ASC Topic 718, Stock Based Compensation. Stock-based compensation to employees consisting of stock option grants and restricted shares are recognized in the statement of operations based on their fair values at the date of grant. The Company accounts for equity instruments issued to non-employees in accordance with the provisions of ASC Topic 718, based upon the fair-value of the underlying instrument.   465005925 EX-101.SCH 11 sbfm-20201231.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statement of Operations and Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statement of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statement of Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - 1. Description of Business link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - 2. Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - 3. Going Concern link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - 4. Patents link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - 5. Capital Stock link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - 6. Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - 7. Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - 8. Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - 9. Notes Payable Related Party link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - 10. Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - 11. Acquisition and Disposition of Atlas Pharma Inc. link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - 12. Leases link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - 13. Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - 2. Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - 2. Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - 6. Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - 7. Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - 11. Acquisition and Disposition of Atlas Pharma Inc. (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - 2. Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - 2. Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - 6. Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - 7. Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - 7. Income Taxes (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - 7. Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - 8. Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - 9. Notes Payable Related Party (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - 11. Acquisition and Disposition of Atlas Pharma Inc. (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - 11. Acquisition and Disposition of Atlas Pharma Inc. (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - 11. Acquisition and Disposition of Atlas Pharma Inc. (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - 11. Acquisition and Disposition of Atlas Pharma Inc. (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 12 sbfm-20201231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 13 sbfm-20201231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 14 sbfm-20201231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Equity Components [Axis] Common Stock Capital Paid In Excess Of Par Value Preferred Shares Comprehensive Income Accumulated Deficit Temporary Difference Tax Effect Property, Plant and Equipment, Type [Axis] Office Equipment Laboratory Equipment Vehicles Class of Stock [Axis] Series A Preferred Stock Series B Preferred Stock Debt Instrument [Axis] Note 1 Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Emerging Growth Company Entity Small Business Entity Ex Transition Period Entity Shell Company Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Entity Interactive Data Current Entity Incorporation State Country Code Entity File Number Statement [Table] Statement [Line Items] ASSETS Current Assets: Cash and cash equivalents Accounts receivable Inventory Prepaid expenses Deposits Total Current Assets Equipment (net of $51,485 and $37,109 depreciation, respectively) Patents (net of $58,918 amortization and $556,120 impairment) TOTAL ASSETS LIABILITIES AND SHAREHOLDERS' EQUITY Current Liabilities: Notes payable Notes payable - related party Accounts payable and accrued expenses Interest payable Total Curent Liabilities Long-term portion of notes payable TOTAL LIABILITIES SHAREHOLDERS' EQUITY Preferred Stock Common Stock, $0.001 par value per share; Authorized 3,000,000,000 Shares; Issued and outstanding 346,419,296 and 35,319,990 at December 31, 2020 and December 31, 2019, respectively Capital paid in excess of par value Accumulated other comprehensive income Accumulated (Deficit) TOTAL SHAREHOLDERS' DEFICIT TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT Equipment depreciation Patent amortization Patent impairment Preferred stock, par value Preferred stock shares authorized Preferred stock shares issued Preferred stock shares outstanding Common stock, par value Common stock shares authorized Common stock shares issued Common stock shares outstanding Income Statement [Abstract] Revenue Cost of Revenues Gross Profit General & Administrative Expenses: Accounting Consulting Legal Office Officer & Director remuneration R&D Depreciation Total General & Administrative Income (Loss) from Operations Other (expense): Loss on debt conversions Foreign exchange gain (loss) Interest expense Miscellaneous income Debt release Gain on interest forgiveness Total Other Income (Expenses) Net income (loss) before income taxes Income taxes Net Income (loss) from continuing operations Net Income (loss) from discontinued operations Net Income (loss) Unrealized gain (loss) from foreign exchange transactions Comprehensive Income (Loss) Basic income (loss) from continuing operations per common share Basic income (loss) from discontinued operations per common share Basic income (loss) per common shares Weighted Average Common Shares Outstanding Statement of Cash Flows [Abstract] Cash Flows From Operating Activities: Net Income (Loss) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Foreign exchange (gain) loss Stock issued for services Stock issued for payment of interest Loss on debt conversion Gain on interest and debt forgiven Loss on disposition of subsidiary (Increase) in accounts receivable (Increase) decrease in inventory (Increase) in prepaid expenses (Increase) in deposits (Decrease) in accounts payable & accrued expenses Increase in interest payable Net Cash Flows (Used) in Operations Cash Flows From Investing Activities: Advances from discontinued operations Purchase equipment Net Cash Flows (Used) in Investing Activities Cash Flows From Financing Activities: Proceed from note payable Payment of notes payable Notes Payable - Interest expense Note payable used to pay origination fees & interest Net Cash Flows Provided by Financing Activities Cash and cash equivalents at beginning of period Net Increase (Decrease) In Cash and cash equivalents Foreign currency translation adjustment Cash and cash equivalents at end of period Supplementary Disclosure Of Cash Flow Information: Cash paid for interest Cash paid for income taxes Stock issued for note conversions Begining balance, shares Begining balance, amount Stock issued for acquisition, shares Stock issued for acquisition, amount Common stock issued to directors Common stock issued for services, shares Common stock issued for services, amount Common stock issued for equipment, shares Common stock issued for equipment, amount Common stock issued for the reduction of notes payable and payment of interest, shares Common stock issued for the reduction of notes payable and payment of interest, amount Preferred stock issued for services, shares Preferred stock issued for services, amount Net (loss) Ending balance, shares Ending balance, amount Organization, Consolidation and Presentation of Financial Statements [Abstract] Description of Business Accounting Policies [Abstract] Summary of Significant Accounting Policies Going Concern Going Concern Goodwill and Intangible Assets Disclosure [Abstract] Patents Equity [Abstract] Capital Stock Earnings Per Share [Abstract] Earnings per share Income Tax Disclosure [Abstract] Income Taxes Notes Payable [Abstract] Notes Payable Notes Payable Related Party Related Party Transactions [Abstract] Related Party Transactions Business Combinations [Abstract] Acquisition and Disposition of Atlas Pharma Inc. Leases [Abstract] Leases Subsequent Events [Abstract] Subsequent Events IMPACT OF CORONAVIRUS (COVID-19) PANDEMIC PRINCIPLES OF CONSOLIDATION USE OF ESTIMATES CASH AND CASH EQUIVALENTS PROPERTY AND EQUIPMENT EARNINGS PER SHARE INCOME TAXES FUNCTIONAL CURRENCY CONCENTRATION OF CREDIT RISKS FINANCIAL INSTRUMENTS AND FAIR VALUE OF FINANCIAL INSTRUMENTS NOTES PAYABLE ACCOUNTING FOR DERIVATIVES LIABILITIES EQUITY INSTRUMENTS ISSUED TO EMPOYEES OR NON-EMPLOYEES FOR ACQUIRING GOODS OR SERVICES BASIC AND DILUTED NET GAIN (LOSS) PER SHARE REVENUE RECOGNITION RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS LEGAL FEES DATE OF MANAGEMENT'S REVIEW Estimated useful lives of property plant and equipment Schedule of earnings per share computation Temporary differences Income tax reconciliation Acquisition Discontinued Operations Income Statement Discontinued Operations Balance Sheet Long-Lived Tangible Asset [Axis] Estimated useful lives Cash Net (loss) attributable to common stockholders Basic weighted average outstanding shares of common stock Dilutive effects of common share equivalents Dilutive weighted average outstanding shares of common stock Net loss per share of common stock - basic and diluted Deferred tax assets: Net operating loss US Other differences Net deferred tax assets Valuation allowance Total deferred tax asset Deferred tax liabilities Net deferred tax asset U.S. Federal statutory graduated income tax rate State income tax rate, net of federal benefit Net income tax rate Net operating loss used Net operating loss for which no tax benefit is currently available Income tax rate Canada Federal statutory rate Canada Provincial rate Net rate Net operating loss used (Canada) Net operating loss for which no tax benefit is currently available (Canada) Federal net operating loss carryforwards Deferred tax asset net operating loss carryforwards Change in the valuation allowance Interest accrued on note Face value Accrued interest Cash Accounts receivable Prepaids Property and equipment Goodwill Liabilities assumed ($172,899 Canadian) Total consideration Cost of revenues Revenues Gross profit General and administrative expenses Gain (Loss) from operations Other income (expense) - Interest Income (Loss) from Operations Loss on disposal Net income (loss) from discontinued operations ASSETS Current Assets: Cash and cash equivalents Accounts receivable Total Current Assets Equipment (net of $0 and $34,959 depreciation) Goodwill TOTAL ASSETS LIABILITIES Current Liabilities: Notes payable Notes payable - related party Related party advances Accounts payable & accrued expenses Total Current Liabilities TOTAL LIABILITIES Cash flows used in discontinued operations Custom Element. Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Gross Profit General and Administrative Expense Operating Income (Loss) Induced Conversion of Convertible Debt Expense Interest Expense Extinguishment of Debt, Amount Nonoperating Income (Expense) Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Net Income (Loss) Attributable to Parent Foreign Currency Transaction Gain, before Tax Gain (Loss) on Disposition of Assets Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Repayments of Notes Payable Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) Shares, Issued Substantial Doubt about Going Concern [Text Block] Deferred Tax Assets, Valuation Allowance Operating Loss Carryforwards, Valuation Allowance Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Disposal Group, Including Discontinued Operation, Interest Expense Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net Disposal Group, Including Discontinued Operation, Goodwill DisposalGroupIncludingDiscontinuedOperationsNotesPayable DisposalGroupIncludingDiscontinuedOperationsNotesPayableRelatedParty EX-101.PRE 15 sbfm-20201231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 16 R1.htm IDEA: XBRL DOCUMENT v3.21.1

Document and Entity Information - USD ($)
12 Months Ended

Dec. 31, 2020

Mar. 30, 2021

Jun. 30, 2020

Cover [Abstract]

Entity Registrant Name Sunshine Biopharma, Inc

Entity Central Index Key 0001402328

Document Type 10-K

Document Period End Date Dec. 31, 2020

Amendment Flag false

Current Fiscal Year End Date --12-31

Is Entity a Well-known Seasoned Issuer? No

Is Entity a Voluntary Filer? No

Is Entity's Reporting Status Current? Yes

Entity Filer Category Non-accelerated Filer

Entity Emerging Growth Company true

Entity Small Business true

Entity Ex Transition Period true

Entity Shell Company false

Entity Public Float $ 2,790,475

Entity Common Stock, Shares Outstanding 465,005,925

Document Fiscal Period Focus FY

Document Fiscal Year Focus 2020

Entity Interactive Data Current Yes

Entity Incorporation State Country Code CO

Entity File Number 000-52898

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Cover page.
+ References
No definition available.
+ Details

Name: dei_CoverAbstract

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details

Name: dei_EntityExTransitionPeriod

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details

Name: dei_EntityFileNumber

Namespace Prefix: dei_

Data Type: dei:fileNumberItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationStateCountryCode

Namespace Prefix: dei_

Data Type: dei:edgarStateCountryItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-T
-Number 232
-Section 405
+ Details

Name: dei_EntityInteractiveDataCurrent

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.
+ References
No definition available.
+ Details

Name: dei_EntityPublicFloat

Namespace Prefix: dei_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
+ References
No definition available.
+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
+ References
No definition available.
+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

Document and Entity Information - USD ($)	12 Months Ended
Dec. 31, 2020	Mar. 30, 2021	Jun. 30, 2020
Cover [Abstract]
Entity Registrant Name	Sunshine Biopharma, Inc
Entity Central Index Key	0001402328
Document Type	10-K
Document Period End Date	Dec. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Small Business	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Public Float			$ 2,790,475
Entity Common Stock, Shares Outstanding		465,005,925
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2020
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	CO
Entity File Number	000-52898

XML 17 R2.htm IDEA: XBRL DOCUMENT v3.21.1

Consolidated Balance Sheets - USD ($)

Dec. 31, 2020

Dec. 31, 2019

Current Assets:

Cash and cash equivalents $ 989,888 $ 40,501

Accounts receivable 1,916 430

Inventory 23,771 15,910

Prepaid expenses 2,778 1,255

Deposits 7,590 7,590

Total Current Assets 1,025,943 65,686

Equipment (net of $51,485 and $37,109 depreciation, respectively) 19,531 32,456

Patents (net of $58,918 amortization and $556,120 impairment) 0 0

TOTAL ASSETS 1,045,474 98,142

Current Liabilities:

Notes payable 820,454 586,307

Notes payable - related party 143,661 129,261

Accounts payable and accrued expenses 62,870 96,882

Interest payable 24,320 21,077

Total Curent Liabilities 1,051,305 833,527

Long-term portion of notes payable 949,006 0

TOTAL LIABILITIES 2,000,311 833,527

SHAREHOLDERS' EQUITY

Common Stock, $0.001 par value per share; Authorized 3,000,000,000 Shares; Issued and outstanding 346,419,296 and 35,319,990 at December 31, 2020 and December 31, 2019, respectively 346,418 35,320

Capital paid in excess of par value 18,820,343 16,616,426

Accumulated other comprehensive income (2,871) (2,495)

Accumulated (Deficit) (20,218,727) (17,434,636)

TOTAL SHAREHOLDERS' DEFICIT (954,837) (735,385)

TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT 1,045,474 98,142

Series A Preferred Stock

SHAREHOLDERS' EQUITY

Preferred Stock 0 0

Series B Preferred Stock

SHAREHOLDERS' EQUITY

Preferred Stock $ 100,000 $ 50,000

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(4))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(3))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_DepositsAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InterestPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before valuation reserves of merchandise or goods held by the entity that are readily available for sale and items held by the entity which are partially complete or in the process of being readied for sale.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(1),(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryFinishedGoodsAndWorkInProcess

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_NotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a)(5))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_NotesPayableRelatedPartiesClassifiedCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 18 R3.htm IDEA: XBRL DOCUMENT v3.21.1

Consolidated Balance Sheets (Parenthetical) - USD ($)
12 Months Ended

Dec. 31, 2020

Dec. 31, 2019

Equipment depreciation $ 51,485 $ 37,109

Patent amortization 58,918 $ 58,918

Patent impairment $ 556,120

SHAREHOLDERS' EQUITY

Common stock, par value $ 0.001 $ 0.001

Common stock shares authorized 3,000,000,000 3,000,000,000

Common stock shares issued 346,419,296 35,319,990

Common stock shares outstanding 346,419,296 35,319,990

Series B Preferred Stock

SHAREHOLDERS' EQUITY

Preferred stock, par value $ 0.10 $ 0.10

Preferred stock shares authorized 1,000,000 500,000

Preferred stock shares issued 1,000,000 500,000

Preferred stock shares outstanding 1,000,000 500,000

X

- References
No definition available.
+ Details

Name: SBFM_PatentAccumulatedAmortization

Namespace Prefix: SBFM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275
+ Details

Name: us-gaap_ImpairmentOfIntangibleAssetsFinitelived

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 19 R4.htm IDEA: XBRL DOCUMENT v3.21.1

Consolidated Statement of Operations and Comprehensive Income (Loss) - USD ($)
12 Months Ended

Dec. 31, 2020

Dec. 31, 2019

Income Statement [Abstract]

Revenue $ 71,410 $ 21,121

Cost of Revenues 25,847 11,050

Gross Profit 45,563 10,071

General & Administrative Expenses:

Accounting 81,524 89,253

Consulting 15,360 74,124

Legal 89,587 107,196

Office 89,022 74,904

Officer & Director remuneration 271,930 277,252

R&D 60,948 15,204

Depreciation 14,066 13,774

Total General & Administrative 622,437 651,707

Income (Loss) from Operations (576,874) (641,636)

Other (expense):

Loss on debt conversions (2,057,513) (314,752)

Foreign exchange gain (loss) 4,891 (15,099)

Interest expense (168,105) (115,901)

Miscellaneous income 3,000 0

Debt release 7,674 7,967

Gain on interest forgiveness 2,836 1,367

Total Other Income (Expenses) (2,207,217) (436,418)

Net income (loss) before income taxes (2,784,091) (1,078,054)

Income taxes 0 0

Net Income (loss) from continuing operations (2,784,091) (1,078,054)

Net Income (loss) from discontinued operations 0 (582,237)

Net Income (loss) (2,784,091) (1,660,291)

Unrealized gain (loss) from foreign exchange transactions 376 1,243

Comprehensive Income (Loss) $ (2,783,715) $ (1,659,048)

Basic income (loss) from continuing operations per common share $ (0.01) $ (0.10)

Basic income (loss) from discontinued operations per common share 0 (0.05)

Basic income (loss) per common shares $ (0.01) $ (0.15)

Weighted Average Common Shares Outstanding 204,096,338 10,932,813

X

- Definition
Custom Element.
+ References
No definition available.
+ Details

Name: SBFM_FinancialConsulting

Namespace Prefix: SBFM_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_OfficeExpense

Namespace Prefix: SBFM_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(22))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(24))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(26))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate cost of goods produced and sold and services rendered during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_CostOfRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross amount of debt extinguished.
+ References
No definition available.
+ Details

Name: us-gaap_ExtinguishmentOfDebtAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 35
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895
+ Details

Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_GeneralAndAdministrativeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599
+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of income (loss) from continuing operations attributable to the parent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4613673-111683

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.13)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794
+ Details

Name: us-gaap_IncomeLossFromContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1)(i))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.3)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(20))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-03(13))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868656-224227

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsPerBasicShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(12))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3B
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337
+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(12))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(14))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585
+ Details

Name: us-gaap_IncomeTaxesPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 40
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=120517889&loc=d3e6835-112609
+ Details

Name: us-gaap_InducedConversionOfConvertibleDebtExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).
+ References
No definition available.
+ Details

Name: us-gaap_InterestAndOtherIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (210.5-03(11))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_LegalFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of revenue and income classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.4)
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263
+ Details

Name: us-gaap_OtherIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07.2(a),(b),(c),(d))
-URI http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 220
-Section 45
-Paragraph 3
-Subparagraph (k)
-URI http://asc.fasb.org/extlink&oid=118262090&loc=SL114874205-224268
+ Details

Name: us-gaap_ProfessionalFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 20 R5.htm IDEA: XBRL DOCUMENT v3.21.1

Consolidated Statement of Cash Flows - USD ($)
12 Months Ended

Dec. 31, 2020

Dec. 31, 2019

Cash Flows From Operating Activities:

Net Income (Loss) $ (2,784,091) $ (1,660,291)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization 14,066 13,774

Foreign exchange (gain) loss (4,891) 15,099

Stock issued for services 50,000 261,690

Stock issued for payment of interest 42,233 17,197

Loss on debt conversion 2,057,513 314,752

Gain on interest and debt forgiven 10,510 (9,334)

Loss on disposition of subsidiary 0 582,237

(Increase) in accounts receivable (1,486) (430)

(Increase) decrease in inventory (7,861) (15,910)

(Increase) in prepaid expenses (1,523) (7,676)

(Increase) in deposits 0 0

(Decrease) in accounts payable & accrued expenses (35,012) (18,692)

Increase in interest payable 3,243 11,786

Net Cash Flows (Used) in Operations (657,299) (495,798)

Cash Flows From Investing Activities:

Advances from discontinued operations 0 (14,416)

Purchase equipment (1,191) (860)

Net Cash Flows (Used) in Investing Activities (1,191) (15,276)

Cash Flows From Financing Activities:

Proceed from note payable 1,674,246 441,230

Payment of notes payable (106,600) (53,000)

Notes Payable - Interest expense 40,607 25,795

Note payable used to pay origination fees & interest 0 28,230

Net Cash Flows Provided by Financing Activities 1,608,253 442,255

Cash and cash equivalents at beginning of period 40,501 115,216

Net Increase (Decrease) In Cash and cash equivalents 949,763 (68,819)

Foreign currency translation adjustment (376) (5,896)

Cash and cash equivalents at end of period 989,888 40,501

Supplementary Disclosure Of Cash Flow Information:

Cash paid for interest 20,963 0

Cash paid for income taxes 0 0

Stock issued for note conversions $ 2,515,015 $ 717,726

X

- References
No definition available.
+ Details

Name: SBFM_DispositionIncludingDiscontinuedOperationsAdvances

Namespace Prefix: SBFM_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_LossOnConversionOfNotesPayable

Namespace Prefix: SBFM_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_StockIssuedForPaymentInterestOnNotesPayable

Namespace Prefix: SBFM_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section 45
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840
+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(f))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
+ Details

Name: us-gaap_DebtInstrumentDecreaseForgiveness

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906
+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before tax of foreign currency transaction realized and unrealized gain recognized in the income statement.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895
+ Details

Name: us-gaap_ForeignCurrencyTransactionGainBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_GainLossOnDispositionOfAssets1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585
+ Details

Name: us-gaap_IncomeTaxesPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net cash inflow or outflow for the increase (decrease) in the beginning and end of period deposits balances.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3095-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 230
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121551529&loc=d3e60009-112784
+ Details

Name: us-gaap_IncreaseDecreaseInDeposits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInInterestPayableNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 17
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585
+ Details

Name: us-gaap_InterestPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Expenses paid for obtaining loans which includes expenses such as application and origination fees.
+ References
No definition available.
+ Details

Name: us-gaap_LoanProcessingFee

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The gross value of stock issued during the period upon the conversion of convertible securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 21 R6.htm IDEA: XBRL DOCUMENT v3.21.1

Consolidated Statement of Shareholders' Equity - USD ($)

Common Stock

Capital Paid In Excess Of Par Value

Preferred Shares

Comprehensive Income

Accumulated Deficit

Total

Begining balance, shares at Dec. 31, 2018 4,282,620 500,000

Begining balance, amount at Dec. 31, 2018 $ 4,283 $ 15,668,047 $ 50,000 $ (3,738) $ (15,774,345) $ (55,753)

Common stock issued to directors $ 9,150 195,150 204,300

Common stock issued for services, shares 1,455,000

Common stock issued for services, amount $ 1,455 55,935 57,390

Common stock issued for equipment, amount 0

Common stock issued for the reduction of notes payable and payment of interest, shares 20,432,370

Common stock issued for the reduction of notes payable and payment of interest, amount $ 20,432 697,294 717,726

Net (loss) 1,243 (1,660,291) (1,659,048)

Ending balance, shares at Dec. 31, 2019 35,319,990 500,000

Ending balance, amount at Dec. 31, 2019 $ 35,320 16,616,426 $ 50,000 (2,495) (17,434,636) (735,385)

Common stock issued for the reduction of notes payable and payment of interest, shares 311,099,306

Common stock issued for the reduction of notes payable and payment of interest, amount $ 311,098 2,203,917 2,515,015

Preferred stock issued for services, shares 500,000

Preferred stock issued for services, amount $ 50,000 50,000

Net (loss) (376) (2,784,091) (2,784,467)

Ending balance, shares at Dec. 31, 2020 346,419,296 1,000,000

Ending balance, amount at Dec. 31, 2020 $ 346,418 $ 18,820,343 $ 100,000 $ (2,871) $ (20,218,727) $ (954,837)

X

- References
No definition available.
+ Details

Name: SBFM_CommonStockIssuedForReductionOfNotePayableAmount

Namespace Prefix: SBFM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_CommonStockIssuedForReductionOfNotePayableShares

Namespace Prefix: SBFM_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_EquityStatementNetIncomeLoss

Namespace Prefix: SBFM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_StockIssuedToBuyEquipment

Namespace Prefix: SBFM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_SharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares of stock issued attributable to transactions classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesOther

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of shares of stock issued attributable to transactions classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 22 R7.htm IDEA: XBRL DOCUMENT v3.21.1

1. Description of Business
12 Months Ended

Dec. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Description of Business
Sunshine Biopharma, Inc. (the "Company") was originally incorporated under the name Mountain West Business Solutions, Inc. on August 31, 2006 in the State of Colorado. Until October 2009, the Company was operating as a business consultancy firm.

Effective October 15, 2009, the Company acquired Sunshine Biopharma, Inc. in a transaction classified as a reverse acquisition. Sunshine Biopharma, Inc. was holding an exclusive license to a new anticancer drug bearing the laboratory name, Adva-27a (the “License Agreement”). Upon completion of the reverse acquisition transaction, the Company changed its name to Sunshine Biopharma, Inc. and began operating as a pharmaceutical company focusing on the development of the licensed Adva-27a anticancer drug.

In October 2012, the Company published the results of its initial preclinical studies of Adva-27a in the peer-reviewed journal, ANTICANCER RESEARCH. The preclinical studies were conducted in collaboration with Binghamton University, a State University of New York. The publication is entitled “Adva-27a, a Novel Podophyllotoxin Derivative Found to Be Effective Against Multidrug Resistant Human Cancer Cells” [ANTICANCER RESEARCH Volume 32, Pages 4423-4432 (2012)].

In July 2014, the Company formed a wholly owned Canadian subsidiary, Sunshine Biopharma Canada Inc. (“Sunshine Canada”) for the purposes of offering generic pharmaceutical products in Canada and elsewhere around the world. Sunshine Canada has signed licensing agreements for four (4) generic prescription drugs for treatment of breast cancer, prostate cancer and BPH (Benign Prostatic Hyperplasia).

In December 2015, the Company acquired all worldwide issued (US Patent Number 8,236,935, and 10,272,065) and pending patents under PCT/FR2007/000697 and PCT/CA2014/000029 for the Adva-27a anticancer compound from Advanomics Corporation, a related party, in exchange for an aggregate of 803,264 shares of Common Stock valued at $835,394 and terminated the License Agreement. In 2016, the remaining value of these patents was impaired. The Company is however continuing development of the Adva-27a anticancer drug covered by these patents.

On January 1, 2018, the Company acquired all of the issued and outstanding shares of Atlas Pharma Inc. (“Atlas”), a Canadian privately held analytical chemistry company. The purchase price for the shares was Eight Hundred Forty-Eight Thousand Dollars $848,000 Canadian ($676,748 US). The purchase price included a cash payment of $100,500 Canadian ($80,289 US), plus the issuance of 50,000 shares of the Company’s Common Stock valued at $238,000, and a promissory note (“Atlas Debt”) in the principal amount of $450,000 Canadian ($358,407 US), with interest payable at the rate of 3% per annum. Effective April 1, 2019, the Company re-assigned all of its stock in Atlas back to the original owner in exchange for the Atlas Debt. The loss on the disposition was $580,125. See Note 11, below for a more detailed explanation of this disposition.

In March 2018, the Company formed NOX Pharmaceuticals, Inc., a wholly owned Colorado corporation and assigned all of the Company’s interest in the Adva27a anticancer drug to that company. NOX Pharmaceuticals Inc.’s mission is to research, develop and commercialize proprietary drugs including Adva-27a.

In December 2018, the Company launched its first over-the-counter product, Essential 9™, a nutritional supplement comprised of the nine (9) essential amino acids that the human body cannot make. Essential 9tm has been authorized for marketing by Health Canada under NPN 80089663.

Effective February 1, 2019, the Company completed a 20 to 1 reverse split of its Common Stock, reducing the issued and outstanding shares of Common Stock from 1,713,046,242 to 85,652,400 (the “First Reverse Stock Split”). The Company’s authorized capital of Common Stock remained as previously established at 3,000,000,000 shares.

In November 2019, the Company received Health Canada approval for a new Calcium-Vitamin D supplement. Health Canada issued NPN 80093432 through which it authorized the Company to manufacture and sell the new Calcium-Vitamin D supplement under the brand name Essential Calcium-Vitamin Dtm.

Effective April 6, 2020, the Company completed another 20 to 1 reverse split of its Common Stock, reducing the issued and outstanding shares of Common Stock from 1,193,501,925 to 59,675,417 (the “Second Reverse Stock Split”). The Company’s authorized capital of Common Stock remained as previously established at 3,000,000,000 shares.

On May 22, 2020, the Company filed a patent application in the United States for a new treatment for Coronavirus infections. The Company’s patent application covers composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease (Mpro), an enzyme that is essential for viral replication. The patent application has a priority date of May 22, 2020.

On June 17, 2020, the Company filed an amendment to its Articles of Incorporation (the “Amendment”) with the State of Colorado, to eliminate the Series “A” Preferred Shares consisting of Eight Hundred and Fifty Thousand (850,000) shares, par value $0.10 per share, and the designation thereof, which shares were returned to the status of undesignated shares of Preferred Stock. In addition, the Amendment increased the number of authorized Series “B” Preferred Shares from Five Hundred Thousand (500,000) to One Million (1,000,000) shares.

Also on June 17, 2020, the Company issued Five Hundred Thousand (500,000) shares of Series “B” Preferred Stock in favor of Dr. Steve N. Slilaty, the Company’s CEO, in consideration for the COVID-19 treatment technology he developed. The Series “B” Preferred Stock is non-convertible, non-redeemable, non-retractable and has a superior liquidation value of $0.10 per share. Each share of Series “B” Preferred Stock is entitled to 1,000 votes per share. This issuance brought the total number of Series “B” Preferred Stock held by Dr. Slilaty to 1,000,000 shares.

On September 8, 2020, the Company executed a financing agreement with RB Capital Partners, Inc., La Jolla, CA, who has agreed to provide the Company with a minimum of $2 million in convertible debt financing over the next three to six months pursuant to the terms and conditions included in relevant Promissory Notes (the “Promissory Notes”). The Promissory Notes will bear interest at the rate of 5% per annum and will be fully convertible into shares of shares of the Company’s Common Stock at a conversion price equal to the market value of the Company’s Common Stock on the applicable conversion date or $0.30 per share, whichever is greater. The Promissory Notes will have a maturity date of two years from the date of issuance and must be fully converted on or before the maturity date. The Company has the right under these Promissory Notes to pay off all or any part of the Promissory Notes at any time without penalty. As of December 31, 2020, the Company has received a total of $1,350,000 in funding under this agreement.

Effective October 6, 2020, the Company entered into a Research Agreement (the “Agreement”) with the University of Georgia Research Foundation, Inc. (“UGARF”), representing the University of Georgia (“UGA”). The purpose of the Agreement is to memorialize the terms of the Company working together with UGA to conduct the necessary research and development to advance the Company’s Anti-Coronavirus lead compound, SBFM-PL4 (or derivatives thereof) through various stages of preclinical development, animal studies and clinical trials for Coronavirus infections. The Agreement grants the Company an exclusive worldwide license for all of the intellectual property developed by UGA, whether alone or jointly with the Company.

The Company's financial statements reflect both the First and Second Reverse Stock Split on a retroactive basis and represent the consolidated activity of Sunshine Biopharma, Inc. and its subsidiaries (Sunshine Biopharma Canada Inc. and NOX Pharmaceuticals Inc.) herein collectively referred to as the "Company".

During the last twelve month period the Company has continued to raise money through the issuance of convertible debt. The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding to operationalize the Company’s proprietary drug development program and other business activities.

X

- Definition
The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 23 R8.htm IDEA: XBRL DOCUMENT v3.21.1

2. Summary of Significant Accounting Policies
12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Summary of Significant Accounting Policies
This summary of significant accounting policies is presented to assist the reader in understanding the Company's financial statements. The consolidated financial statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity. These accounting policies conform to Generally Accepted Accounting Principles and have been consistently applied in the preparation of the financial statements.

IMPACT OF CORONAVIRUS (COVID-19) PANDEMIC

In March 2020, the World Health Organization declared Coronavirus and its associated disease, COVID-19, a global pandemic. Conditions surrounding the Coronavirus outbreak are evolving rapidly and government authorities around the world have implemented emergency measures to mitigate the spread of the virus. The outbreak and related mitigation measures have had and will continue to have a material adverse impact on the world economies and the Company's business activities. It is not possible for the Company to predict the duration or magnitude of the adverse conditions of the outbreak and their effects on the Company’s business or ability to raise funds. No adjustments have been made to the amounts reported in the Company's financial statements as a result of this matter.

PRINCIPLES OF CONSOLIDATION

The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

USE OF ESTIMATES

The preparation of financial statements in conformity with US Generally Accepted Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant estimates and assumptions made by management are valuation of equity instruments, depreciation of property and equipment, and deferred tax asset valuation. Actual results could differ from those estimates as the current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.

CASH AND CASH EQUIVALENTS

For the Balance Sheets and Statements of Cash Flows, all highly liquid investments with maturity of 90 days or less are considered to be cash equivalents. The Company had a cash balance of $989,888 and $40,501 as of December 31, 2020 and December 31, 2019, respectively. At times such cash balances may be in excess of the FDIC limit of $250,000 or the equivalent in Canada.

PROPERTY AND EQUIPMENT

Property and equipment is reviewed for recoverability when events or changes in circumstances indicate that its carrying value may exceed future undiscounted cash inflows. As of December 31, 2020 and 2019, the Company had not identified any such impairment. Repairs and maintenance are charged to operations when incurred and improvements and renewals are capitalized.

Property and equipment are stated at cost. Depreciation is calculated using the straight-line method for financial reporting purposes and accelerated methods for tax purposes. Their estimated useful lives are as follows:

Office Equipment: 5-7 Years

Laboratory Equipment: 5 Years

Vehicles: 5 Years

EARNINGS PER SHARE

The Company has adopted the Financial Accounting Standards Board (FASB) ASC Topic 260 regarding earnings / loss per share, which provides for calculation of “basic” and “diluted” earnings / loss per share. Basic earnings / loss per share includes no dilution and is computed by dividing net income / loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings / loss per share reflect the potential dilution of securities that could share in the earnings of an entity similar to fully diluted earnings / loss per share.

INCOME TAXES

In accordance with ASC 740 – Income Taxes, the provision for income taxes is computed using the asset and liability method. The liability method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities have been adjusted to reflect changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized.

The Company expects to recognize the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a "more-likely-than-not" threshold, the amount to be recognized in the financial statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. As of December 31, 2020 the Company had no uncertain tax positions. The Company recognizes interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. The Company currently has no federal or state tax examinations nor has it had any federal or state examinations since its inception. To date, the Company has not incurred any interest or tax penalties.

For Canadian and US tax purposes, the Company’s 2017 through 2019 tax years remain open for examination by the tax authorities under the normal three-year statute of limitations.

FUNCTIONAL CURRENCY

The U.S. dollar is the functional currency of the Company which is operating in the United States. The functional currency for the Company's Canadian subsidiary is the Canadian dollar.

The Company translates its Canadian subsidiary's financial statements into U.S. dollars as follows:

● Assets and liabilities are translated at the exchange rate in effect as of the financial statement date.

● Income statement accounts are translated using the weighted average exchange rate for the period.

The Company includes translation adjustments from currency exchange and the effect of exchange rate changes on intercompany transactions of a long-term investment nature as a separate component of shareholders’ equity. There are currently no transactions of a long-term investment nature, nor any gains or losses from non U.S. currency transactions.

CONCENTRATION OF CREDIT RISKS

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents and trade receivables. The Company places its cash equivalents with high credit quality financial institutions.

FINANCIAL INSTRUMENTS AND FAIR VALUE OF FINANCIAL INSTRUMENTS

The Company applies the provisions of accounting guidance, FASB Topic ASC 825, Financial Instruments. ASC 825 requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of December 31, 2020 and 2019, the fair value of cash, accounts receivable and notes receivable, accounts payable, accrued expenses, and other payables approximated carrying value due to the short maturity of the instruments, quoted market prices or interest rates which fluctuate with market rates.

The Company defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).

● Level 1 – Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

● Level 2 – Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability.

● Level 3 – Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.

The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared.

NOTES PAYABLE

Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently carried at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the income statement over the period of the borrowings using the effective interest method.

ACCOUNTING FOR DERIVATIVES LIABILITIES

The Company evaluates stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of ASC Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity’s Own Equity. The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income or other expense.

Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date. The Company determined that none of the Company’s financial instruments meet the criteria for derivative accounting as of December 31, 2020 and 2019.

EQUITY INSTRUMENTS ISSUED TO EMPLOYEES OR NON-EMPLOYEES FOR ACQUIRING GOODS OR SERVICES

The stock-based compensation expense for both employee and non-employee awards is generally recognized on a straight-line basis over the requisite service period of the award. The Company accounts for stock-based compensation to employees in conformity with the provisions of ASC Topic 718, Stock Based Compensation. Stock-based compensation to employees consisting of stock option grants and restricted shares are recognized in the statement of operations based on their fair values at the date of grant. The Company accounts for equity instruments issued to non-employees in accordance with the provisions of ASC Topic 718, based upon the fair-value of the underlying instrument.

BASIC AND DILUTED NET GAIN (LOSS) PER SHARE

The Company computes loss per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement.

Basic net income (loss) per share is calculated by dividing net (loss) by the weighted-average common shares outstanding. Diluted net income per share is calculated by dividing net income by the weighted-average common shares outstanding during the period using the treasury stock method or the two-class method, whichever is more dilutive. As the Company incurred net losses for the year ended December 31, 2020 no potentially dilutive securities were included in the calculation of diluted earnings per share as the impact would have been anti-dilutive.

Therefore, basic and dilutive net (loss) per share were the same as of December 31, 2020 and 2019.

REVENUE RECOGNITION

As of January 1, 2018, the Company adopted ASU No. 201409, “Revenue from Contracts with Customers” (ASC 606). Under the new guidance, an entity will recognize revenue to depict the transfer of promised goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. A five-step model has been introduced for an entity to apply when recognizing revenue. The new guidance also includes enhanced disclosure requirements. The guidance was effective January 1, 2018 and was applied on a modified retrospective basis. The adoption did not have an impact on the Company's financial statements. All of the revenues of the Company are the Company's wholly owned Canadian subsidiary, which sells nutritional supplements through Amazon.com and Amazon.ca.

In Canada, governmental regulations require that companies recognize revenues upon completion of the work by issuing an invoice and remitting the applicable sales taxes (GST and QST) to the appropriate government agency. The Company’s wholly owned Canadian subsidiary's revenue recognition policy is in compliance with these local regulations.

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

In December 2019, the FASB issued ASU 2019-12 “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.” This guidance removes certain exceptions to the general principles in Topic 740 and provides consistent application of U.S. GAAP by clarifying and amending existing guidance. The effective date of the new guidance for public companies is for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the timing of adoption and impact of the updated guidance on its financial statements.

LEGAL FEES

During the years ended December 31, 2020 and 2019, the legal fees incurred were related to services provided to the Company to assist with its regulatory requirements with the Securities and Exchange Commission, patenting costs and one ongoing litigation.

DATE OF MANAGEMENT’S REVIEW

Subsequent events have been evaluated through March 29, 2021, which is the date the Financial Statements were available to be issued.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_BasisOfAccounting

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R9.htm IDEA: XBRL DOCUMENT v3.21.1

3. Going Concern
12 Months Ended

Dec. 31, 2020

Going Concern

Going Concern
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. In the course of its life, the Company has had limited operations and Working Capital deficit. This raises substantial doubt about the Company’s ability to continue as a going concern. The Company believes it can raise capital through equity sales and borrowing to fund its operations. Management believes this will contribute toward its subsequent profitability. The accompanying Financial Statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

X

- References
No definition available.
+ Details

Name: SBFM_GoingConcernAbstract

Namespace Prefix: SBFM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 40
-URI http://asc.fasb.org/subtopic&trid=51888271
+ Details

Name: us-gaap_SubstantialDoubtAboutGoingConcernTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R10.htm IDEA: XBRL DOCUMENT v3.21.1

4. Patents
12 Months Ended

Dec. 31, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Patents
The following is a summary of the patents held by the Company at December 31, 2020 and 2019:

In December 2015, the Company acquired all worldwide issued (US Patent Number 8,236,935, and US Patent Number 10,272,065) and pending patents under PCT/FR2007/000697 and PCT/CA2014/000029 for the Adva-27a anticancer compound from Advanomics Corporation, a related party, in exchange for an aggregate of 803,264 shares of Common Stock valued at $835,394 and terminated the License Agreement. In 2016, the remaining value of these patents was impaired. The Company is however continuing development of the Adva-27a anticancer drug covered by these patents.

On May 22, 2020, the Company filed a patent application in the United States for a new treatment for Coronavirus infections. The Company’s patent application covers composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease (Mpro), an enzyme that is essential for viral replication. The patent application has a priority date of May 22, 2020.

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all or part of the information related to intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-URI http://asc.fasb.org/topic&trid=2144416
+ Details

Name: us-gaap_IntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R11.htm IDEA: XBRL DOCUMENT v3.21.1

5. Capital Stock
12 Months Ended

Dec. 31, 2020

Equity [Abstract]

Capital Stock
The Company’s authorized capital is comprised of 3,000,000,000 shares of $0.001 par value Common Stock and 30,000,000 shares of $0.10 par value Preferred Stock, to have such rights and preferences as the Directors of the Company have or may assign from time to time. Out of the authorized Preferred Stock, the Company had designated 850,000 shares as Series “A” Preferred Stock (“Series A”). At December 31, 2020 and December 31, 2019, the Company had no issued and outstanding shares of Series A. On June 17, 2020, the Company filed an amendment to its Articles of Incorporation (the “Amendment”) eliminating the Series A shares and the designation thereof, which shares were returned to the status of undesignated shares of Preferred Stock. In addition to eliminating the Series A shares, the Amendment also increased the number of authorized Series B Preferred Shares from Five Hundred Thousand (500,000) to One Million (1,000,000) shares.

During the year ended December 31, 2015, the Company authorized 500,000 shares of $0.10 par value Series “B” Preferred Stock (“Series B”). The Series B Preferred Stock is non-convertible, non-redeemable and non-retractable. It has superior liquidation rights to the Common Stock at $0.10 per share and gives the holder the right to 1,000 votes per share. All shares of the Series B Preferred Stock are held by the CEO of the Company.

On June 17, 2020, the Company issued Five Hundred Thousand (500,000) shares of Series “B” Preferred Stock in favor of the Company’s CEO, in consideration for the COVID-19 treatment technology he developed. This issuance brought the total number of Series B Preferred Stock held by the Company’s CEO to 1,000,000 shares.

Through December 31, 2020 and December 31, 2019, the Company has issued and outstanding a total of 346,419,296 and 35,319,990 shares of Common Stock, respectively. Through the same periods, the Company has issued and outstanding a total of -0- and -0- shares of Series A Preferred Stock and 1,000,000 and 500,000 shares of Series B Preferred Stock, respectively.

During the fiscal year ended December 31, 2020, the Company issued an aggregate of 311,099,306 shares of its Common Stock in connection with the conversion of $373,269 in debt and interest of $ 42,233 resulting in a $1,416,313 loss on conversion.

During the fiscal year ended December 31, 2019, the Company issued an aggregate of 31,037,370 shares of its Common Stock as follows:

● 9,150,000 shares valued at $204,300 as compensation to the Company’s Directors and Officers

● 1,455,000 shares for services rendered to the Company by third parties valued at $57,390

● 20,432,370 shares valued at $717,726 in connection with the conversion of $385,778 in debt and interest of $6,689 resulting in a $314,751 loss on conversion

The Company has declared no dividends since inception.

X

- References
No definition available.
+ Details

Name: SBFM_CapitalStockTextBlock

Namespace Prefix: SBFM_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 27 R12.htm IDEA: XBRL DOCUMENT v3.21.1

6. Earnings Per Share
12 Months Ended

Dec. 31, 2020

Earnings Per Share [Abstract]

Earnings per share
The following table sets forth the computation of basic and diluted net income per share for the years ended December 31:

2020 2019

Net gain (loss) attributable to Common Stock $ (-) $ (1,660,291 )

Basic weighted average outstanding shares of Common Stock 10,392,813

Dilutive effects of common share equivalents -0- -0-

Dilutive weighted average outstanding shares of Common Stock - 10,932,813

Net gain (loss) per share attributable to Common Stock $ (0 ) $ (0.15 )

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-URI http://asc.fasb.org/topic&trid=2144383

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R13.htm IDEA: XBRL DOCUMENT v3.21.1

7. Income Taxes
12 Months Ended

Dec. 31, 2020

Income Tax Disclosure [Abstract]

Income Taxes
The Company files a United States federal income tax return and a Canadian branch return on a calendar year basis. The Company and its wholly-owned subsidiaries, Sunshine Biopharma Canada Inc., have not generated taxable income since inception.

Deferred income taxes arise from the temporary differences between financial statement and income tax recognition of net operating losses and other items. These loss carryovers are limited under the Internal Revenue Code should a significant change in ownership occur. The Company accounts for income taxes pursuant to ASC 740, “Accounting for Income Taxes”, which requires, among other things, an asset and liability approach to calculating deferred income taxes. The components of the deferred income tax assets and liabilities arising under ASC No. 740 were as follows:

December 31, 2020 December 31, 2019

Amount Tax Effect Amount Tax Effect

Deferred tax assets:

Net operating loss $ - $ - $ 1,660,291 $ 407,767

Other differences $ (-) $ (-) $ (235,633 ) $ (57,871 )

Net deferred tax assets $ - $ - $ 1,424,658 $ 349,896

Valuation allowance $ (-) $ (-) $ (1,424,658 ) $ (349,896 )

Total deferred tax asset $ -0- $ -0- $ -0- $ -0-

Deferred tax liabilities: $ -0- $ -0- $ -0- $ -0-

Net deferred tax asset $ -0- $ -0- $ -0- $ -0-

Deferred income taxes arise from the temporary differences between financial statement and income tax recognition of net operating losses. These loss carryovers are limited under the Internal Revenue Code should a significant change in ownership occur.

As of December 31, 2020, the Company had net operating loss carry forwards of $10,611,921 that may be available to reduce future years’ taxable income through 2037 and $5,329,161 may be available to reduce future years’ taxable income indefinitely. At December 31, 2020 and December 31, 2019, a deferred tax asset at each date of approximately $690,352 and $239,044, respectively, resulting from the loss carryforwards has been offset by a 100% valuation allowance. The change in the valuation allowance for the period ended December 31, 2020 and December 31, 2019 was approximately $(451,307) and $149,054, respectively.

A reconciliation of the U.S. statutory federal income tax rate to the effective tax rate is as follows:

December 31,

2020

December 31,

2019

U.S. Federal statutory graduated income tax rate 21.00 % 21.00 %

State income tax rate, net of federal benefit 3.56 % 4.12 %

Net income tax rate 24.56 % 25.12 %

Net operating loss used 0.00 % 0.00 %

Net operating loss for which no tax benefit is currently available 0.00 % 0.00 %

Canada Federal statutory rate 15.00 % 15.00 %

Canada Provincial rate 11.80 % 11.80 %

Net Canada rate 26.80 % 26.80 %

Net operating loss used (Canada) 0.00 % 0.00 %

Net operating loss for which no tax benefit is currently available (Canada) -26.80 % -26.80 %

The Company’s income tax filings are subject to audit by various taxation authorities. The Company’s open audit periods are 2018, 2019, and 2020, although, the statute of limitations for the 2018 tax year will expire effective October 15, 2020. In evaluating the Company’s provisions and accruals, future taxable income, and reversal of temporary differences, interpretations and tax planning strategies are considered. The Company believes its estimates are appropriate based on current facts and circumstances.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R14.htm IDEA: XBRL DOCUMENT v3.21.1

8. Notes Payable
12 Months Ended

Dec. 31, 2020

Notes Payable [Abstract]

Notes Payable
The Company’s Notes Payable at December 31, 2020 consisted of the following:

On April 1, 2017, the Company received monies in exchange for a Note Payable having a Face Value of $100,000 Canadian ($74,970 US at September 30, 2020) with interest payable quarterly at 9%, which Note was due April 1, 2019. The Note is convertible any time after issuance into $0.001 par value Common Stock at a price of $0.015 Canadian (approximately $0.011 US) per share. The Company estimates that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion. In June 2018, the Company filed an action in the Superior Court of the Province of Quebec in the District of Montreal (Canada) against the holder of this Note. The complaint alleges among other things, claims of misrepresentations and misleading conduct resulting in damages to the Company in an amount of approximately $200,000 Canadian (approximately $143,000 US). A date for the hearings to commence was set for November 16, 2020. On November 10, 2020, the Company elected to pay off the Note together with accrued interest of $14,696 Canadian (approximately $10,500 US) and terminate the proceedings.

On September 10, 2018, the Company issued two Notes Payable having an aggregate Face Value of $36,500 with interest accruing at 8%. The two Notes were issued for services rendered to the Company and had maturity dates in June 2019. The Company was unable to pay the notes and on November 30, 2019 the Company issued a new Note which included accrued interest and accelerated interest of $7,059 for a total Face Value of $43,559. The new Note accrues interest at 8% and is convertible after 180 days from issuance into Common Stock at a price 35% below market value. The new Note was due August 31, 2020. During the year ended December 31, 2020, the entire principal amount of $43,559 of this Note plus accrued interest of $2,523 was converted into 14,198,048 shares of Common Stock valued at $86,685 resulting in a loss of $40,603.

On December 24, 2018, the Company received monies in exchange for a Note Payable having a Face Value of $87,000 with interest accruing at 8% was due December 24, 2019. The Note is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. As of December 31, 2020, the entire principal amount of $87,000 of this Note plus accrued interest of $9,639 was converted into 43,986,317 shares of Common Stock valued at $276,396 resulting in a loss of $161,036.

On January 8, 2019, the Company received monies in exchange for a Note Payable having a Face Value of $54,000 with interest accruing at 8% was due January 8, 2020. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. During the year ended December 31, 2020, the entire principal amount of $54,000 of this Note plus accrued interest of $9,814 was converted into 44,931,640 shares of Common Stock valued at $365,787 resulting in a loss of $301,973.

On February 5, 2019, the Company received monies in exchange for a Note Payable having a Face Value of $37,450 with interest accruing at 8% was due October 10, 2019. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. During the year ended December 31, 2020, the entire principal amount of $37,450 of this Note plus accrued interest of $2,996 was converted into 38,263,409 shares of Common Stock valued at $217,971 resulting in a loss of $182,790.

On July 2, 2019, the Company received monies in exchange for a Note Payable having a Face Value of $40,000 with interest accruing at 8% was due April 30, 2020. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. During the year ended December 31, 2020, the entire principal amount of $40,000 of this Note plus accrued interest of $1,600 was converted into 13,099,359 shares of Common Stock valued at $58,684 resulting in a loss of $17,084.

On July 26, 2019, the Company received monies in exchange for a Note Payable having a Face Value of $50,000 with interest accruing at 8%, which became due July 26, 2020. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. During the year ended December 31, 2020, the entire principal of $50,000 of this Note plus accrued interest of $4,909 was converted into 43,522,363 shares of Common Stock valued at $131,370 resulting in a loss of $76,461.

On September 12, 2019, the Company received monies in exchange for a Note Payable having a Face Value of $43,000 with interest accruing at 8% is due July 15, 2020. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. During the year ended December 31, 2020, the entire principal amount of $43,000 of this Note plus accrued interest of $1,720 was converted into 38,855,726 shares of Common Stock valued at $117,177 resulting in a loss of $72,457.

On December 14, 2019, the Company received monies in exchange for a Note Payable having a Face Value of $42,800 with interest accruing at 8% and which is due December 14, 2020. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. During the year ended December 31, 2020, the entire principal amount of $42,800 of this Note plus accrued interest of $1,712 was converted into 18,592,605 shares of Common Stock valued at $81,796 resulting in a loss of $37,284.

A Note Payable dated December 31, 2019 having a Face Value of $30,120 and accruing interest at 12% was due December 31, 2020. On December 1, 2020, the Company paid off the entire principal balance of this Note, together with accrued interest of $3,614 by issuing cash payment of $33,734.

A Note Payable dated December 31, 2018 having a Face Value of $136,744 and accruing interest at 12% was due December 31, 2019. On October 1, 2019, the holder of this note requested to convert $30,000 in principal amount into 1,500,000 shares of Common Stock, leaving a principal balance $106,744. On December 31, 2019, the Company renewed the remaining principal balance of this Note, together with accrued interest of $15,509 for a 12-month period. The new Note has a Face Value of $122,253 and accrues interest at 12%. This Note matures on December 31, 2020. On August 27, 2020, the holder of this Note transferred all of its interest therein to a third party and on September 4, 2020, the Company agreed to render the Note convertible at $0.001 per share. During the year ended December 31, 2020, an aggregate principal amount of $58,225 of this Note plus accrued interest of $9,775 was converted into 68,000,000 shares of Common Stock valued at $1,286,400 resulting in a loss of $1,218,400. This note is currently past due and the Company is in discussion with the holder to extend the due date.

On April 17, 2020, the Company’s Canadian subsidiary received a CEBA Loan (Canada Emergency Business Account Loan) from CIBC (Canadian Imperial Bank of Commerce) in the principal amount of $40,000 Canadian ($29,352 US) as part of the Canadian government’s COVID-19 relief program. The CEBA Loan is non-interest bearing if repaid on or before December 31, 2022 (the “Termination Date”). The CEBA Loan is considered repaid in full if the borrower repays 75% of the Principal Amount on or before the Termination Date. If the CEBA Loan is not repaid in full on or before the Termination Date, the lender will automatically extend the term of the loan by three years until December 31, 2025 (the “Extension Period”). During the Extension Period, interest will be charged, and will accrue on the outstanding amount of the CEBA Loan at a fixed rate of 5% per year, calculated daily and compounded monthly. The outstanding balance of the CEBA Loan and all accrued interest will be due at the end of the Extension Period.

On April 27, 2020, the Company received a Paycheck Protection Program loan ("PPP Loan") in the principal amount of $50,655 from the US Small Business Administration (“SBA”) as part of the US government’s COVID-19 relief program. This loan accrues interest at the rate of 1% per annum. The Company is obligated to make payments of principal and interest totaling $2,133 each month commencing on November 27, 2020, with any remaining balances due and payable on or before April 27, 2022. The proceeds derived from this loan may only be used for payroll costs, interest on mortgages, rent and utilities (“Admissible Expenses”). In addition, the Paycheck Protection Program provides for conditional loan forgiveness if the Company utilizes at least 75% of the proceeds from the loan to pay Admissible Expenses. On December 15, 2020, the Company applied to the funding bank for forgiveness of this loan per SBA guidance. On December 18, 2020, the Company received notification that the funding bank has approved forgiveness of the loan in its entirety and that it has submitted a request to the SBA for final approval. On February 22, 2021, the funding bank informed the Company that the SBA has fully forgiven the loan.

On June 1, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $42,000 with interest accruing at 8% is due June 1, 2021. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. On December 2, 2020, the Company paid off the entire principal balance of this Note, together with accrued interest and prepayment penalties of $13,435 by issuing payment of $55,435.

On June 9, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $37,000 with interest accruing at 8% is due June 9, 2021. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. On December 2, 2020, the Company paid off the entire principal balance of this Note, together with accrued interest and prepayment penalties of $11,779 by issuing payment of $48,779.

On July 7, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $48,000 with interest accruing at 8% is due July 7, 2021. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. The Company will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on January 3, 2021 which is 180 days after the issuance date.

On July 27, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $102,000 with interest accruing at 8% is due July 27, 2021. The Note is convertible after 180 days from issuance into Common Stock at a price 30% below market value. The Company will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on January 23, 2021 which is 180 days after the issuance date.

On August 14, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $67,000 with interest accruing at 8% is due August 14, 2021. The Note is convertible after 180 days from issuance into Common Stock at a price 30% below market value. The Company will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on February 10, 2021 which is 180 days after the issuance date.

On September 14, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $250,000 with interest accruing at 5% is due September 14, 2022. The Note is convertible after 180 days from issuance into Common Stock at a price equal to $0.30 per share. The Company will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on March 13, 2021 which is 180 days after the issuance date.

On September 24, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $50,000 with interest accruing at 5% is due September 24, 2022. The Note is convertible after 180 days from issuance into Common Stock at a price equal to $0.30 per share. The Company will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on March 23, 2021 which is 180 days after the issuance date.

On October 20, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $250,000 with interest accruing at 5% is due October 20, 2022. The Note is convertible after 180 days from issuance into Common Stock at a price equal to $0.30 per share. The Company will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on April 18, 2021 which is 180 days after the issuance date.

On November 19, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $250,000 with interest accruing at 8% is due August 19, 2021. The Note is convertible after 180 days from issuance into Common Stock at a price 35% below market value. The Company will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on May 18, 2021 which is 180 days after the issuance date.

On November 24, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $260,000 with interest accruing at 8% is due November 24, 2021. The Note is convertible after 180 days from issuance into Common Stock at a price 30% below market value. The Company will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on May 23, 2021 which is 180 days after the issuance date.

On November 25, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $250,000 with interest accruing at 5% is due November 25, 2022. The Note is convertible after 180 days from issuance into Common Stock at a price equal to $0.30 per share. The Company will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on May 24, 2021 which is 180 days after the issuance date.

On December 2, 2020, the Company received monies in exchange for a Note Payable having a Face Value of $104,215 with interest accruing at 5% is due December 2, 2022. The Note is convertible after 180 days from issuance into Common Stock at a price equal to $0.30 per share. The Company will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on May 31, 2021 which is 180 days after the issuance date.

At December 31, 2020 and December 31, 2019, total accrued interest on Notes Payable was $24,320 and $21,077, respectively.

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564
+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NotesPayableAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 30 R15.htm IDEA: XBRL DOCUMENT v3.21.1

9. Notes Payable Related Party
12 Months Ended

Dec. 31, 2020

Notes Payable [Abstract]

Notes Payable Related Party
Outstanding Notes Payable at December 31, 2020 held by related parties consist of the following:

A Note Payable dated December 31, 2019 held by the CEO of the Company having a Face Value of $128,269 and accruing interest at 12% was due December 31, 2020. On December 31, 2020, the Company renewed the Note together with accrued interest of $15,392 for a 12-month period. The new Note has a face Value of $143,661, accrues interest at 12% per annum, and has a maturity date of December 31, 2021.

X

- References
No definition available.
+ Details

Name: SBFM_NotesPayableRelatedPartyDisclosureTextBlock

Namespace Prefix: SBFM_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NotesPayableAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 31 R16.htm IDEA: XBRL DOCUMENT v3.21.1

10. Related Party Transactions
12 Months Ended

Dec. 31, 2020

Related Party Transactions [Abstract]

Related Party Transactions
In addition to the transactions specified under Note 9 above, during the period ended December 31, 2020, the Directors and Officers of the Company were paid $271,930 in cash. Of this amount, $177,000 was paid to Advanomics Corporation (now known as TRT Pharma Inc.), a company controlled by the CEO of the Company. During the period ended December 31, 2020, the Company issued to its CEO 500,000 shares of Series B Preferred Stock valued at $50,000.

For the period ended December 31, 2019, the Company issued to the Board of Directors 1,950,000 shares of Common Stock valued at $74,100, 3,300,000 shares of Common Stock valued at $99,000, and 3,900,000 shares of Common Stock valued at $31,200. The Company also issued 550,000 shares of Common Stock valued at $16,500 to the CFO for consulting services rendered to the Company in 2019. During the year ended December 31, 2019 the Directors and officers were paid $72,916 in cash. Of this amount, $28,000 was paid to Advanomics Corporation, a company controlled by the CEO of the Company.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-URI http://asc.fasb.org/topic&trid=2122745

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R17.htm IDEA: XBRL DOCUMENT v3.21.1

11. Acquisition and Disposition of Atlas Pharma Inc.
12 Months Ended

Dec. 31, 2020

Business Combinations [Abstract]

Acquisition and Disposition of Atlas Pharma Inc.
On January 1, 2018 the Company acquired all of the issued and outstanding shares of Atlas Pharma Inc. (“Atlas”), a privately held Canadian company providing analytical chemistry testing services (“Atlas Business”). The purchase price for the shares was $848,000 Canadian ($676,748 US). The purchase price included cash payment of $100,500 Canadian ($80,289 US), plus the issuance of 50,000 shares of the Company’s Common Stock valued at $238,000, and a promissory note in the principal amount of $450,000 Canadian ($358,407 US), with interest payable at the rate of 3% per annum (“Atlas Note”). The following table summarizes the allocation of the purchase price as of the acquisition date:

Cash $ 4,942

Accounts receivable $ 79,508

Prepaids $ 1,428

Property and equipment $ 62,990

Goodwill $ 665,697

Liabilities assumed ($172,899 Canadian) $ (137,817 )

Total consideration $ 676,748

Effective April 1, 2019, the Company disposed of Atlas by re-assigning all of its stock in Atlas back to the original owner in exchange for the Atlas Note. As a consequence of the sale, the operating results and the assets and liabilities of the discontinued Atlas Business are presented separately in the Company's financial statements. Summarized financial information for the discontinued Atlas Business is shown below. Prior period balances have been reclassified to present the operations of the Atlas Business as discontinued operations.

Discontinued Operations Income Statement:

Audited

December 31,

2020

Audited

December 31,

2019

Revenues $ 0 $ 119,522

Cost of revenues 0 81,920

Gross profit 0 37,602

General and administrative expenses 0 36,196

Gain (Loss) from operations 0 1,406

Other income (expense) – Interest 0 ) (3,518 )

Net Income (Loss) from operations 0 ) (2,112 )

Loss on Disposal 0 (580,125 )

Net Income (Loss) from Discontinued Operations 0 (582,237 )

The individual assets and liabilities of the discontinued Atlas Business are in the captions "Assets of Discontinued Operation" and "Liabilities of Discontinued Operation" in the Consolidated Balance Sheet. The carrying amounts of the major classes of assets and liabilities included part of the discontinued business are presented in the following table:

Discontinued Operations Balance Sheets:

Audited

December 31,

2020

Audited

December 31,

2019

ASSETS

Current Assets:

Cash and cash equivalents $ - $ -

Accounts receivable - -

Total Current Assets - -

Equipment (net of $ 0 and $34,959 depreciation) - -

Goodwill - -

TOTAL ASSETS $ - $ -

LIABILITIES

Current Liabilities:

Notes payable - -

Notes payable - related party - -

Related party advances - -

Accounts payable & accrued expenses - -

Total Current Liabilities - -

TOTAL LIABILITIES $ - $ -

Discontinued Operations Cash Flows:

Cash flows used in discontinued operations for the period ended December 31, 2020 and 2019 were $-0-and $8,510, respectively. There were no cash flows used in or provided by investing or financing activities during those periods.

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-URI http://asc.fasb.org/subtopic&trid=2122178

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-URI http://asc.fasb.org/topic&trid=2303972
+ Details

Name: us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R18.htm IDEA: XBRL DOCUMENT v3.21.1

12. Leases
12 Months Ended

Dec. 31, 2020

Leases [Abstract]

Leases
The Company's arrangement in connection with its office space located in Pointe-Claire, Quebec, Canada has no short-term or long-term asset or liability value.

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-URI http://asc.fasb.org/topic&trid=2208923
+ Details

Name: us-gaap_LeasesOfLesseeDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R19.htm IDEA: XBRL DOCUMENT v3.21.1

13. Subsequent Events
12 Months Ended

Dec. 31, 2020

Subsequent Events [Abstract]

Subsequent Events
On January 5, 2021, the Company paid off a Note Payable dated July 7, 2020 by issuing cash payment in the amount of $63,271 comprised of $48,000 in principal and $15,271 in accrued interest and prepayment penalties.

On January 12, 2021, the Company received monies in exchange for a Note Payable having a Face Value of $150,000 with interest accruing at 5%. The Note is convertible after 180 days from issuance into Common Stock at a price equal to $0.30 per share.

On January 12 and 28, and on March 3, 2021, the holder of a Note Payable dated December 31, 2019 elected to convert a total of $53,000 in principal into 53,000,000 shares of Common Stock leaving a principal balance of $11,028.

On January 27, 2021, the Company received monies in exchange for a Note Payable having a Face Value of $300,000 with interest accruing at 5%. The Note is convertible after 180 days from issuance into Common Stock at a price equal to $0.50 per share.

On January 29, 2021, the holder of a Note Payable dated July 27, 2020 elected to convert the entire principal amount of $102,000 and accrued interest of $4,171 into 5,044,456 shares of Common Stock leaving a balance of $-0-.

On February 12, 2021, the Company received monies in exchange for a Note Payable having a Face Value of $700,000 with interest accruing at 5%. The Note is convertible after 180 days from issuance into Common Stock at a price equal to $0.60 per share.

On February 22, 2021, the holder of a Note Payable dated August 14, 2020 elected to convert the entire principal amount of $67,000 and accrued interest of $2,680 into 542,173 shares of Common Stock leaving a balance of $-0-.

On February 22, 2021, the funding bank informed the Company that the SBA has fully forgiven the Company's PPP Loan dated April 27, 2020 in the amount of $50,655.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R20.htm IDEA: XBRL DOCUMENT v3.21.1

2. Summary of Significant Accounting Policies (Policies)
12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

IMPACT OF CORONAVIRUS (COVID-19) PANDEMIC
In March 2020, the World Health Organization declared Coronavirus and its associated disease, COVID-19, a global pandemic. Conditions surrounding the Coronavirus outbreak are evolving rapidly and government authorities around the world have implemented emergency measures to mitigate the spread of the virus. The outbreak and related mitigation measures have had and will continue to have a material adverse impact on the world economies and the Company's business activities. It is not possible for the Company to predict the duration or magnitude of the adverse conditions of the outbreak and their effects on the Company’s business or ability to raise funds. No adjustments have been made to the amounts reported in the Company's financial statements as a result of this matter.

PRINCIPLES OF CONSOLIDATION
The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

USE OF ESTIMATES
The preparation of financial statements in conformity with US Generally Accepted Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant estimates and assumptions made by management are valuation of equity instruments, depreciation of property and equipment, and deferred tax asset valuation. Actual results could differ from those estimates as the current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.

CASH AND CASH EQUIVALENTS
For the Balance Sheets and Statements of Cash Flows, all highly liquid investments with maturity of 90 days or less are considered to be cash equivalents. The Company had a cash balance of $989,888 and $40,501 as of December 31, 2020 and December 31, 2019, respectively. At times such cash balances may be in excess of the FDIC limit of $250,000 or the equivalent in Canada.

PROPERTY AND EQUIPMENT
Property and equipment is reviewed for recoverability when events or changes in circumstances indicate that its carrying value may exceed future undiscounted cash inflows. As of December 31, 2020 and 2019, the Company had not identified any such impairment. Repairs and maintenance are charged to operations when incurred and improvements and renewals are capitalized.

Property and equipment are stated at cost. Depreciation is calculated using the straight-line method for financial reporting purposes and accelerated methods for tax purposes. Their estimated useful lives are as follows:

Office Equipment: 5-7 Years

Laboratory Equipment: 5 Years

Vehicles: 5 Years

EARNINGS PER SHARE
The Company has adopted the Financial Accounting Standards Board (FASB) ASC Topic 260 regarding earnings / loss per share, which provides for calculation of “basic” and “diluted” earnings / loss per share. Basic earnings / loss per share includes no dilution and is computed by dividing net income / loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings / loss per share reflect the potential dilution of securities that could share in the earnings of an entity similar to fully diluted earnings / loss per share.

INCOME TAXES
In accordance with ASC 740 – Income Taxes, the provision for income taxes is computed using the asset and liability method. The liability method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities have been adjusted to reflect changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized.

The Company expects to recognize the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a "more-likely-than-not" threshold, the amount to be recognized in the financial statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. As of December 31, 2020 the Company had no uncertain tax positions. The Company recognizes interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. The Company currently has no federal or state tax examinations nor has it had any federal or state examinations since its inception. To date, the Company has not incurred any interest or tax penalties.

For Canadian and US tax purposes, the Company’s 2017 through 2019 tax years remain open for examination by the tax authorities under the normal three-year statute of limitations.

FUNCTIONAL CURRENCY
The U.S. dollar is the functional currency of the Company which is operating in the United States. The functional currency for the Company's Canadian subsidiary is the Canadian dollar.

The Company translates its Canadian subsidiary's financial statements into U.S. dollars as follows:

● Assets and liabilities are translated at the exchange rate in effect as of the financial statement date.

● Income statement accounts are translated using the weighted average exchange rate for the period.

The Company includes translation adjustments from currency exchange and the effect of exchange rate changes on intercompany transactions of a long-term investment nature as a separate component of shareholders’ equity. There are currently no transactions of a long-term investment nature, nor any gains or losses from non U.S. currency transactions.

CONCENTRATION OF CREDIT RISKS
Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents and trade receivables. The Company places its cash equivalents with high credit quality financial institutions.

FINANCIAL INSTRUMENTS AND FAIR VALUE OF FINANCIAL INSTRUMENTS
The Company applies the provisions of accounting guidance, FASB Topic ASC 825, Financial Instruments. ASC 825 requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of December 31, 2020 and 2019, the fair value of cash, accounts receivable and notes receivable, accounts payable, accrued expenses, and other payables approximated carrying value due to the short maturity of the instruments, quoted market prices or interest rates which fluctuate with market rates.

The Company defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).

● Level 1 – Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

● Level 2 – Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability.

● Level 3 – Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.

The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared.

NOTES PAYABLE
Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently carried at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the income statement over the period of the borrowings using the effective interest method.

ACCOUNTING FOR DERIVATIVES LIABILITIES
The Company evaluates stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of ASC Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity’s Own Equity. The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income or other expense.

Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date. The Company determined that none of the Company’s financial instruments meet the criteria for derivative accounting as of December 31, 2020 and 2019.

EQUITY INSTRUMENTS ISSUED TO EMPOYEES OR NON-EMPLOYEES FOR ACQUIRING GOODS OR SERVICES
The stock-based compensation expense for both employee and non-employee awards is generally recognized on a straight-line basis over the requisite service period of the award. The Company accounts for stock-based compensation to employees in conformity with the provisions of ASC Topic 718, Stock Based Compensation. Stock-based compensation to employees consisting of stock option grants and restricted shares are recognized in the statement of operations based on their fair values at the date of grant. The Company accounts for equity instruments issued to non-employees in accordance with the provisions of ASC Topic 718, based upon the fair-value of the underlying instrument.

BASIC AND DILUTED NET GAIN (LOSS) PER SHARE
The Company computes loss per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement.

Basic net income (loss) per share is calculated by dividing net (loss) by the weighted-average common shares outstanding. Diluted net income per share is calculated by dividing net income by the weighted-average common shares outstanding during the period using the treasury stock method or the two-class method, whichever is more dilutive. As the Company incurred net losses for the year ended December 31, 2020 no potentially dilutive securities were included in the calculation of diluted earnings per share as the impact would have been anti-dilutive.

Therefore, basic and dilutive net (loss) per share were the same as of December 31, 2020 and 2019.

REVENUE RECOGNITION
As of January 1, 2018, the Company adopted ASU No. 201409, “Revenue from Contracts with Customers” (ASC 606). Under the new guidance, an entity will recognize revenue to depict the transfer of promised goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. A five-step model has been introduced for an entity to apply when recognizing revenue. The new guidance also includes enhanced disclosure requirements. The guidance was effective January 1, 2018 and was applied on a modified retrospective basis. The adoption did not have an impact on the Company's financial statements. All of the revenues of the Company are the Company's wholly owned Canadian subsidiary, which sells nutritional supplements through Amazon.com and Amazon.ca.

In Canada, governmental regulations require that companies recognize revenues upon completion of the work by issuing an invoice and remitting the applicable sales taxes (GST and QST) to the appropriate government agency. The Company’s wholly owned Canadian subsidiary's revenue recognition policy is in compliance with these local regulations.

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

In December 2019, the FASB issued ASU 2019-12 “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.” This guidance removes certain exceptions to the general principles in Topic 740 and provides consistent application of U.S. GAAP by clarifying and amending existing guidance. The effective date of the new guidance for public companies is for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the timing of adoption and impact of the updated guidance on its financial statements.

LEGAL FEES
During the years ended December 31, 2020 and 2019, the legal fees incurred were related to services provided to the Company to assist with its regulatory requirements with the Securities and Exchange Commission, patenting costs and one ongoing litigation.

DATE OF MANAGEMENT'S REVIEW
Subsequent events have been evaluated through March 29, 2021, which is the date the Financial Statements were available to be issued.

X

- References
No definition available.
+ Details

Name: SBFM_BasicAndDilutedNetGainLossPerSharePolicyTextBlock

Namespace Prefix: SBFM_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_EquityInstrumentsIssuedToEmployeesOrNonEmployeesForAcquiringGoodsOrServicesPolicyTextBlock

Namespace Prefix: SBFM_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_ImpactOfCoronavirusPandemicPolicyTextBlock

Namespace Prefix: SBFM_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_LegalFeesPolicyTextBlock

Namespace Prefix: SBFM_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for credit risk.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 825
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788
+ Details

Name: us-gaap_ConcentrationRiskCreditRisk

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684
+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
+ Details

Name: us-gaap_DebtPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for its derivative instruments and hedging activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121590274&loc=d3e41675-113959

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959
+ Details

Name: us-gaap_DerivativesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for determining the fair value of financial instruments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 60
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-URI http://asc.fasb.org/topic&trid=2175825

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319
+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790
+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for reporting subsequent events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_SubsequentEventsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R21.htm IDEA: XBRL DOCUMENT v3.21.1

2. Summary of Significant Accounting Policies (Tables)
12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Estimated useful lives of property plant and equipment

Office Equipment: 5-7 Years

Laboratory Equipment: 5 Years

Vehicles: 5 Years

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R22.htm IDEA: XBRL DOCUMENT v3.21.1

6. Earnings Per Share (Tables)
12 Months Ended

Dec. 31, 2020

Earnings Per Share [Abstract]

Schedule of earnings per share computation

2020 2019

Net gain (loss) attributable to Common Stock $ (-) $ (1,660,291 )

Basic weighted average outstanding shares of Common Stock 10,392,813

Dilutive effects of common share equivalents -0- -0-

Dilutive weighted average outstanding shares of Common Stock - 10,932,813

Net gain (loss) per share attributable to Common Stock $ (0 ) $ (0.15 )

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R23.htm IDEA: XBRL DOCUMENT v3.21.1

7. Income Taxes (Tables)
12 Months Ended

Dec. 31, 2020

Income Tax Disclosure [Abstract]

Temporary differences

December 31, 2020 December 31, 2019

Amount Tax Effect Amount Tax Effect

Deferred tax assets:

Net operating loss $ - $ - $ 1,660,291 $ 407,767

Other differences $ (-) $ (-) $ (235,633 ) $ (57,871 )

Net deferred tax assets $ - $ - $ 1,424,658 $ 349,896

Valuation allowance $ (-) $ (-) $ (1,424,658 ) $ (349,896 )

Total deferred tax asset $ -0- $ -0- $ -0- $ -0-

Deferred tax liabilities: $ -0- $ -0- $ -0- $ -0-

Net deferred tax asset $ -0- $ -0- $ -0- $ -0-

Income tax reconciliation

December 31,

2020

December 31,

2019

U.S. Federal statutory graduated income tax rate 21.00 % 21.00 %

State income tax rate, net of federal benefit 3.56 % 4.12 %

Net income tax rate 24.56 % 25.12 %

Net operating loss used 0.00 % 0.00 %

Net operating loss for which no tax benefit is currently available 0.00 % 0.00 %

Canada Federal statutory rate 15.00 % 15.00 %

Canada Provincial rate 11.80 % 11.80 %

Net Canada rate 26.80 % 26.80 %

Net operating loss used (Canada) 0.00 % 0.00 %

Net operating loss for which no tax benefit is currently available (Canada) -26.80 % -26.80 %

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of deferred tax liabilities not recognized because of the exceptions to comprehensive recognition of deferred taxes, including a description of the temporary differences, events that would cause the temporary differences to become taxable, the cumulative amounts of the temporary differences and the amounts not recognized as deferred tax liabilities or a statement that the determination of the deferred tax liabilities is not practicable.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6487024&loc=d3e29054-158556

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331
+ Details

Name: us-gaap_SummaryOfDeferredTaxLiabilityNotRecognizedTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R24.htm IDEA: XBRL DOCUMENT v3.21.1

11. Acquisition and Disposition of Atlas Pharma Inc. (Tables)
12 Months Ended

Dec. 31, 2020

Business Combinations [Abstract]

Acquisition

Cash $ 4,942

Accounts receivable $ 79,508

Prepaids $ 1,428

Property and equipment $ 62,990

Goodwill $ 665,697

Liabilities assumed ($172,899 Canadian) $ (137,817 )

Total consideration $ 676,748

Discontinued Operations Income Statement

Audited

December 31,

2020

Audited

December 31,

2019

Revenues $ 0 $ 119,522

Cost of revenues 0 81,920

Gross profit 0 37,602

General and administrative expenses 0 36,196

Gain (Loss) from operations 0 1,406

Other income (expense) – Interest 0 ) (3,518 )

Net Income (Loss) from operations 0 ) (2,112 )

Loss on Disposal 0 (580,125 )

Net Income (Loss) from Discontinued Operations 0 (582,237 )

Discontinued Operations Balance Sheet

Audited

December 31,

2020

Audited

December 31,

2019

ASSETS

Current Assets:

Cash and cash equivalents $ - $ -

Accounts receivable - -

Total Current Assets - -

Equipment (net of $ 0 and $34,959 depreciation) - -

Goodwill - -

TOTAL ASSETS $ - $ -

LIABILITIES

Current Liabilities:

Notes payable - -

Notes payable - related party - -

Related party advances - -

Accounts payable & accrued expenses - -

Total Current Liabilities - -

TOTAL LIABILITIES $ - $ -

X

- References
No definition available.
+ Details

Name: SBFM_DiscontinuedOperationsBalanceSheetTableTextBlock

Namespace Prefix: SBFM_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_DiscontinuedOperationsIncomeStatementTableTextBlock

Namespace Prefix: SBFM_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463
+ Details

Name: us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R25.htm IDEA: XBRL DOCUMENT v3.21.1

2. Summary of Significant Accounting Policies (Details)
12 Months Ended

Dec. 31, 2020

Office Equipment

Estimated useful lives 5-7 Years

Laboratory Equipment

Estimated useful lives 5 Years

Vehicles

Estimated useful lives 5 Years

X

- Definition
Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 35
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=68071081&loc=d3e1205-110223

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 41 R26.htm IDEA: XBRL DOCUMENT v3.21.1

2. Summary of Significant Accounting Policies (Details Narrative) - USD ($)

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Accounting Policies [Abstract]

Cash $ 989,888 $ 40,501 $ 115,216

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section 45
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840
+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 42 R27.htm IDEA: XBRL DOCUMENT v3.21.1

6. Earnings Per Share (Details) - USD ($)
12 Months Ended

Dec. 31, 2020

Dec. 31, 2019

Earnings Per Share [Abstract]

Net (loss) attributable to common stockholders $ (1,660,291)

Basic weighted average outstanding shares of common stock 204,096,338 10,932,813

Dilutive effects of common share equivalents $ 0 $ 0

Dilutive weighted average outstanding shares of common stock 0 10,932,813

Net loss per share of common stock - basic and diluted $ (0.01) $ (0.15)

X

- Definition
Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units.
+ References
No definition available.
+ Details

Name: us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The weighted average number of shares or units and dilutive common stock or unit equivalents outstanding in the calculation of proforma diluted earnings per share (earnings per unit), which is commonly presented in initial public offerings based on the terms of the offering.
+ References
No definition available.
+ Details

Name: us-gaap_ProFormaWeightedAverageSharesOutstandingDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 43 R28.htm IDEA: XBRL DOCUMENT v3.21.1

7. Income Taxes (Details) - USD ($)

Dec. 31, 2020

Dec. 31, 2019

Deferred tax assets:

Net deferred tax assets $ 690,352 $ 239,044

Temporary Difference

Deferred tax assets:

Net operating loss US 0 1,660,291

Other differences 0 (235,633)

Net deferred tax assets 0 1,424,658

Valuation allowance 0 (1,424,658)

Total deferred tax asset 0 0

Deferred tax liabilities 0 0

Net deferred tax asset 0 0

Tax Effect

Deferred tax assets:

Net operating loss US 0 407,767

Other differences 0 (57,872)

Net deferred tax assets 0 349,896

Valuation allowance 0 (349,896)

Total deferred tax asset 0 0

Deferred tax liabilities 0 0

Net deferred tax asset $ 0 $ 0

X

- References
No definition available.
+ Details

Name: us-gaap_ComponentsOfDeferredTaxAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsLiabilitiesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319
+ Details

Name: us-gaap_DeferredTaxAssetsOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=SBFM_TemporaryDifferenceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=SBFM_TaxEffectMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 44 R29.htm IDEA: XBRL DOCUMENT v3.21.1

7. Income Taxes (Details 1)
12 Months Ended

Dec. 31, 2020

Dec. 31, 2019

Income Tax Disclosure [Abstract]

U.S. Federal statutory graduated income tax rate 21.00% 21.00%

State income tax rate, net of federal benefit 3.56% 3.56%

Net income tax rate 24.56% 25.12%

Net operating loss used 0.00% 0.00%

Net operating loss for which no tax benefit is currently available 0.00% 0.00%

Canada Federal statutory rate 15.00% 15.00%

Canada Provincial rate 11.80% 11.80%

Net rate 26.80% 26.80%

Net operating loss used (Canada) 0.00% 0.00%

Net operating loss for which no tax benefit is currently available (Canada) (26.80%) (26.80%)

X

- References
No definition available.
+ Details

Name: SBFM_CanadaNetOperatingLossForWhichNoTaxBenefitIsCurrentlyAvailable

Namespace Prefix: SBFM_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_CanadaNetStatutoryTaxRate

Namespace Prefix: SBFM_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_CanadaProvincialTaxRate

Namespace Prefix: SBFM_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_EffectiveIncomeTaxRate

Namespace Prefix: SBFM_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_IncomeTaxNetOperatingLossUsed

Namespace Prefix: SBFM_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: SBFM_NetOperatingLossForWhichNoTaxBenefitIsCurrentlyAvailable

Namespace Prefix: SBFM_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of domestic federal statutory tax rate applicable to pretax income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.4)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.4)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.4)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.4)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 45 R30.htm IDEA: XBRL DOCUMENT v3.21.1

7. Income Taxes (Details Narrative) - USD ($)

Dec. 31, 2020

Dec. 31, 2019

Income Tax Disclosure [Abstract]

Federal net operating loss carryforwards $ 10,611,921

Deferred tax asset net operating loss carryforwards 690,352 $ 239,044

Change in the valuation allowance $ (451,307) $ 149,054

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319
+ Details

Name: us-gaap_OperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_OperatingLossCarryforwardsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 46 R31.htm IDEA: XBRL DOCUMENT v3.21.1

8. Notes Payable (Details Narrative) - USD ($)

Dec. 31, 2020

Dec. 31, 2019

Notes Payable [Abstract]

Interest accrued on note $ 24,320 $ 21,077

X

- References
No definition available.
+ Details

Name: SBFM_DebtInstrumentAccruedInterest

Namespace Prefix: SBFM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_NotesPayableAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 47 R32.htm IDEA: XBRL DOCUMENT v3.21.1

9. Notes Payable Related Party (Details Narrative) - USD ($)

Dec. 31, 2020

Dec. 31, 2019

Accrued interest $ 24,320 $ 21,077

Note 1

Face value 143,661 $ 128,269

Accrued interest $ 15,392

X

- Definition
Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611
+ Details

Name: us-gaap_DebtInstrumentFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InterestPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentAxis=SBFM_Note1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 48 R33.htm IDEA: XBRL DOCUMENT v3.21.1

11. Acquisition and Disposition of Atlas Pharma Inc. (Details)

Dec. 31, 2019

USD ($)

Business Combinations [Abstract]

Cash $ 4,942

Accounts receivable 79,508

Prepaids 1,428

Property and equipment 62,990

Goodwill 665,697

Liabilities assumed ($172,899 Canadian) (137,817)

Total consideration $ 676,748

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities assumed at the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 55
-Paragraph 37
-URI http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of property, plant, and equipment recognized as of the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 55
-Paragraph 37
-URI http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 49 R34.htm IDEA: XBRL DOCUMENT v3.21.1

11. Acquisition and Disposition of Atlas Pharma Inc. (Details 1) - USD ($)
12 Months Ended

Dec. 31, 2020

Dec. 31, 2019

Business Combinations [Abstract]

Cost of revenues $ 0 $ 119,522

Revenues 0 81,920

Gross profit 0 37,602

General and administrative expenses 0 36,196

Gain (Loss) from operations 0 1,406

Other income (expense) - Interest 0 (3,518)

Income (Loss) from Operations 0 (2,112)

Loss on disposal 0 (580,125)

Net income (loss) from discontinued operations $ 0 $ (582,237)

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3B
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759
+ Details

Name: us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3B
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760
+ Details

Name: us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3B
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759
+ Details

Name: us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section S99
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=26872618&loc=d3e7436-122677

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1063-107759

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1060-107759
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 50 R35.htm IDEA: XBRL DOCUMENT v3.21.1

11. Acquisition and Disposition of Atlas Pharma Inc. (Details 2) - USD ($)

Dec. 31, 2020

Dec. 31, 2019

Current Assets:

Cash and cash equivalents $ 0 $ 0

Accounts receivable 0 0

Total Current Assets 0 0

Equipment (net of $0 and $34,959 depreciation) 0 0

Goodwill 0 0

TOTAL ASSETS 0 0

Current Liabilities:

Notes payable 0 0

Notes payable - related party 0 0

Related party advances 0 0

Accounts payable & accrued expenses 0 0

Total Current Liabilities 0 0

TOTAL LIABILITIES $ 0 $ 0

X

- References
No definition available.
+ Details

Name: SBFM_DisposalGroupIncludingDiscontinuedOperationsNotesPayable

Namespace Prefix: SBFM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: SBFM_DisposalGroupIncludingDiscontinuedOperationsNotesPayableRelatedParty

Namespace Prefix: SBFM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: SBFM_DisposalGroupIncludingDiscontinuedOperationsRelatedPartyAdvances

Namespace Prefix: SBFM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230
+ Details

Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount classified as accounts payable and accrued liabilities attributable to disposal group held for sale or disposed of.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount classified as goodwill attributable to disposal group held for sale or disposed of.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760
+ Details

Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 51 R36.htm IDEA: XBRL DOCUMENT v3.21.1

11. Acquisition and Disposition of Atlas Pharma Inc. (Details Narrative) - USD ($)
12 Months Ended

Dec. 31, 2020

Dec. 31, 2019

Business Combinations [Abstract]

Cash flows used in discontinued operations $ 0 $ 8,510

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Increase (decrease) in cash associated with the entity's discontinued operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInDiscontinuedOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

EXCEL 52 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 53 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 54 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 44 291 1 false 13 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://sunshinebiopharma.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://sunshinebiopharma.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://sunshinebiopharma.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statement of Operations and Comprehensive Income (Loss) Sheet http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveIncomeLoss Consolidated Statement of Operations and Comprehensive Income (Loss) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statement of Cash Flows Sheet http://sunshinebiopharma.com/role/StatementOfCashFlows Consolidated Statement of Cash Flows Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statement of Shareholders' Equity Sheet http://sunshinebiopharma.com/role/StatementOfShareholdersEquity Consolidated Statement of Shareholders' Equity Statements 6 false false R7.htm 00000007 - Disclosure - 1. Description of Business Sheet http://sunshinebiopharma.com/role/DescriptionOfBusiness 1. Description of Business Notes 7 false false R8.htm 00000008 - Disclosure - 2. Summary of Significant Accounting Policies Sheet http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies 2. Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - 3. Going Concern Sheet http://sunshinebiopharma.com/role/GoingConcern 3. Going Concern Notes 9 false false R10.htm 00000010 - Disclosure - 4. Patents Sheet http://sunshinebiopharma.com/role/Patents 4. Patents Notes 10 false false R11.htm 00000011 - Disclosure - 5. Capital Stock Sheet http://sunshinebiopharma.com/role/CapitalStock 5. Capital Stock Notes 11 false false R12.htm 00000012 - Disclosure - 6. Earnings Per Share Sheet http://sunshinebiopharma.com/role/EarningsPerShare 6. Earnings Per Share Notes 12 false false R13.htm 00000013 - Disclosure - 7. Income Taxes Sheet http://sunshinebiopharma.com/role/IncomeTaxes 7. Income Taxes Notes 13 false false R14.htm 00000014 - Disclosure - 8. Notes Payable Notes http://sunshinebiopharma.com/role/NotesPayable 8. Notes Payable Notes 14 false false R15.htm 00000015 - Disclosure - 9. Notes Payable Related Party Notes http://sunshinebiopharma.com/role/NotesPayableRelatedParty 9. Notes Payable Related Party Notes 15 false false R16.htm 00000016 - Disclosure - 10. Related Party Transactions Sheet http://sunshinebiopharma.com/role/RelatedPartyTransactions 10. Related Party Transactions Notes 16 false false R17.htm 00000017 - Disclosure - 11. Acquisition and Disposition of Atlas Pharma Inc. Sheet http://sunshinebiopharma.com/role/AcquisitionAndDispositionOfAtlasPharmaInc. 11. Acquisition and Disposition of Atlas Pharma Inc. Notes 17 false false R18.htm 00000018 - Disclosure - 12. Leases Sheet http://sunshinebiopharma.com/role/Leases 12. Leases Notes 18 false false R19.htm 00000019 - Disclosure - 13. Subsequent Events Sheet http://sunshinebiopharma.com/role/SubsequentEvents 13. Subsequent Events Notes 19 false false R20.htm 00000020 - Disclosure - 2. Summary of Significant Accounting Policies (Policies) Sheet http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies 2. Summary of Significant Accounting Policies (Policies) Policies http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies 20 false false R21.htm 00000021 - Disclosure - 2. Summary of Significant Accounting Policies (Tables) Sheet http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables 2. Summary of Significant Accounting Policies (Tables) Tables http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies 21 false false R22.htm 00000022 - Disclosure - 6. Earnings Per Share (Tables) Sheet http://sunshinebiopharma.com/role/EarningsPerShareTables 6. Earnings Per Share (Tables) Tables http://sunshinebiopharma.com/role/EarningsPerShare 22 false false R23.htm 00000023 - Disclosure - 7. Income Taxes (Tables) Sheet http://sunshinebiopharma.com/role/IncomeTaxesTables 7. Income Taxes (Tables) Tables http://sunshinebiopharma.com/role/IncomeTaxes 23 false false R24.htm 00000024 - Disclosure - 11. Acquisition and Disposition of Atlas Pharma Inc. (Tables) Sheet http://sunshinebiopharma.com/role/AcquisitionAndDispositionOfAtlasPharmaInc.Tables 11. Acquisition and Disposition of Atlas Pharma Inc. (Tables) Tables http://sunshinebiopharma.com/role/AcquisitionAndDispositionOfAtlasPharmaInc. 24 false false R25.htm 00000025 - Disclosure - 2. Summary of Significant Accounting Policies (Details) Sheet http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails 2. Summary of Significant Accounting Policies (Details) Details http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables 25 false false R26.htm 00000026 - Disclosure - 2. Summary of Significant Accounting Policies (Details Narrative) Sheet http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative 2. Summary of Significant Accounting Policies (Details Narrative) Details http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables 26 false false R27.htm 00000027 - Disclosure - 6. Earnings Per Share (Details) Sheet http://sunshinebiopharma.com/role/EarningsPerShareDetails 6. Earnings Per Share (Details) Details http://sunshinebiopharma.com/role/EarningsPerShareTables 27 false false R28.htm 00000028 - Disclosure - 7. Income Taxes (Details) Sheet http://sunshinebiopharma.com/role/IncomeTaxesDetails 7. Income Taxes (Details) Details http://sunshinebiopharma.com/role/IncomeTaxesTables 28 false false R29.htm 00000029 - Disclosure - 7. Income Taxes (Details 1) Sheet http://sunshinebiopharma.com/role/IncomeTaxesDetails1 7. Income Taxes (Details 1) Details http://sunshinebiopharma.com/role/IncomeTaxesTables 29 false false R30.htm 00000030 - Disclosure - 7. Income Taxes (Details Narrative) Sheet http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative 7. Income Taxes (Details Narrative) Details http://sunshinebiopharma.com/role/IncomeTaxesTables 30 false false R31.htm 00000031 - Disclosure - 8. Notes Payable (Details Narrative) Notes http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative 8. Notes Payable (Details Narrative) Details http://sunshinebiopharma.com/role/NotesPayable 31 false false R32.htm 00000032 - Disclosure - 9. Notes Payable Related Party (Details Narrative) Notes http://sunshinebiopharma.com/role/NotesPayableRelatedPartyDetailsNarrative 9. Notes Payable Related Party (Details Narrative) Details http://sunshinebiopharma.com/role/NotesPayableRelatedParty 32 false false R33.htm 00000033 - Disclosure - 11. Acquisition and Disposition of Atlas Pharma Inc. (Details) Sheet http://sunshinebiopharma.com/role/AcquisitionAndDispositionOfAtlasPharmaInc.Details 11. Acquisition and Disposition of Atlas Pharma Inc. (Details) Details http://sunshinebiopharma.com/role/AcquisitionAndDispositionOfAtlasPharmaInc.Tables 33 false false R34.htm 00000034 - Disclosure - 11. Acquisition and Disposition of Atlas Pharma Inc. (Details 1) Sheet http://sunshinebiopharma.com/role/AcquisitionAndDispositionOfAtlasPharmaInc.Details1 11. Acquisition and Disposition of Atlas Pharma Inc. (Details 1) Details http://sunshinebiopharma.com/role/AcquisitionAndDispositionOfAtlasPharmaInc.Tables 34 false false R35.htm 00000035 - Disclosure - 11. Acquisition and Disposition of Atlas Pharma Inc. (Details 2) Sheet http://sunshinebiopharma.com/role/AcquisitionAndDispositionOfAtlasPharmaInc.Details2 11. Acquisition and Disposition of Atlas Pharma Inc. (Details 2) Details http://sunshinebiopharma.com/role/AcquisitionAndDispositionOfAtlasPharmaInc.Tables 35 false false R36.htm 00000036 - Disclosure - 11. Acquisition and Disposition of Atlas Pharma Inc. (Details Narrative) Sheet http://sunshinebiopharma.com/role/AcquisitionAndDispositionOfAtlasPharmaInc.DetailsNarrative 11. Acquisition and Disposition of Atlas Pharma Inc. (Details Narrative) Details http://sunshinebiopharma.com/role/AcquisitionAndDispositionOfAtlasPharmaInc.Tables 36 false false All Reports Book All Reports sbfm-20201231.xml sbfm-20201231.xsd sbfm-20201231_cal.xml sbfm-20201231_def.xml sbfm-20201231_lab.xml sbfm-20201231_pre.xml http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/us-gaap/2020-01-31 true true ZIP 58 0001654954-21-003507-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001654954-21-003507-xbrl.zip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end

Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current Assets:
Cash and cash equivalents	$ 989,888	$ 40,501
Accounts receivable	1,916	430
Inventory	23,771	15,910
Prepaid expenses	2,778	1,255
Deposits	7,590	7,590
Total Current Assets	1,025,943	65,686
Equipment (net of $51,485 and $37,109 depreciation, respectively)	19,531	32,456
Patents (net of $58,918 amortization and $556,120 impairment)	0	0
TOTAL ASSETS	1,045,474	98,142
Current Liabilities:
Notes payable	820,454	586,307
Notes payable - related party	143,661	129,261
Accounts payable and accrued expenses	62,870	96,882
Interest payable	24,320	21,077
Total Curent Liabilities	1,051,305	833,527
Long-term portion of notes payable	949,006	0
TOTAL LIABILITIES	2,000,311	833,527
SHAREHOLDERS' EQUITY
Common Stock, $0.001 par value per share; Authorized 3,000,000,000 Shares; Issued and outstanding 346,419,296 and 35,319,990 at December 31, 2020 and December 31, 2019, respectively	346,418	35,320
Capital paid in excess of par value	18,820,343	16,616,426
Accumulated other comprehensive income	(2,871)	(2,495)
Accumulated (Deficit)	(20,218,727)	(17,434,636)
TOTAL SHAREHOLDERS' DEFICIT	(954,837)	(735,385)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT	1,045,474	98,142
Series A Preferred Stock
SHAREHOLDERS' EQUITY
Preferred Stock	0	0
Series B Preferred Stock
SHAREHOLDERS' EQUITY
Preferred Stock	$ 100,000	$ 50,000

Consolidated Balance Sheets (Parenthetical) - USD ($)	12 Months Ended
Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Equipment depreciation	$ 51,485	$ 37,109
Patent amortization	58,918	$ 58,918
Patent impairment	$ 556,120
SHAREHOLDERS' EQUITY
Common stock, par value	$ 0.001	$ 0.001
Common stock shares authorized	3,000,000,000	3,000,000,000
Common stock shares issued	346,419,296	35,319,990
Common stock shares outstanding	346,419,296	35,319,990
Series B Preferred Stock
SHAREHOLDERS' EQUITY
Preferred stock, par value	$ 0.10	$ 0.10
Preferred stock shares authorized	1,000,000	500,000
Preferred stock shares issued	1,000,000	500,000
Preferred stock shares outstanding	1,000,000	500,000

Consolidated Statement of Operations and Comprehensive Income (Loss) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenue	$ 71,410	$ 21,121
Cost of Revenues	25,847	11,050
Gross Profit	45,563	10,071
General & Administrative Expenses:
Accounting	81,524	89,253
Consulting	15,360	74,124
Legal	89,587	107,196
Office	89,022	74,904
Officer & Director remuneration	271,930	277,252
R&D	60,948	15,204
Depreciation	14,066	13,774
Total General & Administrative	622,437	651,707
Income (Loss) from Operations	(576,874)	(641,636)
Other (expense):
Loss on debt conversions	(2,057,513)	(314,752)
Foreign exchange gain (loss)	4,891	(15,099)
Interest expense	(168,105)	(115,901)
Miscellaneous income	3,000	0
Debt release	7,674	7,967
Gain on interest forgiveness	2,836	1,367
Total Other Income (Expenses)	(2,207,217)	(436,418)
Net income (loss) before income taxes	(2,784,091)	(1,078,054)
Income taxes	0	0
Net Income (loss) from continuing operations	(2,784,091)	(1,078,054)
Net Income (loss) from discontinued operations	0	(582,237)
Net Income (loss)	(2,784,091)	(1,660,291)
Unrealized gain (loss) from foreign exchange transactions	376	1,243
Comprehensive Income (Loss)	$ (2,783,715)	$ (1,659,048)
Basic income (loss) from continuing operations per common share	$ (0.01)	$ (0.10)
Basic income (loss) from discontinued operations per common share	0	(0.05)
Basic income (loss) per common shares	$ (0.01)	$ (0.15)
Weighted Average Common Shares Outstanding	204,096,338	10,932,813

Consolidated Statement of Cash Flows - USD ($)	12 Months Ended
Consolidated Statement of Cash Flows - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Cash Flows From Operating Activities:
Net Income (Loss)	$ (2,784,091)	$ (1,660,291)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	14,066	13,774
Foreign exchange (gain) loss	(4,891)	15,099
Stock issued for services	50,000	261,690
Stock issued for payment of interest	42,233	17,197
Loss on debt conversion	2,057,513	314,752
Gain on interest and debt forgiven	10,510	(9,334)
Loss on disposition of subsidiary	0	582,237
(Increase) in accounts receivable	(1,486)	(430)
(Increase) decrease in inventory	(7,861)	(15,910)
(Increase) in prepaid expenses	(1,523)	(7,676)
(Increase) in deposits	0	0
(Decrease) in accounts payable & accrued expenses	(35,012)	(18,692)
Increase in interest payable	3,243	11,786
Net Cash Flows (Used) in Operations	(657,299)	(495,798)
Cash Flows From Investing Activities:
Advances from discontinued operations	0	(14,416)
Purchase equipment	(1,191)	(860)
Net Cash Flows (Used) in Investing Activities	(1,191)	(15,276)
Cash Flows From Financing Activities:
Proceed from note payable	1,674,246	441,230
Payment of notes payable	(106,600)	(53,000)
Notes Payable - Interest expense	40,607	25,795
Note payable used to pay origination fees & interest	0	28,230
Net Cash Flows Provided by Financing Activities	1,608,253	442,255
Cash and cash equivalents at beginning of period	40,501	115,216
Net Increase (Decrease) In Cash and cash equivalents	949,763	(68,819)
Foreign currency translation adjustment	(376)	(5,896)
Cash and cash equivalents at end of period	989,888	40,501
Supplementary Disclosure Of Cash Flow Information:
Cash paid for interest	20,963	0
Cash paid for income taxes	0	0
Stock issued for note conversions	$ 2,515,015	$ 717,726

Consolidated Statement of Shareholders' Equity - USD ($)	Common Stock	Capital Paid In Excess Of Par Value	Preferred Shares	Comprehensive Income	Accumulated Deficit	Total
Begining balance, shares at Dec. 31, 2018	4,282,620		500,000
Begining balance, amount at Dec. 31, 2018	$ 4,283	$ 15,668,047	$ 50,000	$ (3,738)	$ (15,774,345)	$ (55,753)
Common stock issued to directors	$ 9,150	195,150				204,300
Common stock issued for services, shares	1,455,000
Common stock issued for services, amount	$ 1,455	55,935				57,390
Common stock issued for equipment, amount						0
Common stock issued for the reduction of notes payable and payment of interest, shares	20,432,370
Common stock issued for the reduction of notes payable and payment of interest, amount	$ 20,432	697,294				717,726
Net (loss)				1,243	(1,660,291)	(1,659,048)
Ending balance, shares at Dec. 31, 2019	35,319,990		500,000
Ending balance, amount at Dec. 31, 2019	$ 35,320	16,616,426	$ 50,000	(2,495)	(17,434,636)	(735,385)
Common stock issued for the reduction of notes payable and payment of interest, shares	311,099,306
Common stock issued for the reduction of notes payable and payment of interest, amount	$ 311,098	2,203,917				2,515,015
Preferred stock issued for services, shares			500,000
Preferred stock issued for services, amount			$ 50,000			50,000
Net (loss)				(376)	(2,784,091)	(2,784,467)
Ending balance, shares at Dec. 31, 2020	346,419,296		1,000,000
Ending balance, amount at Dec. 31, 2020	$ 346,418	$ 18,820,343	$ 100,000	$ (2,871)	$ (20,218,727)	$ (954,837)

12. Leases	12 Months Ended
12. Leases	Dec. 31, 2020
Leases [Abstract]
Leases	The Company's arrangement in connection with its office space located in Pointe-Claire, Quebec, Canada has no short-term or long-term asset or liability value.

2. Summary of Significant Accounting Policies (Details)	12 Months Ended
2. Summary of Significant Accounting Policies (Details)	Dec. 31, 2020
Office Equipment
Estimated useful lives	5-7 Years
Laboratory Equipment
Estimated useful lives	5 Years
Vehicles
Estimated useful lives	5 Years

2. Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Cash	$ 989,888	$ 40,501	$ 115,216

6. Earnings Per Share (Details) - USD ($)	12 Months Ended
6. Earnings Per Share (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Earnings Per Share [Abstract]
Net (loss) attributable to common stockholders		$ (1,660,291)
Basic weighted average outstanding shares of common stock	204,096,338	10,932,813
Dilutive effects of common share equivalents	$ 0	$ 0
Dilutive weighted average outstanding shares of common stock	0	10,932,813
Net loss per share of common stock - basic and diluted	$ (0.01)	$ (0.15)

7. Income Taxes (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Deferred tax assets:
Net deferred tax assets	$ 690,352	$ 239,044
Temporary Difference
Deferred tax assets:
Net operating loss US	0	1,660,291
Other differences	0	(235,633)
Net deferred tax assets	0	1,424,658
Valuation allowance	0	(1,424,658)
Total deferred tax asset	0	0
Deferred tax liabilities	0	0
Net deferred tax asset	0	0
Tax Effect
Deferred tax assets:
Net operating loss US	0	407,767
Other differences	0	(57,872)
Net deferred tax assets	0	349,896
Valuation allowance	0	(349,896)
Total deferred tax asset	0	0
Deferred tax liabilities	0	0
Net deferred tax asset	$ 0	$ 0

7. Income Taxes (Details 1)	12 Months Ended
7. Income Taxes (Details 1)	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
U.S. Federal statutory graduated income tax rate	21.00%	21.00%
State income tax rate, net of federal benefit	3.56%	3.56%
Net income tax rate	24.56%	25.12%
Net operating loss used	0.00%	0.00%
Net operating loss for which no tax benefit is currently available	0.00%	0.00%
Canada Federal statutory rate	15.00%	15.00%
Canada Provincial rate	11.80%	11.80%
Net rate	26.80%	26.80%
Net operating loss used (Canada)	0.00%	0.00%
Net operating loss for which no tax benefit is currently available (Canada)	(26.80%)	(26.80%)

7. Income Taxes (Details Narrative) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Federal net operating loss carryforwards	$ 10,611,921
Deferred tax asset net operating loss carryforwards	690,352	$ 239,044
Change in the valuation allowance	$ (451,307)	$ 149,054

8. Notes Payable (Details Narrative) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Notes Payable [Abstract]
Interest accrued on note	$ 24,320	$ 21,077

9. Notes Payable Related Party (Details Narrative) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Accrued interest	$ 24,320	$ 21,077
Note 1
Face value	143,661	$ 128,269
Accrued interest	$ 15,392

11. Acquisition and Disposition of Atlas Pharma Inc. (Details)	Dec. 31, 2019 USD ($)
Business Combinations [Abstract]
Cash	$ 4,942
Accounts receivable	79,508
Prepaids	1,428
Property and equipment	62,990
Goodwill	665,697
Liabilities assumed ($172,899 Canadian)	(137,817)
Total consideration	$ 676,748